The Health Advocates

A podcast that breaks down major health news of the week to help you make sense of it all.

Steven Newmark

“The Health Advocates” is hosted by Steven Newmark, Chief Legal & Policy Officer at GHLF. Our goal is to help you understand what’s happening in the healthcare world to help you make informed decisions to live your best life.

“The Health Advocates” is part of the Global Healthy Living Foundation Podcast Network and hosted by Steven Newmark.

What’s Been Happening In Global Health Policy

This week on The Health Advocates, host Steven Newmark takes a rapid-fire look at four major health stories shaping the future of healthcare in the United States and around the world.

China has entered the race to lead the World Health Organization, raising important questions about global health diplomacy, U.S. influence, and the future of international public health cooperation. Back at home, Medicare Open Enrollment is approaching, and patients need to understand how changes to their coverage could affect access to doctors and medications.

Steven also examines the alarming resurgence of measles in the United States, where confirmed cases have surpassed 4,000 this year, and explores how artificial intelligence is transforming medical billing, potentially creating new opportunities and challenges for patients.

From global health leadership to everyday healthcare costs, these stories share a common question: Are our healthcare systems putting patients first?

What’s Been Happening In Global Health Policy

00:00:00:07 – 00:00:10:11
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:10:12 – 00:00:46:17
Steven Newmark
Welcome to The Health Advocates, a podcast from the Global Healthy Living Foundation where we break down health policy and healthcare issues that matter most to patients and their families. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Today, we’re taking a quick look at several stories making headlines, both here in the United States and around the world. We’ll start with the significant development in global health diplomacy as China enters the race to lead the World Health Organization. Then we’ll turn to Medicare Open Enrollment and the alarming resurgence of measles. These are different stories, but each raises important questions about the future of healthcare and what it means for patients. Let’s get started.

00:00:46:19 – 00:01:08:12
Steven Newmark
Our first story takes us to the world of global health diplomacy, where a major leadership contest is taking shape. China has officially nominated Dr. Song Li to become the next Director General of the World Health Organization, or WHO. The nomination, confirmed on October 8th, brings the number of publicly identified candidates to seven, with an election scheduled for May 2027.

00:01:08:13 – 00:01:41:01
Steven Newmark
Dr. Song is a physician and public health official who previously held a senior position within China’s National Health Commission. She has more than two decades of experience in public health, including maternal and child health, international cooperation, and responding to infectious disease outbreaks. Now, under ordinary circumstances, an election for the head of the WHO might not attract much public attention outside global health circles. But these are hardly ordinary circumstances. The United States announced its withdrawal from the WHO in January of 2025, and declared that withdrawal complete just one year later.

00:01:41:04 – 00:02:15:13
Steven Newmark
The decision has created enormous financial and political challenges for an organization that coordinates international responses to health emergencies, develops public health guidance, and helps countries strengthen their healthcare systems. And China is increasingly stepping into the space that the United States has left behind. According to reporting from Health Policy Watch, China’s projected contributions to the WHO total approximately 320 million over the 2026 and 2027 budget period, much of that through mandatory contributions. China now represents the largest source of assessed contributions among WHO member states.

00:02:15:14 – 00:02:55:01
Steven Newmark
But here’s where the story gets interesting. This isn’t simply about who will run an international organization. It’s about the balance of power in global health. The WHO relies on cooperation among countries that often have very different political priorities and sometimes deeply conflicting interests. Its leadership navigates those differences while preserving the organization’s scientific credibility and independence. And that raises difficult questions. Would a Chinese Director General strengthen the WHO by bringing greater financial and diplomatic engagement from Beijing? Or would it deepen concerns about political influence, particularly following the controversy surrounding transparency in information sharing during the Covid 19 pandemic?

00:02:55:06 – 00:03:38:02
Steven Newmark
Lawrence Gostin, a leading global health law expert at Georgetown University, has warned that a Chinese Director General could further complicate the relationship between Washington and the World Health Organization, potentially making it more difficult for the United States to rejoin the organization in the future. Others point out that China has expanded its investments in public health systems, disease surveillance, and international health cooperation, and that WHO leadership should ultimately depend on qualifications and international independence rather than nationality. Those are important perspectives to consider. And just this week, several candidates participated in a public discussion at the World Health Summit in Berlin debating how the WHO should address financial pressures, strengthen its mission, and rebuild confidence amongst member countries.

00:03:38:03 – 00:04:08:03
Steven Newmark
But let’s bring this back to patients, which is where we live here at GHLF, because ultimately that’s what’s important. When we talk about global health governance, we’re not simply talking about diplomats sitting around a conference table in Geneva. We’re talking about how countries share information when a new infectious disease emerges. We’re talking about the development of international public health guidance, support for vaccination programs, and efforts to improve access to essential medicines. And we’re talking about whether the world can respond quickly and effectively when the next major health emergency occurs.

00:04:08:06 – 00:04:40:05
Steven Newmark
My view is whatever happens in the election, the WHO’s next leader will face a fundamental challenge: demonstrating that scientific evidence, transparency, and the health of patients remain at the center of its mission. We’ll be watching the election next spring as it develops in the coming months. Back here in the United States, our next story is about Medicare. Medicare Open Enrollment began on October 15th and continues through December 7th. This is the time when millions of Americans can review their healthcare coverage and make changes for 2027. And this year, there are some important developments worth paying attention to.

00:04:40:09 – 00:05:05:13
Steven Newmark
The Centers for Medicare and Medicaid Services, known as CMS, projects that average Medicare Advantage premiums will decline in 2027 while average premiums for standalone Medicare prescription drug plans will remain relatively stable. That sounds like good news. Actually, it sounds like great news. But at the same time, some insurers are reducing the number of plans they offer, meaning certain beneficiaries may have fewer choices or need to select a different plan altogether.

00:05:05:15 – 00:05:38:00
Steven Newmark
And here’s something we want to emphasize regularly at GHLF: a lower insurance premium doesn’t necessarily mean better healthcare coverage. For patients living with chronic conditions, the real question often involves access to specialists, prescription drug coverage, and the ability to continue treatments that are already working. Imagine someone with rheumatoid arthritis or Crohn’s disease who has spent months finding the right medication. What happens if that medication is no longer on their plan’s preferred formulary, or if their specialist is suddenly out of network? A change that looks relatively minor on paper could have serious consequences.

00:05:38:02 – 00:06:05:00
Steven Newmark
So if you have Medicare coverage, here are three things I encourage you to do. First, review your annual notice of change to understand how your current plan may change in 2027. Second, make sure your doctors, hospitals, and medications will remain covered. And third, compare your total potential healthcare expenses, not just your monthly premiums. You can review available plans at Medicare.gov and you could also get free assistance through your state health insurance assistance program.

00:06:05:04 – 00:06:27:06
Steven Newmark
One additional consideration: if you’re thinking of switching from Medicare Advantage to original Medicare, check whether you can obtain supplemental Medigap coverage before making that decision. The bottom line is simple: don’t assume that the coverage you have today will work exactly the same way next year. Taking a little time to review your options now could save you significant frustration and potentially significant expense in 2027.

00:06:27:09 – 00:06:57:07
Steven Newmark
Our last story this week is a troubling reminder that public health achievements require continued attention. The Centers for Disease Control and Prevention, the CDC, reports that the United States has now recorded more than 4,000 confirmed measles cases in 2026. That’s a remarkable and deeply concerning number. Remember, the United States declared measles eliminated back in 2000. That meant we had successfully interrupted continuous transmission of the disease within this country. And yet, more than 25 years later, we’re experiencing major outbreaks of a disease we know how to prevent.

00:06:57:10 – 00:07:38:14
Steven Newmark
Measles is one of the most contagious infectious diseases in the world. And contrary to what some people believe, it isn’t simply a childhood illness that produces a rash. Measles can cause pneumonia, neurological complications, hospitalization, and even death. For people living with certain chronic diseases, particularly those taking medications that suppress their immune systems, the consequences can be especially serious. Some immunocompromised individuals cannot safely receive live vaccines, including the measles, mumps, and rubella vaccine, depending on their specific medical circumstances. That means community vaccination rates matter enormously. Two doses of the MMR vaccine provide approximately 97% protection against measles. But when vaccination rates decline, outbreaks become more likely.

00:07:38:18 – 00:08:10:12
Steven Newmark
At GHLF, we work extensively on vaccine education and helping people make informed decisions about their health. And these outbreaks demonstrate why that work remains so important. If you’re unsure whether you’re protected against measles, speak with your healthcare provider. And if you’re immunocompromised, discuss your vaccination needs with the clinician managing your condition. My takeaway is that we should never take public health progress for granted. The elimination of measles was an extraordinary achievement. Preserving that achievement requires continued vigilance, strong vaccination programs, and public confidence in reliable scientific information.

00:08:10:18 – 00:08:34:11
Steven Newmark
So that’s our health news roundup for the week. We began with the changing dynamics of global health leadership, moved to the practical challenges of Medicare coverage, and examined the troubling resurgence of measles. Different stories but one common theme: whether we’re talking about international institutions, insurance companies, public health agencies, healthcare systems must ultimately serve the people who depend on them. At GHLF, that’s what drives our work every day.

00:08:34:12 – 00:08:59:16
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week and helps you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below. And be sure to follow us wherever you get your podcasts. You can find us on Apple Podcasts, Spotify, YouTube, or wherever else you listen to podcasts. Plus, you can find all of GHLF’s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:08:59:22 – 00:09:06:12
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

The Midterm Elections Are Over. What’s Next for Healthcare?

The 2026 midterm elections dramatically reshaped the political landscape, with Democrats winning control of both chambers of Congress and capturing several governorships across the country. While economic concerns, government accountability, and the war with Iran dominated the election, the results could have significant implications for American healthcare.

In this episode of The Health Advocates, host Steven Newmark breaks down the major election results, examines what drove voters to the polls, and explores how the new balance of power in Washington could affect healthcare policy beginning in 2027.

What happens next for Medicare, Medicaid, and Affordable Care Act subsidies? Will Congress increase its oversight of Health and Human Services Secretary Robert F. Kennedy Jr.? And could lawmakers find common ground on prescription drug costs and healthcare affordability?

Steven examines what may change, what will likely remain the same, and why patients should pay attention as the new Congress prepares to take office.

Plus, with flu activity increasing earlier than usual, we close with an important reminder about protecting yourself during the upcoming holiday season.

The Midterm Elections Are Over. What's Next for Healthcare?

00:00:00:07 – 00:00:10:04
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:10:06 – 00:00:51:16
Steven Newmark
Welcome to The Health Advocates, a podcast from the Global Healthy Living Foundation, where we break down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Well, this week we’re talking about the blue tsunami, otherwise known as Election Day 2026. The midterms are officially behind us, although votes are still being counted in a few races. And to say that Tuesday’s election was consequential would be quite the understatement. Democrats won total control of the House of Representatives and the United States Senate by comfortable margins, delivering a significant setback to President Trump and the Republican Party. Democrats also captured several governorships, including some in states that Republicans have controlled for decades.

00:00:51:21 – 00:01:24:14
Steven Newmark
Now, this is a healthcare podcast, not a political campaign show. But elections have consequences for healthcare, whether we’re talking about Medicare, Medicaid, prescription drug prices, scientific research, or the federal agencies responsible for protecting public health. Today, we’re going to look at what was at stake in the election, what happened on Election Day, and what these results might mean for health policy when the new Congress takes office in January 2027. And before we finish, we’ll turn our attention to some recent public health developments. Let’s get started.

00:01:24:16 – 00:01:59:17
Steven Newmark
First, a little context. Midterm elections take place halfway through a president’s four year term, hence the term “midterm.” Every seat in the House of Representatives, that’s 435, is up for election, along with approximately one-third of the Senate. And this year, voters also selected governors in 36 states. Republicans entered the election controlling the White House and both chambers of Congress. That meant President Trump had a significant advantage in advancing his legislative priorities, although narrow congressional margins sometimes complicated those efforts. Democrats were hoping to change that equation, and boy, did they ever.

00:01:59:20 – 00:02:28:16
Steven Newmark
Historically, midterm elections have often been difficult for the president’s party, particularly when voters are dissatisfied with the economy or the direction of the country. This year, the dissatisfaction was particularly widespread with the economy as the clearly dominant concern. And while healthcare wasn’t the leading issue in this election, it certainly was part of the larger conversation around the affordability question. After all, for millions of Americans, health insurance premiums, prescription drugs, deductibles, and medical bills represent enormous household expenses.

00:02:28:21 – 00:03:02:22
Steven Newmark
According to post-election research from the Kaiser Family Foundation, approximately 60% of voters said that they were very concerned about healthcare costs. And asked which political party could better handle healthcare, voters gave Democrats a substantial advantage. Most campaigns this season focused heavily on broader economic and political issues rather than healthcare per se. But healthcare did feature prominently in some races and political advertising, particularly debates about Medicare funding, the Affordable Care Act subsidies, and the cost of coverage did play a role. And as we will discuss, the results could have major implications for these programs.

00:03:03:00 – 00:03:31:21
Steven Newmark
So let’s start with the House of Representatives. Democrats needed a relatively small number of additional seats to regain control, and they did considerably better than that. The party flipped dozens of Republican-held districts, including some in areas that President Trump carried comfortably in the 2024 presidential election. Democrats are poised to have a very substantial majority in the House of Representatives, meaning they will not have to rely on cajoling some potential outliers within their party when it comes to passing legislation.

00:03:32:01 – 00:03:55:14
Steven Newmark
The fundamental result of the election is essentially settled. Democrats are going to control the House quite comfortably beginning in January. That means Democratic lawmakers will set the legislative agenda, control House committees, very important, and decide which issues receive hearings and investigations. House Democratic Leader Hakeem Jeffries is also positioned to become the next speaker of the House, potentially making history as the first black man to hold that position.

00:03:55:19 – 00:04:39:16
Steven Newmark
Now let’s turn to the Senate, where the results were perhaps even more surprising in some ways. Republicans entered the election with a 53-47 advantage, counting the two independents who caucus with the Democrats. So Democrats needed to gain four seats in order to take control of the Senate. They appear now poised to pick up 54 to 56 seats. There are still, as of this recording, two seats outstanding, that’s Mississippi and Alaska. Democrats also won in Republican strongholds of Texas, South Carolina, Iowa. They won easily in North Carolina, flipping that seat. They won very easily and comfortably in Georgia, which had been a reliable red state for many decades. So it was quite the victory when it came to the Senate.

00:04:39:19 – 00:05:33:11
Steven Newmark
Just going through it, in Texas, James Talarico defeated Ken Paxton in a state that has not elected a Democrat to the U.S. Senate in decades. In Ohio, former Senator Sherrod Brown defeated Republican incumbent John Usted, returning him to the Senate after losing his previous election in 2024. And again, going back to Iowa, Maine, South Carolina flipping, I didn’t even mention Kansas. And Democrats also defended important seats in places like Michigan. So this represents a real dramatic change in the political landscape. And similar to the House, having that comfortable margin of more than just 1 or 2 seats in the Senate will enable Democrats to have a little more cushioning when it comes to passing legislation and not having to rely on cajoling some outliers within the party on certain things. This also is important because it makes it even tougher for Republicans to try and retake the Senate in two years.

00:05:33:12 – 00:06:17:19
Steven Newmark
Let’s also talk a little bit about the governors in the states. The election produced significant changes in state government. Democrats flipped five Republican-held governorships. In Texas, Gina Hinojosa defeated longtime Republican Governor Greg Abbott, becoming the state’s first Latina governor. In Georgia, former Atlanta mayor Keisha Lance Bottoms won the governorship, becoming the first black woman ever elected in American history. In Ohio, Democrat Amy Acton, a physician and former state health director, won the governor’s race. In Iowa, Democrat Rob Sand won the governorship. And in Nevada, Democratic Attorney General Aaron Ford defeated Republican incumbent Governor Joe Lombardo. Democrats also successfully defended several closely watched governorships, including Michigan and Wisconsin.

00:06:17:22 – 00:06:58:00
Steven Newmark
So why does that matter for healthcare? Well, governors and state legislators play an enormous role in how healthcare actually works. States administer Medicaid, they regulate portions of the insurance market, they establish many public health policies, and make critical decisions about healthcare funding. Governors also determine how states respond to federal requirements, including changes to Medicaid eligibility. And public health issues such as vaccination policies, healthcare workforce shortages, and access to reproductive healthcare often depend heavily on decisions made at the state level. So although Congress will receive much of the attention, the changes in state leadership could prove equally important for patients in certain parts of the country.

00:06:58:01 – 00:07:53:11
Steven Newmark
So what does this mean for healthcare going into 2027? Let’s focus on four areas. First, Medicare and Medicaid. With Democrats controlling both chambers of Congress, the prospects for another major round of federal spending reductions affecting Medicare or Medicaid have diminished considerably, or pretty much gone down to zero. Democratic leaders have consistently opposed further cuts to these programs, and Republicans no longer have the congressional majorities that helped them pass major healthcare spending changes in 2025. Some provisions that came about in previous years, such as work requirements for certain Medicaid beneficiaries, are scheduled to begin in 2027. Democrats have indicated they want to repeal or substantially revise those changes, but doing so would require legislation, and President Trump could veto any bill that reverses a central part of his domestic agenda. So for patients, Medicaid beneficiaries, and state governments, significant uncertainty remains.

00:07:53:16 – 00:08:29:11
Steven Newmark
Second, let’s turn to the Affordable Care Act. Another major issue involves the enhanced premium tax credits that help many Americans afford health insurance through the ACA marketplaces. Those subsidies expired at the beginning of 2026. As a result, many people who purchased their insurance through the marketplaces have substantially higher premiums. Democrats have identified restoring those subsidies as a priority for the next Congress. But again, the question is whether they can reach an agreement with enough Republicans and the White House. The election increases the political pressure to address healthcare affordability, but it does not guarantee a legislative solution, of course.

00:08:29:15 – 00:08:58:06
Steven Newmark
Third, oversight over the Department of Health and Human Services, and this could be the most potentially intriguing and interesting one. Under RFK Jr., HHS has pursued major changes involving vaccine policy, scientific research, staffing, and general public health priorities. A lot of supporters see those changes as necessary reforms aimed at increasing affordability and addressing chronic disease, while critics have raised concerns about scientific independence, disruptions to public health programs, and the consequences for patients.

00:08:58:08 – 00:09:23:11
Steven Newmark
Starting in 2027, Democratic committee leaders will have considerably more power to investigate the decisions made at HHS. We could see congressional hearings involving Secretary Kennedy himself, involving senior officials from the CDC, FDA, NIH, and CMS. Lawmakers may request documents, they may question agency leaders, they may examine funding decisions, and they may scrutinize changes to vaccine recommendations and scientific advisory processes.

00:09:23:16 – 00:10:00:12
Steven Newmark
Congress also controls federal appropriations, giving lawmakers opportunities to influence agency funding and establish conditions on how certain funds are spent. The Senate will have an additional source of leverage through its power to confirm or reject presidential appointees. Now, oversight does not automatically mean that the administration is going to reverse any of its policies, but it does mean that HHS will face substantially greater scrutiny and potentially more constraints. For patients and advocates, the increased attention could create new opportunities to raise concerns about access to treatments, public health protections, and the role of scientific vaccine and evidence in federal decision making.

00:10:00:14 – 00:10:39:00
Steven Newmark
Fourth, prescription drug costs and health care affordability generally. Even with a divided government, there may be opportunities for bipartisan agreement. When it comes to the practices of pharmacy benefit managers, for example, or insurance transparency and certain Medicaid payment reforms, this could attract interest from both sides of the aisle. Democrats have discussed expanding certain drug price negotiations and pursuing other steps to reduce healthcare costs. Now, not every proposal is going to advance, and some are going to face serious political and fiscal disagreements. But these are issues where policymakers may find common ground. And from the standpoint of patient advocacy, that is worth watching.

00:10:39:03 – 00:11:13:05
Steven Newmark
So what’s the big takeaway from Tuesday’s election? Democrats are going to control Congress while President Trump will remain in the White House. Healthcare was part of the election, but it was not the dominant subject on Tuesday. The economy, affordability, concerns about government accountability and corruption, and the war with Iran all shaped the outcome. Further, healthcare consequences are going to unfold as a result of the election. We can reasonably expect greater congressional oversight, we could also expect fewer opportunities for large, sweeping new cuts to federal programs, and more attention focused on affordability generally.

00:11:13:07 – 00:11:39:10
Steven Newmark
But, and this is a big but, restoring previous Medicaid spending levels or the Affordable Care Act subsidies will require political negotiation. And those negotiations could prove difficult. The election changed who holds the power in Congress. It did not instantly change the law governing healthcare coverage. So the next two years will be about whether the new balance of power leads to meaningful improvements in affordability, access to care, and confidence in our public health institutions.

00:11:39:12 – 00:12:19:11
Steven Newmark
Before we finish, I just want to turn quickly to a public health story that deserves attention regardless of what’s happening in Washington. Flu season is getting underway. And as we discussed on this podcast earlier this fall, we’re seeing increased flu activity earlier than usual. According to the CDC’s latest available surveillance report, national flu activity remains relatively low, but several measures of the activity have been increasing since late August and early September. The CDC estimates that the season has already resulted in at least 1 million illnesses, 16,000 hospitalizations, and sadly, 900 deaths. So if you haven’t done it already, please go out and get your vaccine. Tell your friends and family to do the same.

00:12:19:12 – 00:12:42:14
Steven Newmark
Thanks for joining me on this special post-election edition of The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:12:42:16 – 00:12:49:08
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Giant Cell Arteritis: Recognizing the Signs and Living with the Diagnosis

Giant cell arteritis (GCA) is a serious inflammatory condition that affects blood vessels, primarily in adults over 50. Its symptoms can be difficult to recognize, and without prompt diagnosis and treatment, GCA can lead to serious complications, including permanent vision loss.

In this episode of The Health Advocates, host Steven Newmark speaks with Connecticut State Representative Tom O’Dea about his personal experience living with GCA. Representative O’Dea shares his journey from the first signs that something was wrong to receiving a diagnosis, navigating treatment, and managing the condition while balancing the demands of public service.

Together, they explore the challenges of recognizing a relatively uncommon disease, the impact of GCA on everyday life, and why greater awareness and early intervention are so important.

For more information about GCA, including symptoms, treatment options, research, and patient resources, visit https://ghlf.org/gca/.

Giant Cell Arteritis: Recognizing the Signs and Living with the Diagnosis

00:00:00:07 – 00:00:09:09
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:11 – 00:00:50:23
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Today, we’re talking about a condition that many people have probably never heard of, but one that could have serious, even life-changing consequences if doctors don’t recognize and treat it quickly. It’s called giant cell arteritis, or GCA. GCA is an inflammatory disease that affects blood vessels, particularly arteries, in the head and neck. It almost exclusively affects adults over the age of 50, and its symptoms can sometimes resemble those of much more common conditions. But GCA can also lead to permanent vision loss, which makes early recognition and treatment especially important.

00:00:51:01 – 00:01:32:23
Steven Newmark
We’re fortunate to have a guest who knows firsthand what living with this condition means. Connecticut State Representative Tom O’Dea is joining us to share his personal experience with GCA, from his first symptoms and diagnosis to treatment and the impact the condition has had on his life. But first, let’s spend a couple of minutes just explaining what GCA actually is and why awareness matters. GCA is a form of vasculitis, which is a medical term for inflammation of blood vessels. The disease frequently affects arteries around the temples, which is why people sometimes call it temporal arteritis, but can also affect other arteries throughout the body. Although GCA is relatively uncommon, it’s the most common form of vasculitis in older adults.

00:01:33:03 – 00:02:10:12
Steven Newmark
One of the challenges with GCA is that it’s early symptoms can be difficult to recognize. People may experience headaches, fatigue, fever, or just a general feeling that something isn’t right. Others develop tenderness around the scalp, pain the jaw when chewing, or changes in their vision. And that last symptom is particularly concerning. The inflammation caused by GCA can restrict blood flow to the eyes. Without prompt treatment, the disease can cause permanent vision loss. That’s why a new unexplained headache, particularly when accompanied by jaw pain or scalp tenderness in someone over 50, deserves urgent medical attention. Sudden changes in vision require immediate emergency care.

00:02:10:13 – 00:02:48:19
Steven Newmark
Diagnosing GCA can also present challenges. Doctors typically consider a patient’s symptoms and medical history along with blood tests and look for inflammation. They may also use ultrasound or other imaging, or perform a biopsy of the temporal artery. Treatment often begins with steroids, such as prednisone, to help bring inflammation under control quickly, but long-term steroid use can also have significant side effects, including changes in sleep, mood, blood sugar, and bone health. Doctors may also prescribe other medications, including targeted therapies to help manage the disease and reduce patients’ reliance on steroids. So there’s the disease itself, and then there’s the ongoing challenge of managing treatment and maintaining quality of life.

00:02:48:20 – 00:03:17:21
Steven Newmark
And that’s where today’s conversation takes us. We’re very pleased to welcome Connecticut State Representative Tom O’Dea. Representative O’Dea serves as the Deputy Republican leader in the Connecticut House of Representatives, representing the 125th district, which includes New Canaan and portions of Stamford and Darien. He’s also an attorney with a long career in public service. Today, we’re speaking with him about a different aspect of his life, his personal experience with GCA. Representative O’Dea, welcome to The Health Advocates, and thank you for being willing to share your story.

00:03:18:01 – 00:03:31:10
Representative Tom O’Dea
Good afternoon, Steven, and thank you very much for having me and allowing me to talk to people who may be suffering from GCA. I give you credit for being able to to read all that and pronounce it because I have a problem to this day still doing it. So thank you for having me.

00:03:31:12 – 00:03:36:22
Steven Newmark
Let’s start at the beginning. Take us back to when you first noticed something wasn’t right. What were you feeling?

00:03:37:00 – 00:04:10:09
Representative Tom O’Dea
Headaches really is what started me being most concerned. It was right before Christmas I started having headaches to the point where the day after Christmas, I went to a walk in clinic for headaches. And the doctor had given me some migraine medication. We ended up going to Montreal. And I was popping Tylenol and the migraine medication, and it wasn’t really working on the headaches. So I came home after a few days and went right to my doctor. She squeezed me in and she said, “Well, do you have any jaw pain?” And I said, “As a matter of fact, I was having problems with my jaw and I just didn’t really think much of it.”

00:04:10:09 – 00:04:49:14
Representative Tom O’Dea
And she went, “What about vision?” I go, “A little bit.” But, you know, I had had a detached retina, which, of course, I’m not the best patient in the world, so I ignored that. Back in April of 2014, I had a detached retina, ended up having to have four surgeries for that. I had my fourth surgery just recently that finally fixed it. But I was always having problems with my left eye to the point where, people laugh, I tried a case and I used this magnifying glass for depositions. I used it actually in court at trial. So the vision problems and the temporal headaches, I didn’t realize what was going on. And sure enough, my doctor, Dr. Berto, she saved my vision. She may have saved my life because she immediately put me on steroids, prednisone, and that helped.

00:04:49:15 – 00:04:52:11
Steven Newmark
And did she classify it as GCA?

00:04:52:12 – 00:05:12:05
Representative Tom O’Dea
She said, “You know, Tom, I think you may have GCA.” And I had no idea, I had never heard of it before. I’m like, “What’s GCA?” And she said, “Well, it’s giant cell arteritis.” And I’m like, “Giant cell-” I didn’t know. When I went home and did some research, it really frightened me. I was taken aback by the severe consequences if it goes untreated.

00:05:12:06 – 00:05:14:12
Steven Newmark
Yeah. No, absolutely. It’s scary, right?

00:05:14:13 – 00:05:50:14
Representative Tom O’Dea
Yeah. It was January. So Christmas time of last year, so December of 2025, I had the headaches, went to Montreal, went to a migraine specialist because they weren’t sure about the GCA diagnosis. So I was going back and forth. But the doctor, thankfully, she put me on the prednisone. And then they were trying to confirm it. So they did surgery on the temple to take out part of a vein. It’s one of those diagnoses because I was on so much prednisone, a lot of times you can’t tell because it’s already shrunken the vein because of the prednisone. But over time, she confirmed the GCA. So thankfully, I’ve been weaning off the steroids. Being on steroids for a long period of time is not good.

00:05:50:15 – 00:06:13:18
Steven Newmark
Yeah. As we know, our listeners definitely know that. We talk about the long-term effects of steroid use. So let me ask, let’s move to beyond the diagnosis and just living with GCA and managing treatment. As we all know, living with a chronic inflammatory condition can affect everything from your energy level to your daily routines. How has GCA and the treatment that you’re on, or the treatment that you’ve been on changed your day-to-day life?

00:06:13:21 – 00:06:31:14
Representative Tom O’Dea
I will say, my wife certainly noticed that my irritability was high and I felt myself being quite frustrated, angry easier. So that was the biggest impact, quite frankly, and my doctor said it was the steroids that was most likely causing that. But yeah, the lack of sleep. It was a tough few months in particular.

00:06:31:16 – 00:06:40:16
Steven Newmark
And you’re balancing all of this with your responsibilities as a state legislator, as an attorney. Those are demanding jobs, even without managing a chronic medical condition.

00:06:40:18 – 00:07:01:22
Representative Tom O’Dea
And put on top of it, my retina problems and my vision problems. It’s been a tough eight months. It’s gotten a little better over the last couple with my fourth eye surgery to fix most of my vision in my left eye. And with tapering off the steroids, I’m down to one milligram a day of the steroid. And hopefully by next week, I’m going to see my doctor and go off the completely.

00:07:02:04 – 00:07:29:17
Steven Newmark
Okay. Well that’s good that you’re able to, you know, start to manage the symptoms, which of course is crucial. As we start to wrap up, I want to come back to something discussed at the beginning of the episode. Most people have never heard of GCA, and many of its initial symptoms, like headaches or fatigue, are things that people might dismiss or attribute to something else. You’ve been through with the experience of recognizing symptoms, receiving a diagnosis, and now managing the condition. If you could tell someone over the age of 50 one thing about GCA, what would it be?

00:07:29:21 – 00:08:05:16
Representative Tom O’Dea
Hopefully you have a good doctor. If you’re having bad headaches, don’t just dismiss it. I was lucky my doctor was able to ask the right questions about my jaw pain that I just kind of didn’t even realize it was related to what was going on with the GCA. The advice I would have is, you know, if you’ve got headaches, you’ve got problems that is not normal, you’re not feeling normal, whether it’s your vision, the headaches, jaw pain, go to your doctor, get it checked out. Because untreated, it leads to blindness and death. It is a serious condition. It scares you. But I would tell particularly those over 50 that if something’s bothering you, particularly around your eyes, your head, go see your doctor, don’t be afraid.

00:08:05:19 – 00:08:32:17
Steven Newmark
Yeah, I think that’s an important message. And it’s really at the heart of why we wanted to have this conversation. One of the most valuable and powerful things we can do as patient advocates is to help people understand when their symptoms deserve more attention and encourage them to ask questions and seek appropriate care. And when people like you, particularly someone so esteemed in the community, shares their experiences, you help make a relatively unfamiliar condition more recognizable to others. So Representative O’Dea, thank you for joining us and being so open about your experience.

00:08:32:20 – 00:08:56:15
Representative Tom O’Dea
No, thank you for having me. Thank you for what you do. Educating people on rare diseases is so important. And GCA in particular, I’m honored that you would reach out and allow me to speak to people about it. You know, even if we can save just one person with what you’re doing, it’s a wonderful thing you’re doing. You should be very proud of yourself and your staff. I’m very happy to be here and encourage your listeners to go see your doctor if something’s unusual. But I really do appreciate all you’re doing.

00:08:56:16 – 00:09:11:14
Steven Newmark
Yeah, absolutely. GCA may not be a household name, but recognizing its warning signs could help protect your vision. And again, for more information about GCA, including educational materials, research, and patient stories, please visit ghlf.org/gca.

00:09:11:16 – 00:09:37:04
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below and be sure to follow us wherever you get your podcasts. We’re on YouTube, Spotify, Apple, and everywhere else you can find podcasts. You can find all of GHLF/s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:09:37:06 – 00:09:43:21
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

The New Dementia Patient: Rethinking Diagnosis, Treatment, and Care

The science of Alzheimer’s disease and dementia is changing rapidly. Advances in biomarkers, diagnostics, treatments, and prevention could allow clinicians to identify disease earlier than ever before, sometimes even before noticeable symptoms emerge.

In this special episode of The Health Advocates, recorded for Steven Newmark’s visit to London for the 2026 World Dementia Council Summit, Steven explores what this new era could mean for patients, caregivers, and health systems.

What happens when someone receives a diagnosis before they feel sick? Are health systems prepared for greater demand for testing and treatment? How could AI, digital tools, and biomarkers change dementia care? And how do we make sure scientific progress reaches patients equitably?

Steven examines why the next challenge in dementia may not simply be advancing the science, but building the policies, infrastructure, workforce, and patient support needed to put that science into practice.

The New Dementia Patient: Rethinking Diagnosis, Treatment, and Care

00:00:00:07 – 00:00:10:09
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:10:11 – 00:00:38:06
Steven Newmark
Welcome to The Health Advocates. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Our goal is to help you stay informed to make the best decisions to live your healthiest life. This week, I’m in London for the 2026 World Dementia Council Summit at the Francis Crick Institute. And the theme of this year’s gathering captures just how dramatically the conversation around Alzheimer’s disease and dementia is changing. It’s called “The New Patient: Before Symptoms, After Diagnosis.”

00:00:38:08 – 00:01:03:07
Steven Newmark
For decades, when we talked about dementia, we were usually talking about a condition diagnosed after someone had already developed noticeable cognitive symptoms. But science is changing that timeline. Advances in biomarkers, diagnostic tools, treatment, and our understanding of risk are creating the possibility of identifying Alzheimer’s disease much earlier in its progression, potentially even before someone experiences obvious symptoms.

00:01:03:09 – 00:01:33:07
Steven Newmark
And that raises enormous questions. What happens when our ability to identify disease moves faster than the symptoms we have built to care for people with it? That’s one of the central questions bringing leaders from science, medicine, public health, government, advocacy, and health systems together here in London this week. And it’s also an important question for patients and their families, because you or a loved one might be someone that develops Alzheimer’s someday. And that’s tough to think about. But we want to see some advances when it comes to treatments.

00:01:33:09 – 00:02:12:10
Steven Newmark
An earlier diagnosis can create better opportunities for all of us. It can give us more time to understand what’s happening, more time to make decisions about your health and your future, and it can create opportunities for earlier treatment and for interventions aimed at reducing risk or slowing progression. But earlier diagnosis also raises new challenges. What exactly do we tell someone who has a biological evidence of Alzheimer’s disease but may still feel perfectly healthy? How do we explain risk and uncertainty? What happens after diagnosis? And how do we make sure that earlier detection actually leads to better care, rather than simply giving someone information without the support or treatment that they need?

00:02:12:13 – 00:02:42:20
Steven Newmark
Those questions go well beyond the laboratory. They require us to think differently about the entire dementia care pathway. If more people seek testing, health systems need the capacity to evaluate them. If biomarkers become increasingly important, patients need access to those tests. If new treatments become available, health systems need clinicians who can prescribe and monitor them. And if people begin living for longer periods knowing that they have early stage of disease, we will need new models for ongoing care, counseling, monitoring, and support.

00:02:43:00 – 00:03:24:05
Steven Newmark
There is also a broader public health conversation taking place around brain health. We spend a lot of time here at GHLF talking about all different kinds of conditions. One of them is heart health. We understand things like blood pressure, physical activity, smoking, and other factors and how they can influence cardiovascular risk over many years. Increasingly, however, researchers and public health leaders are asking whether we need a similar approach to brain health across the lifespan. What can people do to reduce their risk of Alzheimer’s and other brain diseases? When should those conversations begin? And how do we communicate prevention without suggesting that every case of dementia could somehow have been avoided? That balance is incredibly important.

00:03:24:08 – 00:03:56:22
Steven Newmark
Another major issue is technology. Biomarkers, digital testing, remote monitoring, and AI could fundamentally change how we identify and follow cognitive decline. Those technologies could expand access and make care more efficient. But technology also raises familiar questions. Who gets access? Who pays for the access? How do we make sure the tools work across different populations? And could advances that are supposed to expand access actually widen disparities if they are concentrated in wealthy health systems or among people who have already strong access to specialty care?

00:03:57:03 – 00:04:25:13
Steven Newmark
The last question is particularly important. Scientific progress only becomes meaningful public health progress when patients can actually benefit from it. A breakthrough diagnostic test that patients cannot access is not enough. That is why gatherings like the World Dementia Council Summit matter. The challenge is no longer simply whether we can develop better science. It is whether our policies, health systems, payment structures, workforce, and patient support systems can evolve quickly enough to put that science into practice.

00:04:25:17 – 00:04:56:03
Steven Newmark
And there’s another piece of this conversation I think we sometimes underestimate: what patients themselves actually want. As testing becomes easier and public awareness increases, more people may actively seek information about their cognitive health. Some will want to know as early as possible. Others may not. People have different views when it comes to testing, treatment, risk, and how much certainty they are comfortable living with. That means patient engagement simply cannot come at the end of the process. Patients and caregivers need to help shape these systems as they are being built.

00:04:56:07 – 00:05:30:10
Steven Newmark
For those of us working in patient advocacy, this moment also presents an important opportunity. Advocacy has traditionally focused heavily on raising awareness, increasing research funding, supporting caregivers, and improving access to care. And those, of course, remain critical. But the advocacy agenda is expanding. We now also need to be part of conversations about access to diagnostics, treatment, infrastructure, reimbursement, workforce capacity, health equity, and how we communicate increasingly complicated information about risk and disease. In other words, scientific progress changes the advocacy landscape, too.

00:05:30:12 – 00:05:57:21
Steven Newmark
I’ll be listening closely to those conversations here in London, because ultimately, the most important question isn’t simply how much the science of dementia has changed. It’s whether we can translate that progress into something meaningful for the millions of people and families affected by these diseases. Earlier diagnosis, better treatment, better prevention, better support, and health systems capable of delivering all of them fairly, that is the challenge of the next era in dementia. And it is a conversation that is only beginning.

00:05:57:23 – 00:06:24:02
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below. And be sure to follow us wherever you get your podcasts. You can find us on Apple, Spotify, YouTube, or anywhere else podcasts can be found. And you can find all of GHLF’s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:06:24:03 – 00:06:30:16
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Could a Blood Test Change Colorectal Cancer Screening? What Patients Should Know

Colorectal cancer screening can save lives, yet millions of eligible Americans still do not complete recommended screening. Could a simple blood draw help reach some of the people who currently go unscreened?

In this episode of The Health Advocates, Steven Newmark speaks with Dr. Sam Asgarian, Chief Medical Officer at Guardant Health, and Oliver Rocroi, Advocacy Relations Officer at Guardant Health, about the emerging role of blood-based colorectal cancer screening.

They discuss how these tests work, who may qualify, their benefits and limitations, what happens after a positive result, and how blood-based testing fits alongside colonoscopy and stool-based screening. The conversation also explores the broader public health question of whether giving people additional screening options could help overcome barriers and lead to more cancers being detected earlier.

Plus, Oliver rejoins the program with an important update on recent changes to the U.S. Preventive Services Task Force and what those developments could mean for future consideration of newer colorectal cancer screening options.

The message for patients remains simple: understand your risk, know your screening options, and talk with your healthcare provider about the approach that makes sense for you.

Could a Blood Test Change Colorectal Cancer Screening? What Patients Should Know

00:00:00:07 – 00:00:08:17
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:08:19 – 00:00:30:05
Steven Newmark
Welcome to The Health Advocates, a podcast from the Global Healthy Living Foundation where we break down major health news of the week to help you make sense of it all. Today, we’re talking about colorectal cancer, which remains a major public health challenge. But screening gives us an important opportunity to find cancer earlier and in some cases, identify changes before people ever develop symptoms.

00:00:30:06 – 00:01:02:06
Steven Newmark
The challenge is that millions of Americans who should receive colorectal cancer screening do not complete it. For some, the barriers involve preparation, scheduling, transportation, discomfort, or simply putting off something that does not feel urgent when you feel perfectly healthy. Now, blood-based tests have entered the colorectal cancer screening landscape, creating another potential option for some adults. Today, we’re going to talk about what these tests actually do, who they may help, and what making screening easier could mean for the cancer prevention and public health.

00:01:02:10 – 00:01:22:08
Steven Newmark
We’re joined by two people with great information and great impact in this area. First, we have Dr. Sam Asgarian, who’s the Chief Medical Officer from Guardant Health, one of the manufacturers of a blood-based screening tool, and Oliver Rocroi, who does advocacy for Guardant Health. Sam and Oliver, thank you so much for being with us today.

00:01:22:10 – 00:01:24:02
Dr. Sam Asgarian
Thank you for having us. Appreciate it.

00:01:24:03 – 00:01:25:12
Steven Newmark
Thank you. Steven.

00:01:25:14 – 00:01:36:16
Steven Newmark
We’ll start with Sam. Could you give us a little background of how you came to where you currently are, some of your medical background in the area of colorectal cancer, and what led you to Guardant?

00:01:36:21 – 00:02:03:00
Dr. Sam Asgarian
Yeah, absolutely. Happy to. So I’m an internal medicine doc by training and background. I went into kind of the vocation of medicine, really to practice things around early detection and prevention. So that truly meant actively acting as a primary care provider, right? Keeping people healthy, preventing them from getting sick, and when they are sick, getting them hopefully the fastest route to dealing with what they’re dealing with and then ultimately getting back to a higher state of health. That’s been a phenomenal clinical path.

00:02:03:01 – 00:02:34:16
Dr. Sam Asgarian
And then on the non-clinical side, is I moved out of the practice of medicine. It’s the same work. It’s building tools and solutions like this for physicians, whether they’re primary care providers or specialists that allow them to detect disease early, treat it, and get people back to maintaining that high state of health. And so colorectal cancer is an easy one, because it is one that has such a high survival rate when you catch it early. There are screening solutions. And then giving physicians blood-based testing for colorectal cancer has been something amazing and something that we’re excited to talk about today.

00:02:34:18 – 00:02:42:17
Steven Newmark
And Oliver, can you tell us a little about what you do to help ensure that more Americans have access to these great tools that are available?

00:02:42:19 – 00:03:10:10
Oliver Rocroi
Yeah, happy to. Thank you, Steven. So in my capacity, I lead US government affairs for the company. And really what that is, is the front line advocates, trying to expand patient access either through legislation or regulation at both the federal, state, and local levels. Really, in that capacity, it’s about ensuring that reimbursement pathways for advanced diagnostics like ours remain competitive and again, that patients have access to timely innovation in the most beneficial way possible.

00:03:10:12 – 00:03:19:22
Steven Newmark
Excellent. Before we get into blood testing, let’s start with colorectal cancer itself. How significant of a health problem is colorectal cancer in the United States?

00:03:20:00 – 00:03:53:11
Dr. Sam Asgarian
It’s a significant one. You know, cancer in general is something that we are always struggling to work against and to fight. Colorectal cancer specifically, number two leading cause of death in the United States due to cancer. Number one leading cause of death for those that are 50 and younger. And so it’s one of those that really is an issue that we’ve got to face. The good news is when it’s caught early, again, 91% chance of survival. The problem is when it’s caught later it’s a 14% chance of survival. So it is really one of those that we work really hard to detect early and improve the odds of survival for those that do face this disease.

00:03:53:12 – 00:04:10:07
Steven Newmark
Wow. I mean, that’s quite a spread. 14% versus 91%. I mean, it really does show the need for detecting colorectal cancer earlier. So, Oliver, why are so many Americans not getting screened? Why is that 14% number even out there?

00:04:10:12 – 00:04:40:05
Oliver Rocroi
I think, unfortunately, the honest answer is none of us are very good about taking care of our individual health. My wife likes to remind me that I will live longer because I’m married to her. And because of her, I will actually follow through on recommended screening, annual physicals, that sort of thing. But more seriously, I think especially for CRC, if you’ll allow me to take a quick step back, prior to 2010, which was the passage of the Affordable Care Act, there was no universal requirement to provide preventative services for every insured American.

00:04:40:06 – 00:05:17:07
Oliver Rocroi
That paradigm changed after the passage of that law, and very specifically, it required no co-pay, so free of cost to the patient, screening for the five cancers that currently have guideline recommended screening: colorectal, lung, breast, cervical, and prostate. That increased screening rates a little bit. But I think overall the biggest challenge is a question, like everything else in life, time, access, how close you are to a center that offers a colonoscopy, how willing you are to take the time to remember that you need to be screened starting now at the age of 45, it used to be 50. So combination of reasons.

00:05:17:07 – 00:05:35:10
Oliver Rocroi
But if I could sum it up in one word, it’s mostly the fact that, again, most of us are not very diligent about taking care of our health until it’s too late. We often only go to the doctor when something hurts. We should be better about trying to go to the doctor preemptively to make sure that we don’t get to the point where we have symptoms or things start to hurt.

00:05:35:14 – 00:06:31:23
Steven Newmark
Right. And if I could just chime in, just the idea that you turn 45 and the recommendation is to get a colonoscopy, if you have no symptoms and have never gotten a colonoscopy, there’s a lot of fear involved. You’re dealing with a minimum of day off of work, really a day and a half, because you’ve got to deal with the prep that’s involved when it comes to a colonoscopy. Not everyone is capable of doing that. And those who are, it’s still somewhat of a burden. There’s the fear of you will be sedated. So you’re going under, so to speak. There’s that fear. It’s an invasive procedure of sorts. There’s that aspect to it. It’s not fun. I’ve had colonoscopies. It’s not really a fun experience, particularly the prep work for it. So the idea that there are advances for screening for something like colorectal cancer, that really can lead to positive outcomes is such a great breakthrough. But of course, the challenge is not simply developing these technologies. We need to make sure that these screenings are accessible and achievable for most people.

00:06:32:01 – 00:06:52:21
Dr. Sam Asgarian
Exactly. And I think that’s the goal, right? As much as we’ve built something that’s phenomenal, it’s whether people use it or not that ultimately becomes the value that it provides, right? So from a healthcare perspective, it was very frustrating knowing you had this amazing test, but you had to convince people to go and use it. And if they felt fine, that ability to convince them was much more difficult.

00:06:52:23 – 00:07:14:04
Steven Newmark
Right. It is essentially just a higher barrier. So let’s get into the actual blood-based colorectal cancer screening test. Let’s walk through it. We have the option now for a blood-based cancer screening. What does that mean? What does it look for? How can evidence of cancer developing the colon or rectum appear in someone’s bloodstream? What does the test tell us, and what does it not tell us?

00:07:14:10 – 00:07:46:08
Dr. Sam Asgarian
Yeah. It’s amazing science, right? What we did was we said, great, they’re all of these advances and innovations in sequencing DNA. So we just can do it to ourselves. We have different use cases. Obviously a lot of people know it from prenatal testing, right? If I can see if there’s issues with the fetus, I can use blood to obviously capture that signal and then provide those results. Well, if we see that and we’re able to do that, we can also just look at the blood for other issues without having to think about pregnancy, right? Just in general life issues. And one of those is cancer.

00:07:46:08 – 00:08:34:22
Dr. Sam Asgarian
And the science behind it is basic biology, right? A tumor has to grow. And in order to grow, it has to shed what it wasted as it grows somewhere. And here that’s the bloodstream. So it is growing, it is kind of multiplying, whether it’s early stage or late stage, that’s going into the bloodstream. And when we take a blood sample, we’re sequencing all of the different molecules that are in that sample. And we’re looking for tumor DNA and specifically tumor DNA that we feel came from the colon, right? So we can tell a physician and the patient definitively there’s something in the blood that shouldn’t be there. And we believe very strongly, based on all the work that we’ve done, that that’s colon cancer. That gives everyone kind of the confidence they need to then go and confirm what the blood test is saying and then start treating it if it’s confirmed.

00:08:34:22 – 00:09:07:11
Dr. Sam Asgarian
And that’s no different than any other kind of clinical pathway where you use blood tests, right, to get to an answer. The good news too is if it doesn’t find anything, the test is so strong that that really, truly means that the person doesn’t have colon cancer. So they can go back to their regular life for, you know, the next three years and then come back and get screened again when that time is due for them to get screened one more time. So it’s using kind of really neat DNA technology and then ultimately built into the way the physicians use blood tests today as it is to give them one more really cool tool in their toolkit.

00:09:07:13 – 00:09:34:01
Steven Newmark
It’s amazing. I almost want to ask why would someone not choose to get this test? But we’ll leave that rhetorical and get into some of the policies as to why that might be in a bit. What happens next? So you told us what a negative result means, which is really fantastic. Where does the colonoscopy come into play? Does this fully replace a colonoscopy or does a positive result still then send the patient into a need to obtain a colonoscopy for more scoping.

00:09:34:07 – 00:10:06:07
Dr. Sam Asgarian
That’s, you know, where you described the pros and the cons of the colonoscopy. One of the biggest pros, of course, is that it’s such a great screening test that it also can treat if it finds something suspicious at the same time, right? That’s very rare. Like an X-ray doesn’t do that. An X-ray tells you that a bone is broken, but you can’t use the X-ray to treat the broken bone. But a colonoscopy tells you, hey, there’s cancer there. And because you’re there, you’re at the site, you can remove the suspicious tumor. You can start to kind of biopsy it to confirm. You can do things because you’re physically there.

00:10:06:08 – 00:10:54:12
Dr. Sam Asgarian
And so yes. So a positive blood test for the Shield Blood Test then means that you have to get a colonoscopy. But that colonoscopy, it’s much more of a direct, “I’m looking for something. I want to be able to find it and treat it.” And then from a patient perspective, you can imagine if they had any kind of trepidation about getting that colonoscopy before, it really goes away, because now they’re thinking, “Okay, even though I feel fine, something was in my blood and we got to take care of it.” No different than, you know, again, when you treat a patient that feels fine, but their glucose levels are really high and you’re like, “You may have diabetes.” And they’re like, “Okay, well let’s treat that,” right? So you start to get that adoption from the patient perspective. And from a physician perspective, you’re still just treating them the same pathway and providing the colonoscopy now. You’re just a little bit more confident that that colonoscopy is really there to treat something that isn’t, you know, what you expected to be there.

00:10:54:13 – 00:11:24:23
Steven Newmark
Absolutely. I think you kind of hit on something that’s really key for the individual patient, the idea of getting a colonoscopy or, you know, any major procedure, is very different when there’s an actual cause or an underlying reason to do so, more than just “We want to take a look.” So I want to zoom out from the individual patient and talk a little bit more about the public health opportunity. So, Oliver, if we suddenly have another screening option that involves something as familiar as having blood drawn, what could that mean from a public health perspective?

00:11:25:01 – 00:12:13:21
Oliver Rocroi
It’s a great question, Steven. I think, you know, overall, from a public health perspective, this is a tale as old as time, right? That prevention and earlier disease detection can have a more measurable long-term impact than treating disease after the fact. One quick statistic to highlight that point, there was an NIH study, National Institutes of Health Studies, that showed that between 1975 and 2020, so over 45 year period, screening and prevention prevented more deaths from the five cancers that have guideline recommended screening than the therapies that address those cancers, right? So again, it just highlights the fact, Sam said it earlier, especially for CRC, the earlier you detect it and the earlier you can address any indication, precancerous lesions, advanced adenomas, etc. the more manageable that disease becomes.

00:12:13:22 – 00:12:53:12
Oliver Rocroi
So from a public health perspective, we know that today in the US, unfortunately, there are roughly 50 million Americans that remain unscreened or under screened. So these are people that maybe have gotten screened one time and then never followed up with either a colonoscopy every ten years or a noninvasive test every three years. Or people that have had a conversation with a physician, in some cases for decades, and just have not completed the actual steps of getting screened. Obviously, you’re right, the very easy answer to your question, by making it somewhat more accessible for people to get screened, we can bend the curve on the number of people that remain unscreened.

00:12:53:13 – 00:13:34:14
Oliver Rocroi
We will never, and we’ve got to be humble about this, even a test like ours, unfortunately, we will never be able to get to 100% of screening rates. But the national average set by the American Cancer Society is that we should try to do our best to get to 80% of guideline recommended screening for eligible-aged Americans. Right now, the national average is about 62%. So we believe and we’re very optimistic that, again, the introduction of a modality like ours, and we are very proud to have been the first company to receive FDA approval, there are others, there will be more, hopefully, the more options in the toolkit, as Sam said earlier, the more we can collectively tackle this issue.

00:13:34:15 – 00:14:08:10
Oliver Rocroi
But yeah, from a public health standpoint, we’re very optimistic that, again, we can reduce that number of Americans that remain unscreened, get people more compliant with the idea of getting screened, and maybe more importantly, get comfortable with the idea that maybe a blood test is right for you today. Maybe three years from now, you use another noninvasive test. Stool tests are the most common. Maybe you start getting a colonoscopy every ten years. But at the end of the day, it’s about a test that gets done and a heightened awareness about the need and the benefits for Americans to be better and more compliant with recommended screening.

00:14:08:12 – 00:14:16:04
Steven Newmark
So in terms of eligibility, Oliver, can you give us a basic overview of eligibility when it comes to this important test?

00:14:16:06 – 00:15:20:09
Oliver Rocroi
Sure, Steven, of course. So the eligibility criteria for most cancer screening, including colorectal, is determined by the development of clinical guidelines that are developed either by professional societies like the American Cancer Society, which I think is one that everybody is familiar with. And in particular, I mentioned earlier that the Affordable Care Act had expanded no-cost access to preventative screening for every eligible insured American. That access is gated by some guidelines that are developed by a federal agency called the United States Preventive Services Task Force. And that’s a bit of a mouthful. But in 2010, when Congress enacted the Affordable Care Act, that again set the laws for what insurers are required to offer patients, they delegated the job of updating those guidelines to the USPSTF in the hopes that the USPSTF, and this is written in the law for the Affordable Care Act, would at least once every five years, examine each of the recommendations and update them as necessary based on new science, new technology, new innovation.

00:15:20:11 – 00:16:11:05
Oliver Rocroi
The challenge that patients face today for broader access is that those USPSTF guidelines are outdated. They were last updated in 2021. Tests like ours were approved by the FDA in July of 2024. And so there’s a bit of a gap right now between the most updated guidelines nationally and other society guidelines. The American Cancer Society, for example, updated theirs earlier this year. And what I’m really talking about here now is not necessarily the eligibility, which is the age and how often you should screen, but it’s more the types of tests that are allowable. So today under the USPSTF guidelines, you start screening at 45. If it’s a colonoscopy, which is an allowable test, you screen every ten years. If it’s a noninvasive test, the most common is a stool test, you screen every three years.

00:16:11:05 – 00:16:39:23
Oliver Rocroi
But unfortunately, those guidelines do not allow for this new type of test like ours, a blood modality. So Sam touched on it earlier, we’re spending a fair amount of time in hoping that patient advocacy groups would support our efforts to encourage the Health and Human Services Agency to have the USPSTF meet, look at the evidence, look at the science, look at the new innovation, and hopefully update those guidelines to allow blood as a type of allowable test within the existing guidelines.

00:16:40:03 – 00:16:48:00
Steven Newmark
So important question for our audience. What role can patient organizations and community groups play in getting the word out there about this test?

00:16:48:05 – 00:17:29:19
Oliver Rocroi
I think groups like the Global Healthy Living Foundation and any of the disease-specific patient groups have the fundamental role of really helping educate patients, raising awareness, and then advocating for, not unlike this conversation, more awareness about what’s new and available. We have the luxury of working for a company that is dedicated to beating cancer through the blood tests that we make. So we are up-to-date with the latest and greatest science. Not every American is, not every policymaker is, not every regulator is. So I think patient advocacy organizations really play a role in helping to highlight the challenge, the opportunity, and then the shared solution to address the problem.

00:17:29:21 – 00:17:38:07
Steven Newmark
So if someone listening is 45 or older, has been putting off colorectal cancer screening, and hears this conversation, what should they do next?

00:17:38:09 – 00:18:30:21
Dr. Sam Asgarian
Have that conversation with your doctor. There are new ways to get screened, like the Shield Blood Test, that you may not have thought of, that you may not be aware of. Have that conversation about what the right test is for you at that stage in your life, right? And work to get screened, right? To Oliver’s point, the goal of all of this is to get screened, because as long as you get screened, then it’s one less thing that you’ve got to worry about. One thing that you can check off of your list of things that may be there, that even though you don’t feel it, is starting to kind of accrue because you’ve reached a certain age in life. And you’ve got to address it. And if they have that conversation with their doctor, and it’s the first step towards getting screened, and then if they do get screened, if it’s positive, good news you got screened early, and you have the opportunity to start to treat this disease. And if it’s negative, then relax and then come back when it’s time to get screened again and have that conversation again about, is this the same test that I want to take or what are my other options?

00:18:31:02 – 00:19:04:10
Oliver Rocroi
Steven, if I could add one note into there. I think the other importance about having that initial conversation with your doctor is he or she will be able to determine some very important factors that also go into the screening dynamic. Do you have family history? Are you high risk? Do you have symptoms? Are there things that are going on in your life that allow you to maybe get a colonoscopy in a more easy manner? Because, you touched on it earlier, you’re employed, you could get a ride, you live in an environment where access to a colonoscopy is reasonable. If not, maybe a stool test that gets mailed to your house is an option.

00:19:04:11 – 00:19:43:12
Oliver Rocroi
If that isn’t an option, maybe going down the hallway and having a blood draw right then and there is the option. But again, it’s that initial conversation that determines, one, the awareness level, two, engages you as an individual consumer of healthcare to go, “Oh yeah, that’s right.” Because I assume, I presume I should say, that the vast majority of even the people listening to this podcast don’t wake up in the morning with a checklist going, “Gee, am I up to date on colorectal? Am I up to date on my mammogram? Am I up to date on this?” Right? Most of us again are not that disciplined about things. So again, that initial doctor visit allows you to raise that awareness level and then determine which option is the best suited for you and your lifestyle.

00:19:43:14 – 00:20:16:00
Steven Newmark
Yeah, it’s really incredible. I mean, to sort of put a fine point on this conversation, prevention is really the key here. It’s better to prevent something, catch it early, certainly, than to deal with it down the road. You don’t want to be at that 14% number. If something were to develop, you want to be in that 91% number, right? And with something as simple as a blood test to help you identify that, you’ve got to take advantage. You’ve got to take control of your health. So with that, thank you both so much for your time today. This is an important conversation. Any final words of wisdom for folks out there?

00:20:16:02 – 00:21:00:14
Oliver Rocroi
I have one, and I’m going to kick it over to the doctor. I think we would be remiss if in the course of the conversation, we don’t highlight the fact that noninvasive tests, and Sam touched on it earlier, whether it’s our test or any other noninvasive test, the initial screening after a positive indication requires you to get a colonoscopy. So we also, whether it’s our company, patient advocacy groups, regulators, policymakers, everybody involved in this conversation, has a shared responsibility in ensuring that anybody that gets screened with a noninvasive test is navigated towards that diagnostic colonoscopy so that we can intervene, right? Because we could go out and screen 2 million people tomorrow. If none of those positive follow up with a colonoscopy, it’s like screening nobody.

00:21:00:18 – 00:21:35:08
Steven Newmark
Yeah, absolutely. And I think like we were seeing earlier, some of those barriers are a little overcome if you will, if you have a more immediate reason to be getting the colonoscopy, if something shows up and the doctor is now telling you this is somewhat critical. And it’s interesting, as Dr. Asgarian was saying, with a colonoscopy, you’re doing both looking for the cause but also potentially treating it simultaneously. So now you’re asking someone to get a colonoscopy that includes potential treatment which changes the equation somewhat and hopefully lowers that barrier or increases the desire to go along with that.

00:21:35:09 – 00:21:36:03
Dr. Sam Asgarian
Exactly.

00:21:36:07 – 00:22:20:01
Steven Newmark
Before we wrap up this episode, we want to add a brief update because something significant happened after we recorded our original conversation. The Department of Health and Human Services recently announced eight new members of the US Preventive Services Task Force, or the USPSTF, including a new chair. That name may sound bureaucratic, but the task force plays an important role in evaluating the evidence behind preventive services, including cancer screening, and its current colorectal cancer screening recommendation dates back to 2021, before some of the newer blood-based screening options we’ve been discussing were available with the evidence that we have today. Oliver Rocroi from Guardant Health has rejoined us for a few minutes to help explain what this development does and does not mean. Oliver, welcome back.

00:22:20:05 – 00:22:22:19
Oliver Rocroi
Of course. Thank you Steven. Thank you for having us back.

00:22:22:23 – 00:22:32:05
Steven Newmark
For somebody listening who has never heard of the US Preventive Services Task Force, can you give us the 30 second version? What is this body and why do its recommendations matter to patients?

00:22:32:10 – 00:23:20:13
Oliver Rocroi
In a nutshell, the reason the USPSTF is so important, when US Congress passed the Affordable Care Act in 2010, it delegated the ability to decide what services would be covered with no co-pay for every insured American to this task force. The task force historically has reviewed a number of screening recommendations, including for the five cancers that have guideline recommended screening: colorectal, lung, breast, cervical, and prostate. And so really, the critical factor is anything that is included in the USPSTF guidelines is covered with no co-pay for every patient. So the reason my wife gets a mammogram for free, or the reason we get colonoscopies or stool tests today for free as part of an annual preventive visit is because those tests are included in USPSTF guidelines.

00:23:20:15 – 00:23:34:21
Steven Newmark
Excellent. And I think an important distinction here is that the announcement of these new members is a process development, not a new colorectal cancer screening recommendation. So what has actually changed with this announcement? And just as importantly, what has not changed?

00:23:34:23 – 00:24:33:03
Oliver Rocroi
Yeah. Fantastic question. I think we’re excited. The announcement changes the paradigm that’s existed over the last two years, which is really the uncertainty about what was going to happen with the USPSTF. There was a court case that was adjudicated by the Supreme Court a few years ago that put their authority into question. The Supreme Court ruled in favor of HHS, that the task force should and shall continue to exist. But really, in the interim, there have been some transitions. So the announcement a few weeks ago that I think should be celebrated by a lot of the patient groups that hopefully will be listening to this podcast, is that we finally have a reconstituted USPSTF. All 16 members are now appointed. Some of them include some specialty doctors, including some oncologists and some folks that have expertise in prevention. And to your point about process, the announcement hopefully signals their intent to have a meeting soon. And when they do have that meeting, to review and potentially consider updating some of the most outdated guidelines, including colorectal cancer.

00:24:33:09 – 00:24:59:09
Steven Newmark
So the reason we’re discussing this now is that quite a lot has happened in colorectal cancer screening since the USPSTF last issued its recommendation way back in 2021. The science has evolved, new screening technologies have become available, and other organizations have been looking at newer evidence. So my question for you is what would need to happen for the task force to take another look at colorectal cancer screening and evaluate the newer evidence, including evidence around blood-based cancer screening?

00:24:59:13 – 00:25:50:14
Oliver Rocroi
Yeah. So we don’t think necessarily anything needs to happen other than scheduling a meeting and putting the topic on to the agenda. To your point, in the last two and a half years, the FDA has approved three new screening modalities. The American Cancer Society has updated their guidelines. The National Comprehensive Cancer Network updated their guidelines. Medicare reaffirmed their coverage. So there’s a preponderance of evidence and data that exists because of that. In addition, a few of the larger national health insurers, UnitedHealth in particular, but then some of the laboratory benefit managers, Evercore and Carillon, have also proactively decided to cover these tests. So really, it’s about ensuring that the USPSTF puts a date on the books, holds the meeting, and then considers all of the available evidence today and makes a decision about whether or not all of these screening modalities should be included in the current recommendation.

00:25:50:15 – 00:26:29:20
Oliver Rocroi
We think, you know, obviously, I don’t want to discredit the process or the review timelines, but we certainly think that between that and the amount of real-world evidence that exists from utilization over the last two years, right, as a reminder, Guardant alone has screened about 200,000 Americans, we know the performance of the test. We know how it works in real life. That is part of the consideration that the USPSTF takes into account. And and we have been and we would certainly encourage any listeners of this podcast to continue urging HHS and the USPSTF to hold that meeting, review the data, and either come to a conclusion or decide that they need more time or more data, right? But let’s at least have that conversation and initiate the process.

00:26:30:00 – 00:27:02:13
Steven Newmark
Yeah. Excellent. I want to finish this conversation where we started this entire episode, which is with the patients. One of the themes of our conversation has been that millions of people who should be screened for colorectal cancer still don’t complete recommended screening. Different patients face different barriers, as we’ve discussed, and having additional options could potentially help reach some of these people. That’s really the public health question that we all care about. So from the patient perspective, why does it matter that the task force eventually examines the newest evidence that considers how the colorectal cancer screening landscape has changed?

00:27:02:19 – 00:27:54:12
Oliver Rocroi
The easiest answer to that, and it’s unfortunately the reality and a component of why more people are not up to date today, any barrier to screening, it could be lifestyle, it could be transportation, it could just be, you know, getting time off of work, it could be any of those things, but one of the primary barriers to better adherence is the elimination of any patient co-pay or any co-insurance. Unfortunately, there’s some great data from Harvard from a few years ago. Even an $8 copay for a mammogram depressed the use of those mammograms by women. So the real critical point, back to your first question, is if the task force meets and updates the guidelines to include every option, then every single American will have equal access to cost-free prevention, and that’s really the pathway to trying to get more people up to date and having more people adherent.

00:27:54:13 – 00:28:29:13
Steven Newmark
Oliver, thanks for coming back to give us that update. For listeners, the main takeaway is that this is an important development in the process, but it is not a new screening recommendation. The USPSTF has new members and new leadership. What happens next, including when it revisits colorectal cancer screening and what conclusions it ultimately reaches after reviewing the evidence, remain to be seen. And none of this changes the most important message from our original conversation: if you’re eligible for colorectal cancer screening, don’t wait for the policy process to play itself out. Talk with your healthcare provider about your risk and the screening options that are appropriate for you.

00:28:29:18 – 00:29:01:16
Steven Newmark
Well, again, thank you both so much. A very important, episode today on The Health Advocates, a real learning for me and hopefully for most of our listeners. Now, our job is to go out into the community and spread the word, because, you mentioned that 80% number, we’ve got to go well beyond that 80% number, right? There really should be nobody 45 years or older, nobody who is at risk for colorectal cancer that should not be getting screened. It should be part of the diagnostic when you’re seeing your primary care doctor, at minimum. But we’ll get to that, we’ll deal with that, and we’ll go forward from there.

00:29:01:18 – 00:29:23:13
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:29:23:15 – 00:29:30:06
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Osteoarthritis: Treatment, Innovation, and Giving Patients More Options

Osteoarthritis affects millions of people, but living with OA can involve much more than joint pain. It can change how people work, exercise, socialize, sleep, and participate in everyday life. And for many patients, the path from conservative treatments to possible joint replacement can feel frustrating and unclear.

In this episode of The Health Advocates, we speak with orthopedic surgeon and researcher Dr. Vinod Dasa about what patients should understand about osteoarthritis today. We discuss how OA develops, when to seek care, available treatment options, shared decision-making, gaps in care between symptom management and surgery, and the barriers that can affect access to treatment.

Dr. Dasa also shares his perspective on innovation in osteoarthritis and what emerging approaches could mean for patients in the years ahead.

If you or someone you care about is living with osteoarthritis, this conversation offers practical questions to bring to your next appointment and a look at why expanding treatment options matters.

Osteoarthritis: Treatment, Innovation, and Giving Patients More Options

00:00:00:07 – 00:00:09:01
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:03 – 00:00:26:17
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Today, we’re talking about osteoarthritis, one of the most common chronic conditions in the country and one that millions of people live with every day.

00:00:26:22 – 00:00:56:18
Steven Newmark
For some people, osteoarthritis may begin as an occasional stiffness or discomfort, but for others it can progress into persistent pain, difficulty walking or exercising, limitations at work, trouble sleeping, and a significant loss of independence and quality of life. And yet, the treatment journey can sometimes feel surprisingly limited. Patients may hear some version of: lose weight, exercise, take an anti-inflammatory medication, try an injection, and eventually if things get bad enough, consider joint replacement.

00:00:56:19 – 00:01:24:02
Steven Newmark
But is that really the full picture? What should patients understand about osteoarthritis today? How should they think about the choices available to them? And what might the future of OA treatment look like? To help us answer those questions, we’re joined today by Dr. Vinod Dasa, an orthopedic surgeon and researcher at LSU Health Sciences Center who has spent much of his career caring for and studying patients with osteoarthritis. Dr. Dasa, thank you so much for joining us.

00:01:24:07 – 00:01:26:22
Dr. Vinod Dasa
Sure. No problem. Thanks for having me.

00:01:27:00 – 00:01:35:12
Steven Newmark
Before we get into it, can you give a little bit of your background, how you came into the world of osteoarthritis, the world of medicine generally and osteoarthritis specifically?

00:01:35:14 – 00:02:12:13
Dr. Vinod Dasa
Sure. So I was a son of two physicians. So I kind of grew up in healthcare and in medicine. And to a certain extent, I’m somewhat of an impatient person, so I need to fix things right away. So arthritis is kind of a nice area because I have patients that walk into my office, whether it’s a walker or a wheelchair, and they walk out normal. This is one of the areas of medicine where it fits an impatient personality, if you will. So between being brought up in medicine and wanting to get things taken care of and do it well right away, orthopedics kind of fit for me, whether it’s a fracture or arthritis. You see a problem, you fix it, and everybody’s happy.

00:02:12:14 – 00:02:34:06
Dr. Vinod Dasa
So the other interesting thing around arthritis is obviously it affects so many people. You know, here in the United States alone, there are 40 million patients with what we call symptomatic knee osteoarthritis, where arthritis is bad enough where they need to do something about it. And so you imagine that huge disease burden, on top of the fact that I don’t like waiting and watching, that lends me to arthritis type work.

00:02:34:06 – 00:02:59:13
Dr. Vinod Dasa
So knee replacements, I’m the knee guy, if you will, here in our practice at LSU and here in New Orleans. And we’ve been doing a lot of research in this space for some time now, both basic science, health economics, outcomes research, and then working on some pioneering work around reducing opioids and reducing pain around knee replacement to the point now where we’re doing opioid-free knee replacement surgery. Put all that together, and that’s where I am today.

00:02:59:15 – 00:03:05:13
Steven Newmark
Wow. Well, it’s funny you said that you’re an impatient person. I hope you’re not impatient with your patients.

00:03:05:15 – 00:03:07:17
Dr. Vinod Dasa
No, they all behave. So we’re in good shape.

00:03:07:19 – 00:03:22:12
Steven Newmark
Okay, fair enough. So it’s sometimes said that osteoarthritis is like wear and tear on the joints. Is that an accurate way of thinking about the disease? And, you know, tell us what’s actually happening inside the joint when someone has osteoarthritis.

00:03:22:14 – 00:04:17:20
Dr. Vinod Dasa
Yeah. So in the classic sense, wear and tear is osteoarthritis. So a lot of patients will get confused between rheumatoid arthritis or lupus or some others. That’s where the body attacks itself. And the cartilage gets damaged because patients have this inflammatory process that they were born with. Osteoarthritis, on the other hand, like you said, is somewhat wear and tear arthritis, kind of like the rubber on your tire, right? The more miles you drive and the longer it’s on there, the rubber wears out to the point where it’s completely gone. And when that happens, that’s what we kind of call bone-on-bone arthritis. Now that’s a simplified way of looking at it. We know osteoarthritis is a combination of a bunch of different things, right? Because if you injure the cartilage, you have a meniscus tear, for example, and your shock absorbers damage, that cartilage is going to wear out faster than if it was still intact and healthy. If you’re obese, you’ve got diabetes, you’ve got a lot of other issues, we know that cartilage is going to wear out faster than it would otherwise.

00:04:18:00 – 00:05:13:23
Dr. Vinod Dasa
Osteoarthritis is linked to a lot of biological processes where some of the cartilage cells may not be as strong, or your body may not adapt to the damage as quickly as other folks. So there’s a lot of biology that goes on, you know, where maybe we can’t signal the cartilage cells to heal as well. And that’s where a lot of the new innovation is working on, you know, can we deliver new therapies to the knee or maybe even to the body through pills or through the vein where we can influence how that cartilage behaves, maybe slow down the disease progression, maybe make the rubber a little stronger or make the rubber cells, if you will, create more rubber. And so that way we prolong or slow down the disease process. So there’s a lot going on here that goes beyond just kind of wear and tear in biology. And we’re slowly learning. You know, every year there’s new data and science that comes out where we understand arthritis a little bit more, potentially create strategies to target those new areas that we’re learning about.

00:05:14:01 – 00:05:40:03
Steven Newmark
Fascinating. I kind of want to ask if it’s something that everyone is likely to develop? What I mean by that is, I once asked a doctor about osteoarthritis. I said, “You know, what is osteoarthritis and, you know, am I going to get that one day? People talk about getting old, getting arthritis.” And she said to me, “It’s like getting gray hair. Some people get it when they’re young. Some people get it when they’re old. But almost nobody makes it until the end of their life, living a long life, and escapes without any gray hairs.”

00:05:40:05 – 00:05:56:03
Dr. Vinod Dasa
That’s right. And the question there is, is it one gray hair or is it five or is it a whole head of hair, right? So just about everyone’s going to get at least one, going to get a little bit of arthritis. Again, how quickly does it progress, you know, how long are you going to live? There’s a lot of variables here at play.

00:05:56:06 – 00:06:26:01
Steven Newmark
Absolutely. And obviously stopping the progression of gray hair, that’s for vanity purposes. But this is something that’s much more serious. You know, we talk to patients here at GHLF with osteoarthritis and, you know, some stop taking the stairs. Some will say they’ve stopped taking long walks. They’re declining invitations because they’ll worry about how far they’ll have to walk or whether they’ll be able to sit comfortably for prolonged periods of time. So from your experience, how significant can the impact of osteoarthritis become beyond just having a pain in your knee?

00:06:26:07 – 00:07:13:08
Dr. Vinod Dasa
Yeah. So there’s a bunch of different ways to look at this. So I’ve got some patients who basically are couch potatoes. They just sit on the couch all day and they adjust their life to the arthritis. And so for them, it’s not as much of a problem. I’ve got other patients who have very active lifestyles. They travel, they’ve got grandchildren, they’re still working. You know, they have a lot of daily activities, they play tennis or what have you. And so in those folks, the arthritis really impacts their quality of life. So remember, this is not a heart attack. It’s not a brain tumor. We don’t have to rush off and do anything. Really, arthritis becomes important when it impacts your quality of life. And so it’s up to each individual patient to decide are they going to adjust their life to the arthritis or not? And if they’re not, then we have strategies to kind of help them make the arthritis tolerable.

00:07:13:11 – 00:07:48:22
Dr. Vinod Dasa
Unfortunately, as the disease progresses, those strategies are less effective. Although new ones are coming out and we’re becoming more and more aggressive. Ultimately, you know, leading to a knee replacement when things get bad enough. But I’ll tell you some of the new innovations coming out, I can foresee a day where we may have a lot of options where we could potentially treat the arthritis long enough, where, you know, knee replacement may become a smaller portion of the treatment toolbox than it is today. Again, ultimately, how does the arthritis affect your quality of life? And are you willing or able to really deal with that or not?

00:07:49:03 – 00:08:07:06
Steven Newmark
Yeah, no, this is really fascinating. So one of the reasons we wanted to have this conversation is that osteoarthritis affects such an enormous number of people, but many patients don’t necessarily think of it as an area of medical innovation. How active is OA research today? What kinds of new approaches are researchers exploring?

00:08:07:10 – 00:08:41:21
Dr. Vinod Dasa
Steven, I’ll tell you the innovation in osteoarthritis research is actually quickly growing. You know, if you think about it, the traditional paradigm was Tylenol, Advil, Aleve, steroid injections, which was what the surgeon would offer you. And then ultimately a knee replacement. And, you know, for decades, those were really the three main pillars of how we managed osteoarthritis. And what a lot of people don’t realize is there are so many options now in between those three options. Traditionally, we had gel injections. There’s some new data coming out around PRP injections. We’ve got lasers, we’ve got acupuncture.

00:08:41:22 – 00:09:21:00
Dr. Vinod Dasa
You know, back in 2013, the American Academy of Orthopedic Surgery did a set of guidelines. So they looked at all the research that’s out there for knee osteoarthritis, especially the good research, the high-end research that we talk about randomized control trials, what we call the gold standard. Or something similar to that. And back then, there were about 13 or 14 options that they felt that the research justified potentially analyzing that. Fast forward, the guidelines were redone about 4 or 5 years ago. That number jumped up to almost 30. So we went from about 14 to 15 options to 30 options that had a significant amount of research that was worth analyzing.

00:09:21:02 – 00:10:07:04
Dr. Vinod Dasa
And so if you look at the data all the way from, you know, bracing and shoes to gel injections. Now we’ve got new types of injections that are in the midst of FDA study where can we take umbilical cord growth factors and then dry them out, if you will, and then take those growth factors and reconstitute them with saline, inject that into the knee to try to stimulate a more healthy knee. We’ve got new surgeries that we can regrow cartilage with that was FDA approved. And we were lucky enough to be the first site in the country back in 2018 for the FDA study to utilize this new coral, literally, like you take from the ocean. And we removed the arthritic area in the knee, and we implant that coral where that arthritis was, and the new cartilage grows in from the sides over top that coral.

00:10:07:06 – 00:10:53:19
Dr. Vinod Dasa
And what was impressive is it regrew the original, what we call hyaline or collagen type II cartilage. The challenge in the past with regrowing cartilage is it would be kind of this patch-type cartilage. It wasn’t the strong cartilage that we were born with. It was kind of like you put a patch on the asphalt in the road, it’s not the original. And so it would wear out quickly. And, you know, it was better than nothing, I guess, at the time. But this new, device came out and we were again, like I said, lucky enough to do it. And the MRI and all the data shows it’s just as good as the original cartilage. And then there’s another study that we’re about to start with the technology out of South Korea where can we inject stem cells into the arthritic area. And it’s a complicated logistics of getting the cells here and all that kind of stuff. But that shows promise. And that’s been used in South Korea for almost a decade. And now we’re bringing it to the US.

00:10:53:22 – 00:11:21:16
Dr. Vinod Dasa
I mean, there is innovations going on all over the place that we haven’t seen ten years ago. So it’s a really exciting time to be in this space, because you’re starting to see the door open to a lot of options. Now everyone’s saying, hey, can we do better than simply a knee replacement? Can we attack arthritis earlier in the process so that way patients can live a healthier kind of more normal life? Because we know putting a knee replacement in is not the same as your original knee.

00:11:21:19 – 00:11:50:05
Dr. Vinod Dasa
And as we do knee replacements in younger and younger people, they’re less satisfied with how the knee feels because they’re more demanding and their expectations are different. Let’s face it, you know, an 85 year old patient is different than a 55 year old, right, in terms of what they expect and what they need out of that knee. So it’s a really exciting time to see all these new innovations coming out, targeting these younger, earlier arthritic patients. So that way we can keep their native knee as long as possible. And who knows, maybe for a lifetime as the innovations continue.

00:11:50:09 – 00:11:52:16
Steven Newmark
Well, again, thank you so much, Dr. Dasa.

00:11:52:21 – 00:12:23:23
Dr. Vinod Dasa
Thanks for having me. You know, the Global Health Foundation, I think is doing some great work in bringing disease awareness to the space. And I’m hoping that the audience will take the information today and really help us push the envelope. Get your voice out there, tell all your policymakers, insurance companies, your HR, your friends. Tell everyone that we need to put time, energy, and resources into this space so that way we can provide our patients with top-notch innovations and opportunities to really give you the best life possible.

00:12:24:05 – 00:13:00:10
Steven Newmark
Thank you for joining us and helping us understand not only what osteoarthritis is, but also how patients can think differently about their treatment journey. One thing I hope listeners take away from this conversation is that living with OA should not simply mean accepting progressively greater pain and limitation. Patients deserve to understand their options, have meaningful conversations with their clinicians, and participate in decisions about what they want their lives to look like. Continued research and innovation matter because patients need more choices throughout the course of this disease, not simply at the beginning and at the point when surgery becomes necessary. Dr. Dasa, thanks again for being with us.

00:13:00:12 – 00:13:02:08
Dr. Vinod Dasa
You’re welcome. Take care.

00:13:02:10 – 00:13:25:09
Steven Newmark
And thank you for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at ghlf.org/listen and also on YouTube. I’m Steven Newmark, we’ll see you next time.

00:13:25:11 – 00:13:32:02
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Fall Virus Season: What to Expect

As fall approaches, flu and COVID-19 are once again moving to the forefront of public health. In this episode of The Health Advocates, Steven Newmark looks at what the Southern Hemisphere’s flu season may tell us about the months ahead, how this year’s flu vaccine has been updated, and when people should consider getting vaccinated.

He also breaks down the newest COVID-19 vaccine, including which variant it targets, when it will be available, who is currently eligible to receive it in the United States, and how much protection we can realistically expect against infection and severe illness.

The episode also explains why respiratory viruses often gain momentum as children return to school and people spend more time indoors, with practical guidance for patients, caregivers, and people living with chronic illness as they prepare for fall virus season.

Fall Virus Season: What to Expect

00:00:00:07 – 00:00:09:19
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:21 – 00:00:49:12
Steven Newmark
Hello and welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Fall means a lot of things: back to school, apple picking, football, cooler weather, and whether you ask for it or not, pumpkin spiced everything. But fall also means the beginning of respiratory virus season. Kids head back into classrooms, college students return to campus, we start spending more time indoors, eventually, the windows close, holiday gatherings begin, and every year, respiratory illnesses begin making the rounds. So today, I want to help prepare you without making this more complicated than it needs to be.

00:00:49:13 – 00:01:21:13
Steven Newmark
We’re going to focus on the big three: influenza, Covid 19, and RSV. We’ll talk about what we can learn from flu season in the Southern hemisphere. We’ll explain what changes to expect in this year’s flu vaccine. We’ll talk about the newest Covid vaccine, including who can get it and how much protection we should expect. And we’ll spend some time on RSV because it can pose a serious threat to infants, older adults, and some people living with chronic health conditions. The goal today is pretty simple. By the end of this episode, we want you to know what you should be thinking about as we head into the fall.

00:01:21:15 – 00:02:04:04
Steven Newmark
Let’s start with the obvious question: why does everyone seem to get sick once fall arrives? Well, cold weather itself does not cause the flu or a cold or anything like that. Viruses cause the flu. But fall and winter create very good conditions for respiratory viruses to spread. Think about what happens at this time of year. Millions of children go back to school. Families return to their normal schedules. We spend more time indoors. As the weather gets colder, we close windows and share indoor air for longer periods of time. Then come the Halloween parties, Thanksgiving, holiday travel, office gatherings, and everything else that puts people together. For viruses that spread through the air and respiratory droplets, that creates opportunity.

00:02:04:08 – 00:02:36:23
Steven Newmark
Flu and RSV generally follow a pretty reliable seasonal pattern, with large increases during the colder months. Covid is a little less predictable. It circulates throughout the year, and the United States has experienced both summer and winter increases. In fact, recent CDC research has found that Covid activity has tended to peak during both late summer and winter. So Covid does not follow the traditional respiratory virus calendar quite as neatly. But the basic lesson still applies: when people spend more time close together indoors, respiratory viruses have more opportunities to spread.

00:02:37:04 – 00:03:14:08
Steven Newmark
So here’s some good news. As we record this in September, respiratory illness in the United States remains very low overall. Flu activity is low. RSV activity is low. Covid activity is increasing, but overall respiratory illness remains at a very low level. That means this is actually the perfect time to talk about preparation. You don’t want to think about your respiratory season when everyone in your house is already sick. And that is particularly true for people living with chronic illness. If you have asthma, heart disease, diabetes, an autoimmune condition, cancer, or another condition that increases your risks, now is a good time to understand your vaccine options and know what you will do if you get sick.

00:03:14:13 – 00:03:49:07
Steven Newmark
So let’s start with the flu. Every year, public health experts pay close attention to flu season in places like Australia and New Zealand. There’s a simple reason for that. Their winter happens during our summer. So by September, they have already experienced much of the respiratory season that we are about to enter. That gives us some clues, but I want to emphasize the word “clues.” Australia does not have a crystal ball that tells us exactly what will happen in the United States. Different populations have different levels of immunity. Still, Australia gives us useful information about which viruses are circulating and how flu behaves.

00:03:49:11 – 00:04:31:01
Steven Newmark
This year, Australia’s flu season started relatively quiet compared with 2025. But later in the winter, flu activity accelerated dramatically. During one two-week period in August, reported flu cases increased by about 77%. Australian officials said at the time that their national peak probably had not yet occurred. At the same time, Australia had still recorded far fewer total flu cases than it had at the same time in its very difficult 2025 flu season. So what does that mean for us? It does not mean we should expect a terrible flu season. It means flu can take off very quickly, something we already knew. And it reminds us that waiting until flu is everywhere to think about vaccination is probably not the best strategy.

00:04:31:05 – 00:05:03:01
Steven Newmark
There’s also something particularly interesting about this year’s flu vaccine. Scientists updated all three components of the 2026/2027 US flu vaccine. One reasoning involves something that happened last year. A version of influenza called H3N2 became dominant after scientists had already selected the viruses for the previous flu vaccine. Basically, the virus changed after manufacturers had already committed to the recipe. The updated vaccine for this fall includes a new H3N2 component intended to better match that family of viruses.

00:05:03:07 – 00:05:28:06
Steven Newmark
Don’t worry, you don’t have to remember the name H3N2. The larger point itself is more useful. Scientists do not simply give us the exact same flu shot every year. They watch what happens around the globe, they look at which viruses are spreading, and they update the vaccine to try and match what they expect us to encounter. Sometimes the match is excellent. Sometimes the virus changes in ways that scientists do not anticipate. That is one reason a flu vaccine’s effectiveness varies from year to year.

00:05:28:12 – 00:05:57:11
Steven Newmark
The million dollar question, of course, was does the flu vaccine actually work? It does if your expectations are where they’re supposed to be. A flu vaccine will never guarantee that you will not get influenza. That is not the standard we should ever use to judge the flu vaccine. The vaccine can reduce your chances of getting flu, but one of its most important benefits is reducing your chances of becoming seriously ill if you contract the flu. That distinction becomes particularly important for older adults and people with chronic health conditions.

00:05:57:14 – 00:06:33:13
Steven Newmark
Influenza can mean miserable days at home for a healthy person, but for someone else, it can mean pneumonia, hospitalization, or a serious worsening of an existing health problem. Last season, even though the vaccine did not perfectly match one of the major circulating strains, the CDC estimates found meaningful protection against flu-related hospitalization. So when somebody says, “I got a flu shot, but I still got the flu,” that does not necessarily mean that the vaccination accomplished nothing. The better question is, would that illness have been worse without the vaccine? We cannot answer that question for every individual, but across large populations, vaccines reduce serious flu outcomes.

00:06:33:19 – 00:06:53:08
Steven Newmark
So another million dollar question, if you will, is when should you get your flu shot? For most people, it’s pretty straightforward. Annual flu vaccination remains recommended for people ages six months and older, with rare exceptions. September and October are generally good times to get vaccinated. If you have complete control over your schedule, October is a very reasonable target.

00:06:53:09 – 00:07:24:06
Steven Newmark
There’s evidence that getting the vaccine too early can mean some protection has waned by the time flu peaks later in the winter. That is one of the useful points highlighted in recent analysis. But I would not overthink this. If you’re at your doctor in September and the flu vaccine is available, getting vaccinated is perfectly reasonable. If November arrives and you realize you forgot, get vaccinated when you can. Flu season can extend well into winter and sometimes into spring. So the message is not, “You missed October, so forget it.” The message is, “Try to get vaccinated before flu starts circulating heavily.”

00:07:24:08 – 00:08:15:23
Steven Newmark
All right let’s talk about Covid now. Covid is a little more complicated this year and most years, frankly. First, we have a new vaccine for the 26/27 season. The FDA asked manufacturers to update the vaccine to target a variant called XFG. XFG belongs to the larger JN.1 family of the virus. Don’t worry about trying to memorize any of this stuff, the important thing is to understand that Covid continues to evolve. So much like the flu, the Covid vaccine gets updated to better match the versions of the virus that are currently circulating. The FDA chose the XFG because it more closely resembles the viruses currently in circulation rather than the strain used in the previous vaccine. The updated vaccines received approval in late August and have begun reaching pharmacies as we record. So if you’re listening to this in September and asking when the new vaccine will become available, it is becoming available right now.

00:08:16:01 – 00:08:50:02
Steven Newmark
Another million dollar question is who can get the updated Covid vaccine? That is the part that becomes confusing. Federal Covid vaccine policy is a bit different this year. The FDA has approved the updated vaccines for everyone ages 65 and older. For people under 65, the approved population generally includes people who have at least one underlying health condition that increases their risk from severe outcomes from Covid. The precise age depends on the vaccine. For example, Moderna’s Spikevax includes higher risk people beginning at six months of age, while other products begin at older ages.

00:08:50:05 – 00:09:17:15
Steven Newmark
For many people in the GHLF community, this is important. There are many medical conditions that can increase a person’s risk from Covid. So if you were under 65 and living with a chronic condition, do not simply assume that the updated vaccine is not available to you. Talk with your doctor or pharmacist. And because federal policy has changed, it is also worth checking your insurance coverage. For a healthy person under 65, access may look different this year than it did during earlier phases of the pandemic.

00:09:17:20 – 00:10:00:00
Steven Newmark
So how well will the new Covid vaccine work? Well, short answer is we don’t know yet. That’s not me making a dodge of the question, that’s because the vaccine has only just become widely available. It’s impossible to calculate real-world effectiveness until enough people receive a vaccine and researchers have time to compare outcomes. But we can make some reasonable observations. Scientists selected XFG specifically because it better matches the viruses circulating now. That should give the immune system a more up-to-date target. But Covid vaccines have never provided a perfect protections against infection, as we all know, of course. You can receive an updated vaccine and still get Covid. We definitely all know that one by now. Protection against infection also tends to decline over time.

00:10:00:00 – 00:10:33:23
Steven Newmark
So where Covid vaccines have shown their greatest value is in reducing the risk of severe disease, hospitalization, and ultimately death. This is the outcome worth focusing on, particularly if you are older or have a health condition that places you at higher risk. Will Covid increased this fall? Maybe, maybe not. Covid activity is already increasing nationally as we record this in September, but I would avoid confidently announcing that a huge fall wave is coming. Covid has repeatedly shown that it does not follow a perfectly predictable seasonal pattern. After several years of data, we have found recurring peaks both in the late summer and in the winter.

00:10:34:01 – 00:11:07:12
Steven Newmark
What we do know is school is starting, people are going to increasingly spend more time indoors, holiday travel and gatherings will follow. These things will increase opportunities for respiratory viruses to move between people. So rather than trying to predict exactly when the next Covid wave is coming, I think the more useful question is, “What would I want to have done before cases get high?” For someone in an elevated risk, that might mean getting the updated vaccine. It might mean making sure you have enough Covid tests at home. And it might mean knowing whether you qualify for antiviral treatments before you become infected.

00:11:07:14 – 00:11:36:23
Steven Newmark
All right, now let’s turn to RSV. RSV stands for respiratory syncytial virus. Almost everyone gets RSV at some point. Sorry, didn’t mean to scare you, but it’s true. For most healthy adults and older children, it causes something that feels a lot like a cold. But RSV has an unusual pattern when we look at who becomes seriously ill. It can pose a significant risk at both ends of the age spectrum. Very young babies can become seriously ill, so can older adults. And adults with certain chronic health conditions also face a higher risk.

00:11:37:01 – 00:12:25:11
Steven Newmark
The good news is that we now have tools to protect those most at risk. And these options remain fairly new. There are essentially two ways of protecting newborn babies from RSV. One starts before birth. Pregnant women can receive an RSV vaccination during weeks 32 through 36 of pregnancy. The mother develops antibodies and passes that protection to the baby before birth. The other approach protects the infant directly. Babies can receive a long-acting monoclonal antibody after birth. That is technically not a vaccine. Instead of teaching the baby’s immune system to produce antibodies, the injection supplies antibodies directly. Both strategies aim to protect babies during the period when RSV can pose the greatest danger. In most cases, the baby does not need both maternal vaccination and an infant antibody. Parents should discuss which approach makes sense with their obstetrician or their pediatrician.

00:12:25:13 – 00:13:08:22
Steven Newmark
CDC currently recommends one dose of RSV vaccination for everyone ages 75 and older. It also recommends vaccination for people ages 50 through 74 who have an increased risk of severe RSV. That includes people with chronic heart disease, chronic lung disease, weakened immune systems, and certain other medical conditions. That is very relevant to our audience, of course. So if you’re 55 and have significant asthma, RSV vaccination may deserve a conversation with your doctor even though you’re nowhere near 75 years old. And there’s one important difference between RSV vaccination and your flu shot. The RSV vaccine is not an annual vaccine. If you already received one, the CDC does not currently recommend another dose. For eligible people who have never received it, late summer and early fall are good times to get vaccinated.

00:13:08:23 – 00:13:47:18
Steven Newmark
So another question: can I just get all these vaccines at once? For some people, absolutely. If you’re eligible for flu, Covid, and RSV vaccines, you generally do not need three separate medical visits. The CDC allows RSV vaccination at the same time as other routine vaccines, and flu and Covid vaccines can also be administered together. Now, some people prefer to spread them out because they tend to feel tired or achy after vaccination. That is reasonable to discuss with your health care provider. But there’s no general rule saying your immune system cannot handle more than one vaccine during a visit. And convenience matters. If requiring three separate appointments means you only make it to one of them, getting the recommended vaccines during the same visit may make much more sense.

00:13:47:20 – 00:14:40:13
Steven Newmark
Vaccines, of course, are important, but there’s another point worth emphasizing. We sometimes talk about respiratory virus protection as if the entire conversation begins and ends with vaccines. It doesn’t. If you get sick, staying home when you are able to protects other people. If you need to be around others while you have respiratory symptoms, especially around someone who has high risk of severe illness, wearing a good mask can help reduce transmission. Ventilation helps. Handwashing remains particularly useful for infections that can spread through contaminated hands and surfaces. And for people at higher risk, treatment matters. We have antiviral medications for flu and Covid, but they work best when they’re started early. So you have a chronic health condition, ask your doctor now, “What do I do if I test positive for Covid? What do I do if I test positive for the flu? Would I qualify for an antiviral?” Those are much easier questions to answer when you’re feeling perfectly healthy.

00:14:40:15 – 00:15:09:12
Steven Newmark
So let’s make this as simple as possible. If you remember nothing else from today, remember these four things. First, flu. Most people six months or older should get an annual flu vaccine. September and October are great times for this. Second, Covid. There’s a new vaccine targeting XFG, a currently circulating variant. If you’re 65 or older, the updated vaccines include you under current FDA approvals. If you’re younger than 65 and have a health condition that increases your risk of severe Covid, talk with your healthcare provider or your pharmacist.

00:15:09:16 – 00:15:41:16
Steven Newmark
Third, RSV. Think about RSV if you’re 75 or older, or if you were between 50 and 75 and at a higher risk. And remember, the adult RSV vaccine is not an annual flu shot. Fourth, have a plan for when you get sick. Know where your home Covid tests are. There’s also home flu tests that are available over-the-counter as well. Know whom to call if you should get sick and know whether you might qualify for treatment. You don’t need to track every variant. You don’t need to memorize vaccine strain names. You do not need a degree in infectious disease. You just need a plan.

00:15:41:18 – 00:16:13:03
Steven Newmark
So yes, fall respiratory season is coming. That happens every year. But we have more tools than we used to. The goal is to reduce your risk of serious illness. And for people living with chronic health conditions, that can make an enormous difference. So enjoy the fall. Go apple picking. Watch some football. Send your kids back to school. And if pumpkin spice is your thing, enjoy that too. Just add one more item to your fall checklist. Take a few minutes to figure out your respiratory virus plan before respiratory virus season figures it out for you.

00:16:13:05 – 00:16:34:12
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:16:34:14 – 00:16:41:07
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Inside UNGA Week: What Global Health Leaders Are Talking About

Each September, the United Nations General Assembly, or UNGA, brings together policymakers, scientists, advocates, researchers, and health leaders from around the world. In this episode of The Health Advocates, Steven Newmark shares why participating in UNGA Week offers such a valuable opportunity to learn from global colleagues, exchange ideas, and explore new approaches to public health.

Drawing on discussions taking place throughout the week, Steven highlights how different countries are addressing major health challenges, balancing innovation with rising healthcare costs, advancing awareness around areas such as brain health, and identifying programs that can improve outcomes for patients.

The episode also explores why international collaboration matters, how scientific innovation can translate into better care, and the importance of ensuring that the patient perspective remains part of global health conversations.

Inside UNGA Week: What Global Health Leaders Are Talking About

00:00:00:07 – 00:00:09:21
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:23 – 00:00:36:14
Steven Newmark
Hello and welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. I’m recording this during the United Nations General Assembly Week, better known as UNGA, here in New York City. Every September, UNGA brings together world leaders, government officials, scientists, advocates, nonprofit organizations, and others from around the globe.

00:00:36:15 – 00:00:59:23
Steven Newmark
And one of the things that I personally really enjoy about this week is having the opportunity to participate in some of those conversations. This year, I am attending a number of health-focused discussions, including a meeting hosted by Japan’s Health Minister. Another is a conversation focused on advances in brain health awareness. And yet another looking at how different health systems are trying to improve health outcomes while controlling costs.

00:01:00:01 – 00:01:26:11
Steven Newmark
I’m not going to spend this episode walking through my calendar for this week, but instead I want to talk about why a week like UNGA matters for those of us working in public health and patient advocacy. These gatherings create a rare opportunity to hear directly from colleagues around the world about what they are seeing, what is working, where health systems are struggling, and what scientific innovations may change the way we prevent and treat disease. And for me, that is what makes this week so valuable.

00:01:26:12 – 00:01:51:16
Steven Newmark
Let’s start with the basics. What is UNGA? UNGA stands for United Nations General Assembly. It brings together representatives from virtually every country in the world to discuss major global challenges, from international security and economic development to climate change, to human rights and, of course, public health. The official meetings happen at the United Nations, but UNGA Week has grown into something much bigger than what happens just inside the United Nations itself.

00:01:51:18 – 00:02:36:07
Steven Newmark
Throughout New York City, organizations host hundreds, literally hundreds of meetings, roundtables, panels, receptions, and discussions. And during this week, you can find conversations about almost every major global health issue imaginable: infectious disease, cancer, brain health, vaccination, artificial intelligence, chronic disease, healthcare financing, drug development, health equity, pandemic preparedness, the list goes on. So for someone working in health policy and patient advocacy, UNGA creates a remarkable opportunity. You could spend an hour hearing from policymakers in one part of the world, and then walk into another room and hear scientists discussing an entirely different challenge. And often the most interesting part is discovering how connected those issues actually are.

00:02:36:09 – 00:03:27:02
Steven Newmark
One of the reasons I value these conversations is that healthcare systems vary enormously from country to country. Here in the United States, we spend a great deal of time talking about Medicare, Medicaid, private insurance, drug pricing reimbursement, and access. Those debates dominate American health policy. But other countries organize healthcare very differently. They face different pressures. They make different trade offs. And sometimes they have developed approaches that we simply don’t use here. During UNGA Week, we’ll get the opportunity to hear directly from people working within those systems: how they’re dealing with healthcare costs in their countries, how they’re deciding which new treatments they’re going to cover, how they’re addressing chronic diseases, how they’re reaching underserved communities. These are difficult questions everywhere, and no country has solved them. But countries sometimes arrive at very different answers, and it’s fascinating to follow where those lead.

00:03:27:08 – 00:04:03:07
Steven Newmark
Learning what actually works: this may be the part of UNGA Week that I find most useful. There are endless policy reports explaining what healthcare systems should do, but it’s more interesting to hear what people have actually tried in the real world. What’s worked? What’s failed? What has surprised you? What would you do differently? Maybe one country has found a particularly effective way to increase vaccination rates. Maybe another has created a program that helps patients identify chronic disease earlier. Maybe a health system has developed a better way to reach rural communities. Maybe researchers have found a successful approach to improving awareness around brain health.

00:04:03:10 – 00:04:33:22
Steven Newmark
Those experiences matter. Public health does not need every community in every country to start from scratch. If something works somewhere else, that does not mean we can simply copy and paste it into the United States. Our healthcare systems, laws, cultures, and populations may differ dramatically, but we can ask: why did it work, what are the essential ingredients, could we adapt part of that approach, and what can we learn from the mistakes people made along the way? That exchange of ideas is one of the most valuable parts of gatherings like UNGA.

00:04:34:01 – 00:05:16:06
Steven Newmark
The science is global too and a major part of these conversations involves scientific innovation. Medical science is moving incredibly quick right now. We’re seeing extraordinary developments in vaccines, cell and gene therapies, diagnostics, AI, precision medicine, and treatments for diseases where patients historically have had very few options. Scientific discovery does not respect national borders. A researcher in Japan may develop an idea that affects patients here in the United States. A clinical trial conducted in Europe may change treatment guidelines around the world. That is one of the reasons I’m particularly interested in the scientific conversations happening around UNGA. You get a chance to hear what researchers and policymakers think may be coming next.

00:05:16:07 – 00:05:45:22
Steven Newmark
But innovation also raises another question that we talk about frequently on The Health Advocates: who gets access to it? Because developing an extraordinary new treatment is only part of the job. Can patients afford new treatments? Will healthcare systems cover it? And other questions such as: will people in rural and underserved communities have access? Will patients even know the treatment exists? The gap between scientific innovation and real-world access remains one of the biggest challenges in healthcare. And that challenge exists in almost every country.

00:05:46:04 – 00:06:50:09
Steven Newmark
One of the discussions I’m participating in this week looks at how health systems are targeting diseases while also trying to reduce costs. That may sound technical, but it affects nearly every patient. Healthcare spending is continuing to rise all across the world. New treatments provide extraordinary benefits, but some also come with high prices. Governments and health systems have limited resources, as we all know. So policymakers constantly face difficult choices. How do you invest in prevention? How do you pay for innovation? How do you treat people earlier before their conditions become more severe and more expensive? How can we identify programs that improve health outcomes instead of simply adding another layer of costs? The best answer is not always simply spending less. Sometimes investing more upfront saves money later. One obvious example would be vaccinations. Screening for cancer is another. Treating a chronic disease effectively before complications develop may prevent hospitalizations and surgeries, which are much more expensive. Those are the kinds of conversations that benefit from hearing what other healthcare systems have learned.

00:06:50:11 – 00:07:46:11
Steven Newmark
Another lesson from UNGA is how difficult it is to separate health from the other challenges governments face. Take climate change, for example. Extreme heat affects cardiovascular health. Wildfire smoke affects respiratory disease. Changing temperatures can alter where infectious diseases spread. Or think about conflicts. Wars disrupt healthcare systems, interrupt access to medications. They destroy hospitals, they displace patients, and they create enormous mental health needs. Technology creates another connection. AI could dramatically improve health care, but it also raises questions about privacy, access, bias, and whether new technologies widen or narrow existing health disparities. Economic policies matter too. People who cannot afford housing, nutritious food, transportation, or medications face very different health outcomes. So when you bring policy makers from many different fields together, health inevitably becomes part of the conversation. And that is one of the strengths of UNGA.

00:07:46:14 – 00:08:17:10
Steven Newmark
There’s also something that we at GHLF try to bring into these conversations: the patient perspective. Global health discussions can become very abstract, but GHLF makes sure that we keep the conversation focused on systems, financing, data efficiency, but most importantly, on patients. How do all of these decisions affect a person? The person trying to afford a medication. The person living with a chronic disease. We can celebrate a great scientific breakthrough, but we also have to ask whether patients have access to it.

00:08:17:12 – 00:09:00:09
Steven Newmark
Another great part of UNGA Week that is difficult to measure, but it’s incredibly valuable are the relationships that organizations like GHLF makes with fellow patient advocacy organizations around the globe. We do a lot of our work today through email, zoom, teams, and conference calls. And these tools make global collaboration possible. But there’s something different about sitting around a table with people in person. You have conversations that you did not plan to have. You hear about projects that you didn’t know existed. You get introduced to someone serendipitously. And those conversations eventually turn into partnerships. That is part of the value of participating in UNGA Week, particularly for an organization like GHLF. We’re there to learn and listen. But we’re also there to represent the patient communities we serve.

00:09:00:13 – 00:09:57:15
Steven Newmark
As I move from one UNGA discussion to another throughout the week, there’s a few questions I keep coming back to. First, what is working? Not theoretically, but actually in practice. Which programs are actually producing better health outcomes? Second, what can we learn from one another? There are enormous differences between healthcare systems, but there are also common challenges. Every country has patients who struggle to access care. Every country has to think about costs and how to adapt meaningful new medical technologies. And every country has communities that healthcare systems struggle to reach. Third, what scientific developments should we be paying attention to? What’s going to change in medicine five years from now? What may change in the next year? And finally, how do we make sure patients actually benefit? That is the question that connects almost everything we do at GHLF. Innovation matters, policy matters, research matters, but ultimately, the measure of success is whether people live healthier lives.

00:09:57:20 – 00:10:24:05
Steven Newmark
There’s something unique about New York during UNGA Week. Yeah, there are motorcades, there are street closures, and there’s a lot of traffic. And if you’re a New Yorker trying to get across Midtown this week, you may have a slightly less enthusiastic description of the whole experience. But there’s also a great concentration of people and ideas: policymakers from around the world, scientists, researchers, advocates, patient organizations, healthcare leaders, people trying to solve incredibly difficult problems in very different settings.

00:10:24:10 – 00:10:44:22
Steven Newmark
I’m excited and grateful to have the opportunity to participate in some of these conversations this week, to represent the patient experience and the patients we serve. And most importantly, I’m excited to just listen. I want to hear what colleagues around the world are learning, I want to understand which public health programs are working, and I want to hear about the scientific innovations that may change healthcare.

00:10:45:00 – 00:11:05:17
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below and be sure to follow us wherever you get your podcasts. You can find all of us podcasts at ghlf.org/listen. I’m Steven Newmark. We’ll see you next time.

00:11:05:19 – 00:11:12:10
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

The Midterms Are Coming, and Health Care Is on the Ballot

The 2026 midterm elections are approaching, and control of Congress could significantly shape health policy during the final two years of President Trump’s administration. In this episode of The Health Advocates, Steven Newmark explains why patients should pay attention, including the differences between Democratic and Republican priorities on Medicaid, the Affordable Care Act, prescription drug costs, public health, vaccines, and the broader role of government in healthcare.

Steven also looks at the current political landscape, including national polling, closely watched House and Senate races, and the states that could determine control of Congress. Finally, the episode explores how the midterm results could influence the 2028 presidential campaign and the growing debate over the future of the American healthcare system.

The Midterms Are Coming, and Health Care Is on the Ballot

00:00:00:07 – 00:00:10:04
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:10:06 – 00:00:36:20
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. We’re less than two months away from the 2026 midterm elections. There’s no presidential election in November, but every seat in the House of Representatives is on the ballot, along with roughly one third of the United States Senate. And those elections could fundamentally change Washington for the final two years of President Trump’s term.

00:00:36:22 – 00:00:59:22
Steven Newmark
So today, I want to discuss something a little different. Rather than diving deeply into individual pieces of legislation, I want to give you a little bit of a September snapshot of what to expect on the midterms. What are the midterm elections? Why should people who care about healthcare and public health pay attention? What do Democrats and Republicans generally want to do differently when it comes to healthcare? And perhaps most interestingly, what does the election actually look like right now?

00:01:00:03 – 00:01:19:17
Steven Newmark
We’re going to look at some of the polls, some of the forecasts, some of the prediction markets, and then take a quick trip around the country to some of the states that could decide control of Congress. And finally, we’ll look one step further ahead. Whatever happens this November will almost immediately begin shaping the 2028 presidential election. So let’s get into it.

00:01:19:19 – 00:01:51:03
Steven Newmark
First, why do the midterms matter? Let’s start with a little bit of a civics refresher. Every member of the House of Representatives serves a two year term. So all 435 House seats are contested every two years. Senators serve six year terms, which means roughly one third of the Senate comes before voters during each two year election cycle. Republicans currently control both chambers. Their House majority is extremely narrow. In the Senate, Republicans hold 53 seats. Democrats hold 45, with two Independents who caucus with the Democrats.

00:01:51:05 – 00:02:21:10
Steven Newmark
So why does congressional control matter if President Trump will remain in the White House no matter what? Because Congress, as we learned in seventh grade, writes the laws. Congress controls federal spending. The majority party decides which legislation gets hearings and votes. It controls committee chairmanships. Committees oversee agencies such as the Department of Health and Human Services, CMS, the CDC, the FDA, and NIH. And in the Senate, the majority also controls the confirmation process for judges and many senior administration officials.

00:02:21:11 – 00:02:55:11
Steven Newmark
So the midterms can either give a president more ability to pursue an agenda through Congress, or put a significant obstacle in front of it. That is true for almost every area of policy, and it is particularly true for healthcare. So why should patients care? Well, healthcare policy can sound very far removed from everyday life until you start listening to what Congress actually influences: Medicaid, Medicare, the Affordable Care Act subsidies, prescription drug prices, insurance regulation, funding for medical research, funding for public health agencies, long-term care, and so on and so on.

00:02:55:14 – 00:03:25:13
Steven Newmark
Right now, Democrats and Republicans are offering somewhat different versions of what federal health policy ought to look like. That does not mean every Democrat agrees with every other Democrat or every Republican agrees with every other Republican. They absolutely do not. But there are some general broad differences. So what do Republicans generally want to do with healthcare? One major theme for Republicans is a smaller and more targeted federal safety net, combined with greater personal responsibility and more flexibility for each of the 50 states.

00:03:25:17 – 00:03:53:00
Steven Newmark
The Republican healthcare law elected last year created new work and community engagement requirements for many adults receiving Medicaid. Republicans describe those requirements as a way to preserve Medicaid for people who most need it, reduce waste and abuse, encourage employment, and improve the program’s long-term fiscal stability. Those requirements generally call for affected adults to work, study, volunteer, or participate in another qualifying activity for approximately 80 hours each month.

00:03:53:04 – 00:04:29:07
Steven Newmark
Republicans have also continued to advocate for a more consumer-driven healthcare system. That includes expanding health savings accounts, giving people more control over healthcare dollars, increasing insurance choices, and reducing federal regulation. Then, of course, there is a major dividing line in public health. The Trump administration, as an example, has substantially changed federal vaccine policy. The president’s executive order in August, which we covered on a previous episode, reduced the number of childhood vaccinations included in the federal government’s universal recommendation category. It has emphasized more parental choice and called for greater separation of childhood vaccines.

00:04:29:09 – 00:04:49:06
Steven Newmark
So when you think about the current Republican approach to health policy, think broadly about more individual state authority, more individual choice by healthcare consumers, greater use of work requirements and eligibility verifications in public programs such as Medicaid, and a more skeptical approach towards some of the traditional federal public health establishment.

00:04:49:09 – 00:05:14:08
Steven Newmark
What do Democrats generally want? Democrats tend to support a larger federal role in expanding insurance coverage and reducing what patients pay. Democratic leaders have called for protecting and expanding Medicaid, restoring the enhanced Affordable Care Act premium subsidies that expired at the end of 2025, reducing deductibles and out of pocket costs, and building on the federal government’s ability to negotiate prescription drug prices.

00:05:14:12 – 00:05:47:22
Steven Newmark
Some moderate and center-left Democrats have proposed building primarily on the Affordable Care Act, expanding affordability and extending drug cost protections to more Americans. Some further left Democrats want to go even farther. The Congressional Progressive Caucus now explicitly describes its long-term goal as universal healthcare through an expanded Medicare system that eventually reaches Medicare for all. Its 2026 affordability agenda also included proposals for greater federal intervention and prescription drug pricing, and even public production of some generic medications.

00:05:48:01 – 00:06:10:15
Steven Newmark
So the Democratic healthcare debate increasingly contains two questions. One is: how do we strengthen and expand the healthcare system created by the Affordable Care Act? And the other is: should we eventually replace much more of our current insurance system with publicly financed universal coverage? That disagreement within the Democratic Party could become extremely important by 2028. But we’ll come back to that later.

00:06:10:16 – 00:06:31:05
Steven Newmark
So where does the election actually stand? Well, now for the fun part. Let’s start with a disclaimer. It is only September. Polls change, campaigns matter, turnout matters, and a lot can happen before votes are cast in November. None of what I’m about to describe constitutes a prediction of what will happen on November 3rd. This is simply an assessment of where the race stands today.

00:06:31:08 – 00:06:57:17
Steven Newmark
The House environment clearly favors Democrats more than Republicans. The Real Clear Politics’ average of national congressional polling has Democrats ahead by about six percentage points. Nate Silver’s polling average shows a similar Democratic advantage. The Cook Political Report’s House map tells an equally interesting story. Cook currently rates 21 House seats as toss-ups. 16 of those seats are held by Republicans. That imbalance gives Democrats many more opportunities to gain seats than Republicans.

00:06:57:19 – 00:07:16:23
Steven Newmark
The prediction markets tell a similar story. Both Kalshi and Polymarket traders currently favor Democrats to take control of the House by a substantial margin. Again, prediction markets are not election results. They tell us what people willing to put money behind their expectations currently believe. But combined with the polling and the race ratings, they reinforce the same basic picture.

00:07:17:00 – 00:07:46:03
Steven Newmark
As of early September, Democrats are well positioned to compete for control of the House. But the Senate has become the really interesting story. For much of this election cycle, the Senate looks significantly harder for Democrats, but the map has become much more competitive. Republicans currently hold 53 seats. Because the vice president, JD Vance, would break a 50/50 vote in favor of Republicans, Democrats need a net gain of 4 seats to reach 51, assuming that they hold all of their existing seats. That is difficult.

00:07:46:03 – 00:08:12:21
Steven Newmark
But here is what makes the current map fascinating. The Cook Political Report now rates six Senate races as toss-ups. Five of those six seats are currently held by Republicans. They are Alaska, Iowa, Maine, Ohio, and Texas. The sixth is an open Democratic seat in Michigan. Cook also has the Republican-held North Carolina seat leaning Democratic, while Democratic held seats in Georgia and New Hampshire remain competitive but currently lean Democratic.

00:08:12:22 – 00:08:35:07
Steven Newmark
And prediction markets have essentially thrown up their hands. Unlike the House, where the markets show a clear consensus, markets for the Senate control are almost evenly divided. Polymarket currently tilts slightly towards Democratic control, while current Kalshi pricing tilts slightly toward Republican control. In other words, the Senate is genuinely worth watching. So let’s take a quick tour of the map around the country.

00:08:35:09 – 00:09:00:01
Steven Newmark
Let’s begin in North Carolina. Former Democratic Governor Roy Cooper is running against Republican Michael Whatley for the seat being vacated by Republican Thom Tillis. Recent polling has consistently shown Cooper ahead, and Cook currently rates the race as leaning Democratic. For Democrats trying to win the Senate, North Carolina represents one of their clearest pickup opportunities. For Republicans, holding it removes one of the easiest potential Democratic paths to 51 seats.

00:09:00:04 – 00:09:26:05
Steven Newmark
Then there’s Maine. Republican Senator Susan Collins is seeking another term, this time against Democrat Troy Jackson. Collins has repeatedly demonstrated an ability to outperform other Republicans in Maine, but this year looks even more competitive than Collins is used to. Recent public polling has shown Jackson with a small lead, and Cook rates the race as a toss-up. Maine again will test whether Collins’ personal brand can overcome a difficult national environment for Republicans.

00:09:26:07 – 00:09:47:10
Steven Newmark
Ohio may be one of the most interesting races in the country. Republican Senator Jon Husted faces former Democratic Senator Sherrod Brown. Ohio has moved considerably towards Republicans in recent presidential cycles, but Brown has previously won statewide there multiple times. Recent polls have shown a competitive race, with some giving Brown a lead and Cook currently calling the race a toss-up.

00:09:47:12 – 00:10:14:23
Steven Newmark
Michigan, right near Ohio, goes the other way. This is a Democratic-held seat that Democrats essentially need to defend following Senator Gary Peters’ retirement. Democrat Abdul El-Sayed faces Republican Mike Rogers. Recent polling has shown El-Sayed with a modest advantage in several surveys, but Cook still considers the race a toss-up. So Michigan could cancel out a Democratic pickup somewhere else. That is why the Democratic math gets complicated so quickly.

00:10:15:03 – 00:10:39:22
Steven Newmark
Iowa. Iowa was not initially expected to become one of the premier Senate contests of 2026, but now it is. Republican Representative Ashley Hinson faces Democrat Josh Turek for the open seat created by Senator Joni Ernst’s retirement. Recent polls have shown Hinson ahead, although the race remains competitive enough that Cook moved Iowa into its toss-up category. If Iowa remains close into October, it would represent a significant expansion of the Senate battlefield.

00:10:40:03 – 00:11:08:04
Steven Newmark
Alaska gives us another unusual contest. Republican Senator Dan Sullivan faces former Democratic Representative Mary Peltola. Polling has been sparse and somewhat inconsistent. One recent survey showed Peltola ahead, while another survey had Sullivan narrowly ahead. Cook rates the race as a toss-up. Alaska uses ranked-choice voting, which adds another wrinkle to the contest. We should note that Mary Peltola has won statewide office previously in Alaska, so it’ll be interesting to watch.

00:11:08:06 – 00:11:31:16
Steven Newmark
And then there is Texas. If you had told political observers a year ago that Texas would be one of the most closely watched Senate races in America, most would have been skeptical. Republican Attorney General Ken Paxton defeated Senator John Cornyn in the Republican primary, and now faces Democratic State Representative James Talarico. Recent polling has shown the race extremely close, with several surveys showing Talarico narrowly ahead and others showing the race tied.

00:11:31:21 – 00:11:53:15
Steven Newmark
Cook moved Texas to toss-up in August. Kalshi’s market on the individual race had Paxton and Talarico essentially dead even. The competitiveness has attracted national attention and major spending from Republican groups. Texas is important for another reason. If Democrats truly are competitive there in November, it would suggest the national environment has moved considerably beyond the handful of traditional swing states.

00:11:53:20 – 00:12:11:06
Steven Newmark
Democrats also have seats of their own to protect. Democratic Senator John Assaf of Georgia faces Republican Representative Mike Collins. Georgia remains one of the country’s most closely divided states, but recent polling has shown Assaf ahead, and Cook currently places the race in its leaning democratic category rather than as a toss-up.

00:12:11:10 – 00:12:41:12
Steven Newmark
So what does all this have to do with health policy? Potentially quite a lot. If the Democrats win the House while the Republicans retain the Senate, President Trump is still president, of course, and Republicans could block all Democratic legislation in the Senate. But the House Democrats would control committees. That means they could hold hearings and investigations involving Medicaid, vaccines, the CDC, the FDA, Medicare, and so forth. They could pass healthcare bills through the House, even if those bills never became law. And they can control one half of the federal spending process. That would mean a divided government.

00:12:41:12 – 00:12:58:23
Steven Newmark
Now imagine if Democrats somehow capture both chambers. President Trump would still have the power of the veto, of course, so Democrats simply could not implement a healthcare agenda. But they would control the legislative calendar, appropriations oversight, and Senate confirmations. The administration would face a dramatically different final two years.

00:12:59:00 – 00:13:17:01
Steven Newmark
And if Republicans retain both chambers, well, President Trump would continue with unified party control. Republicans would have more opportunities to implement their existing Medicaid changes, pursue further changes to federal health programs, expand consumer-directed healthcare policies, and so forth. That is why these elections matter, even without a presidential race.

00:13:17:03 – 00:13:34:21
Steven Newmark
The other thing about midterm elections is that they are never just about the midterms. The moment the votes are counted, both parties will begin interpreting what happened. Who did voters reward? What did they reject? Which messages worked? And what should each party offer voters in 2028? Healthcare could become one of the clearest places where those lessons emerge.

00:13:35:02 – 00:14:00:06
Steven Newmark
A strong Democratic performance would give the party something it does not currently have in Washington: institutional power. If Democrats take the House, Democratic committee chairs can elevate issues they want at the center of the 2028 debate. They could hold hearings on healthcare affordability. They could vote on restoring the Affordable Care Act assistance. Even if President Trump prevents those bills from becoming law, the votes themselves help define what the Democratic Party intends to run on in 2028.

00:14:00:09 – 00:14:19:00
Steven Newmark
And there’s another dynamic worth watching. The Democratic Party is having an increasingly visible debate about how far government should go in healthcare. The party center remains heavily invested in the Affordable Care Act, but the progressive wing has moved beyond simply defending Obamacare. They are calling for a path forward towards universal Medicare coverage and eventually Medicare for all.

00:14:19:04 – 00:14:40:20
Steven Newmark
People sometimes describe all of this as socialized medicine, but we should be a bit more precise. A single-payer system such as Medicare for all means government finances healthcare coverage. That does not necessarily mean government owns the hospitals or employs the doctors, which would be a socialized version of medicine. If the Democrats take control, essentially it could start shifting the point of the debate, and political change often happens that way.

00:14:41:02 – 00:14:58:11
Steven Newmark
A strong Republican performance would send a very different message. Historically, the president’s party loses congressional seats during the midterm elections. So if Republicans retain control despite the current polling environment, party leaders could argue that voters had endorsed, or at least accepted, much of the governing agenda they enacted during Trump’s first two years.

00:14:58:12 – 00:15:34:23
Steven Newmark
That could strengthen the case within the Republican Party for continuity going into 2028. Medicaid work requirements begin taking effect in 2027, and expansion of that program could be on the agenda. Changes to the Affordable Care Act affordability assistance will have had an additional time to effect enrollment and premiums. The administration’s new vaccine policies will have been operating longer. And its prescription drug pricing initiatives will have produced more measurable results. So by 2028, Republican candidates could campaign on continuing those policies. Democrats could campaign on reversing them. And it will be less about evaluating hypothetical proposals, but rather evaluating actual governing records.

00:15:35:01 – 00:16:04:17
Steven Newmark
So what should patients pay attention to? Well, what does the candidate say about Medicaid? Do they support new work requirements? Do they want to change them? What do they think should happen to the Affordable Care Act subsidies? What is their plan for prescription drug costs? What do they say about Medicare? What role should states play? You don’t need to become an expert on congressional procedure, but healthcare is one area where election results can eventually show up at your pharmacy counter, in your insurance premium, in your Medicaid eligibility, or in the guidance you receive from federal health agencies. That makes this worth following.

00:16:04:19 – 00:16:33:16
Steven Newmark
We still have almost two months until Election Day. A lot can change, but as of early September, the basic picture looks like this: Democrats currently lead national House polling. Political forecasters see many more Republican-held seats at serious risk than Democrat-held seats. Prediction markets strongly favor Democratic control of the House. The Senate is much harder to read, but a race that once looked substantially more favorable to Republicans has expanded into states ranging from North Carolina and Maine to Iowa, Alaska, Ohio, and even Texas.

00:16:33:20 – 00:17:05:01
Steven Newmark
And for patients, there’s a bigger reason to watch than simply seeing whether the maps turn red or blue. The people elected this November will help decide what happens to Medicaid, to the Affordable Care Act, to prescription drug policy. They will help frame a much larger argument heading into 2028 about what role government should play in American healthcare. So over the next several weeks, we’ll be watching. And as Election Day gets closer, we’ll come back and take a deeper look at what each possible outcome could actually mean for health policy during the final two years of the Trump administration.

00:17:05:03 – 00:17:25:16
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:17:25:18 – 00:17:32:11
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Vaccines by Executive Order: What Changed, What Didn’t, and What Families Need to Know

President Trump’s new executive order on childhood vaccines has created fresh questions about what is changing, what is not, and what families should do now.

In this episode of The Health Advocates, Steven Newmark breaks down the order’s major provisions, including proposals to reduce the number of universally recommended vaccines, space out vaccinations, and eventually separate the MMR vaccine into individual measles, mumps, and rubella shots.

He also explains the limits of the executive order, including the fact that states still control school vaccination requirements and that many of the proposed changes would require additional federal action, new products, or further implementation.

The episode also examines the scientific evidence behind the existing vaccine schedule, the risks of delaying vaccination, and why changing recommendations could create particular concerns for people living with chronic illness or weakened immune systems.

Most importantly, Steven offers practical guidance for parents trying to navigate conflicting recommendations and increasing confusion around vaccine policy.

Vaccines by Executive Order: What Changed, What Didn't, and What Families Need to Know

00:00:00:10 – 00:00:07:23
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:08:00 – 00:00:17:22
Steven Newmark
Hello and welcome to The Health Advocates. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Our goal is to help you understand what’s happening in the world of healthcare.

00:00:17:23 – 00:00:45:02
Steven Newmark
Last week, President Trump signed a new executive order that could significantly reshape childhood vaccine policy in the United States. The order calls for fewer vaccines to receive a universal recommendation for all children. It encourages greater spacing between vaccinations, it proposes eventually replacing the combined measles, mumps, and rubella vaccine, or the MMR vaccine, with three separate vaccinations, and it asks states to reconsider some of their school vaccination requirements.

00:00:45:03 – 00:01:12:08
Steven Newmark
That’s a lot. And if you’re a parent trying to figure out whether your child’s vaccination schedule suddenly changed, you have a good reason to feel confused. So today, we’re going to get into each of the three questions and figure out what exactly happened. The three questions, of course, are: what exactly did the presidential order say, what does it change right now, and, perhaps most importantly, what does the medical evidence say about the recommendations families have relied on for decades? Let’s start with the policy.

00:01:12:10 – 00:01:46:12
Steven Newmark
President Trump signed Executive Order 14420 on August 10th. The administration calls its new framework: The Gold Standard Childhood Vaccine Recommendations. Whether it’s actually the gold standard, you can be the judge of. Under the order, the federal government places childhood immunizations into several categories. The first category includes vaccines recommended for all children. That group protects against 11 diseases, including measles, mumps, rubella, polio, pertussis, tetanus, diphtheria, certain forms of bacterial meningitis and pneumonia, HPV, and chickenpox.

00:01:46:13 – 00:02:14:09
Steven Newmark
Other immunizations move into either a higher risk category or something called shared clinical decision making. That second group includes vaccines or immunizations involving hepatitis A, hepatitis B, rotavirus, meningococcal disease, influenza, Covid 19, RSV, and dengue depending on the vaccine and the child’s circumstances. Now, shared clinical decision making sounds fairly innocuous, but this is something we’ve discussed before on this program.

00:02:14:09 – 00:02:43:13
Steven Newmark
It sounds innocuous because, after all, shouldn’t patients and doctors make medical decisions together? Well, of course they should. But in vaccine policy, the phrase has a very specific meaning. It distinguishes a vaccine that is routinely recommended for an entire age group from when the doctors and patients should consider based on individual circumstances. That distinction can influence how clinicians discuss vaccinations, how healthcare systems send reminders, how vaccine programs operate, and ultimately, whether people receive a vaccine at all.

00:02:43:14 – 00:03:05:09
Steven Newmark
The executive order goes even further. It says that to the maximum extent feasible, childhood vaccines should take place during separate medical visits, rather than several vaccines occurring during the same appointment. And it calls for eventually separating the MMR vaccine into individual measles, mumps, and rubella shots once such products become available in the United States. They’re not currently available.

00:03:05:10 – 00:03:29:14
Steven Newmark
Finally, the order gives the Department of Health and Human Services 90 days to develop plans involving vaccine timing, sequencing, single disease vaccines, safety monitoring, and additional research. It also encourages states to reconsider vaccination requirements for schools and other settings. So this is more than just a press release. But that does not mean that every child’s vaccination schedule changed overnight and that distinction matters.

00:03:29:15 – 00:04:03:02
Steven Newmark
Let’s talk about what this order does not do. First, it does not automatically change your state’s school vaccination requirements. States establish those requirements. There is no single federal law that determines which vaccinations children should receive to attend school. The executive order encourages states to reconsider their rules. It also directs federal agencies to support legal challenges involving exemptions. But an executive order cannot simply rewrite every state’s vaccination laws. If your state required certain vaccinations for school before August 10th, you should not assume that those requirements disappeared on August 11th.

00:04:03:03 – 00:04:26:05
Steven Newmark
Second, the order does not remove existing vaccines from pharmacy or pediatrician shelves and it does not revoke FDA approval for vaccines that have already been approved. Third, it does not suddenly create separate MMR vaccines. Those products do not currently exist, as I mentioned, as individually licensed and marketed vaccines in the United States. Manufacturers phased out the previous single disease products years ago.

00:04:26:05 – 00:04:49:14
Steven Newmark
So if you hear that the government has, quote, split up MMR, that has simply not happened. The executive order simply says that the government should work toward making individual vaccines available, and should favor them once they become available. Developing, manufacturing, studying, licensing, distributing, and incorporating new vaccine products involves considerably more than just taking an existing vaccine and dividing it into three syringes.

00:04:49:15 – 00:05:13:17
Steven Newmark
The order also did not emerge out of nowhere. In December of 2025, President Trump directed health officials to compare the US childhood vaccine schedule with schedules of other developed countries. In January, CDC leadership announced a revised framework that reduced the number of vaccines routinely recommended for all children and moved others into different categories. That generated an immediate conflict with major medical organizations.

00:05:13:18 – 00:05:38:17
Steven Newmark
The American Academy of Pediatrics continued to recommend its own childhood immunization schedule, which includes protection against 18 serious diseases. Then in March, a federal judge blocked implementation of the new federal schedule while litigation continued. And now we have the August 10th order, which seeks to move to an entirely new framework when it comes to childhood vaccinations. That history background matters because patients now face something unusual.

00:05:38:17 – 00:06:05:23
Steven Newmark
For many years, parents could look to their pediatrician, The American Academy of Pediatrics, and federal public health agencies and generally receive the same vaccination recommendation. Today, those sources may tell them different things. The fragmentation itself creates a public health problem. One of the most significant recommendations in this new executive order involved the timing of vaccines. The order says childhood immunization should occur during separate medical visits to the maximum extent feasible.

00:06:06:00 – 00:06:41:22
Steven Newmark
That may sound cautious, but let’s be realistic about this. Some parents may understandably wonder whether receiving several vaccines during one appointment places too much of a strain on a child’s immune system. In reality, the evidence does not show that spreading routine vaccines across several visits makes vaccinations safer. Further, the idea of asking parents and children to come back to a doctor’s office multiple times will decrease the amount of opportunity you have to receive vaccines, thus likely creating a situation where less folks are becoming vaccinated, which obviously has an attendant effect on the immunocompromised community.

00:06:41:23 – 00:07:14:19
Steven Newmark
Parents work. Kids get sick. Transportation becomes difficult. Appointments get canceled. Families move. Insurance changes. Every additional visit creates another opportunity for a vaccination to get delayed or missed altogether. CDC’s own immunization guidance has long recognized that simultaneous vaccination increases the likelihood that a person receives appropriate protection at the appropriate age. And remember what spacing actually means. If a child receives one vaccine this month and another vaccine several months later, that child spends those extra months without protection against the second disease.

00:07:14:19 – 00:07:34:14
Steven Newmark
So the question should not simply be: can we spread these vaccines out? Yeah, of course we can. The better question is: does the spreading them out make our society healthier? The evidence has not been established that it does. And in fact, delaying protection carries its own risks. That brings us to the proposal to separate the measles, mumps, and rubella vaccination.

00:07:34:15 – 00:08:03:00
Steven Newmark
The administration wants manufacturers to eventually offer three individual vaccines instead of relying on the combined MMR shot. But we already have decades of experience with MMR. The vaccine provides a very strong protection against measles. One dose produces immunity in about 93% of recipients. Two doses increases protections to approximately 97%. And the timing of this proposal deserves attention. The United States is experiencing its highest level of measles activity in 35 years.

00:08:03:01 – 00:08:25:10
Steven Newmark
That makes this a particularly consequential moment to introduce uncertainty around one of our most important childhood vaccines. Measles is not simply a rash and a few uncomfortable days at home. It can cause pneumonia, hospitalization, inflammation of the brain, permanent complications, and death. It’s also extraordinarily contagious, and this matters enormously for people living with certain chronic illnesses.

00:08:25:10 – 00:08:51:05
Steven Newmark
Some patients who take significant immune-suppressing medications cannot safely receive live vaccines, such as MMR. They rely in part on everyone around them having protection. When enough people receive a vaccination, a virus has fewer opportunities to find someone vulnerable. That is why vaccination involves both individual and community health. For an immunocompromised child, the vaccination decision another family makes can affect his or her risk too.

00:08:51:06 – 00:09:23:23
Steven Newmark
What about the argument that other countries give fewer vaccines? The administration has emphasized that the United States recommends more childhood vaccines than many peer countries. Well, let’s put that into context. Different countries do you have different vaccine schedules. But counting the number of vaccines on two schedules does not tell us which is better. Countries differ when it comes to disease prevalence. They differ in regards to their particular healthcare systems, access to medical care, vaccine uptake, surveillance, population characteristics, school policies, and how governments deliver preventive care services.

00:09:24:02 – 00:09:53:13
Steven Newmark
The relevant scientific question is not necessarily: does Denmark recommend fewer vaccines than the United States? The relevant question is: would adopting Denmark’s schedule produce better health outcomes for the United States? Those are different questions. The American Academy of Pediatrics says it has seen no new scientific evidence that justifies these major changes in childhood immunization recommendations. The organization continues to recommend its 2026 schedule, which protects children and the population at large against 18 serious diseases.

00:09:53:13 – 00:10:12:22
Steven Newmark
That does not mean vaccine recommendations should never change. They should when science evolves, when disease patterns evolve, when new vaccines become available. A good vaccination schedule should evolve with the evidence. But changing the schedule because new evidence demonstrates a better approach differs from changing it because another country has fewer rows on its chart.

00:10:12:23 – 00:10:42:05
Steven Newmark
There’s another part of this debate that also deserves attention. The administration argues that public health institutions have lost trust, and that giving parents more choice may help rebuild it. The loss of trust is real. People emerged from the Covid 19 pandemic with very different experiences and very different attitudes towards public health. Some people believe officials communicated too confidently when evidence remained uncertain. Some people believe political leaders interfered too much with the science. Others believe government placed too many restrictions on individual choice.

00:10:42:06 – 00:11:21:00
Steven Newmark
Public health officials should take those concerns seriously, but rebuilding trust requires more than telling people that every side has an equally strong scientific argument. Sometimes the evidence does point overwhelmingly in one direction. Multiple vaccines at the same site have a very strong safety record, the MMR vaccine works, the vaccines do not cause autism, and vaccine preventable diseases can cause serious harm. Trust requires telling people those things clearly while still allowing them to ask questions. It also means that acknowledging genuine uncertainty when it exists. There is no contradiction between respecting patients and giving them strong medical recommendations. We should be able to do both.

00:11:21:01 – 00:11:52:07
Steven Newmark
At The Health Advocates, we spend a lot of time talking about people who live with chronic conditions. So why should this community pay particular attention to childhood vaccine policy? Because changes in vaccination rates do not affect everyone equally. Consider someone receiving chemotherapy or a child taking immune-suppressing medication for an autoimmune condition or an organ transplant recipient. For these patients, preventing an infectious disease often requires more than making an individual choice. They depend on family members, classmates, and others in the community reducing transmission around them.

00:11:52:07 – 00:12:22:09
Steven Newmark
That is one of the reasons declining vaccination rates concern public health experts. The person who faces the greatest consequences from an outbreak may have very little control over whether that outbreak occurs. And there’s another issue. Conflicting recommendations create additional burdens for patients who already navigate a complicated medical landscape. If the CDC says one thing, the American Academy of Pediatrics says another, a school requirement says something else, an insurance company interprets federal guidance in yet another way, families have to sort through the confusion themselves.

00:12:22:09 – 00:12:46:19
Steven Newmark
For people managing complex health conditions, healthcare already requires enough homework. We should make credible preventive guidance easier to understand, not harder. So where does this leave families? Where does this leave the public at large? First, do not assume that last week’s executive order requires you to change an existing vaccination plan. Talk with your local pediatrician, talk with your local doctor or another trusted healthcare provider.

00:12:46:19 – 00:13:19:20
Steven Newmark
Second, remember that the American Academy of Pediatrics continues to recommend its evidence-based 2026 childhood vaccination schedule. That schedule has not disappeared because the White House issued a different recommendation. Third, if you or your child has a chronic medical condition or take an immune-suppressing medication, discuss vaccinations with the clinicians who understand that condition. Certain vaccines may require different timing or may not be appropriate for certain immunocompromised patients. That makes individualized medical guidance particularly important. If your concern involves school requirements, check your state or local health department.

00:13:19:20 – 00:13:44:22
Steven Newmark
And finally, ask questions. Good medicine should withstand good questions. The debate over vaccines has become intensely political, but viruses and bacteria do not know whether someone votes Republican, Democrat, Independent, or doesn’t vote at all. Measles does not check party registration before spreading through a classroom. The flu doesn’t care which cable news network you watch. And an immunocompromised patient does not become less vulnerable because the country is arguing about public health.

00:13:44:23 – 00:14:07:06
Steven Newmark
Families do not need to wait for those debates to resolve before protecting their public health. We already know a great deal about vaccines. We know that the existing childhood vaccines have prevented enormous amounts of disease, disability, hospitalization and death. Parents deserve accurate information. They deserve the opportunity to ask questions, and they deserve recommendations rooted in evidence rather than confusion.

00:14:07:08 – 00:14:27:08
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please like and subscribe and leave a comment down below. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:14:27:10 – 00:14:34:03
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

When Public Health Warning Lights Start Flashing

Public health threats often seem unrelated until we examine the systems that connect them. In this episode of The Health Advocates, Steven Newmark discusses the record-breaking rise in U.S. measles cases, recent foodborne illness outbreaks, changing COVID-19 activity, and the health risks associated with wildfire smoke.

Steven explains what these developments mean for patients, caregivers, and people living with chronic illness, including practical steps related to vaccination, food recalls, testing, treatment planning, and air quality. He also examines the larger forces shaping these stories, including declining vaccine confidence, gaps in public health communication, and the importance of strong disease surveillance.

The episode also highlights encouraging news, including progress toward a new Ebola vaccine and El Salvador’s elimination of trachoma as a public health problem.

Together, these stories show what happens when public health protections weaken, and what communities can achieve when science, communication, and sustained investment work together.

FDA Egg Sell-by Recall Dates:  July 20th – August 17th, 2026

When Public Health Warning Lights Start Flashing

00:00:00:10 – 00:00:11:19
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:11:21 – 00:00:32:05
Steven Newmark
Hello and welcome to The Health Advocates. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Our goal is to help you understand what’s happening in healthcare world to help make informed decisions to live your best life. It’s the dog days of summer, and there’s a lot happening in the world of public health. Today, we’re taking a broader look at the state of public health overall in the United States.

00:00:32:06 – 00:01:07:03
Steven Newmark
Several stories have emerged at the same time this summer. The country has reached its highest measles case count in decades. Federal officials continue to investigate a major outbreak of illness connected to potentially lettuce or some other vegetable. Millions of eggs have fallen under a salmonella recall. Covid 19 activity remains relatively low, but signs point to an upward trend in parts of the country. And wildfire smoke continues to create questions for people with chronic health conditions. Plus, Anthony Fauci has been hauled to Capitol Hill to testify, and he invoked the Fifth Amendment 11 times. We won’t cover all that today, but we’ll cover some of what is relevant to our community.

00:01:07:04 – 00:01:41:21
Steven Newmark
The stories may sound unrelated, but they share something important. Public health works best when it prevents the emergency that never happens. The child who never develops measles, the contaminated food that never reaches someone’s kitchen, the infection caught before it spreads through a family, the person with asthma who receives enough warning to avoid dangerous smoke. When those protections weaken, patients and families pay the price. So today, we will talk about what these warning signs mean, what people can do now, and why the news does not give us only reasons for concern. It also gives us examples of what sustained public health work can accomplish.

00:01:41:22 – 00:02:10:15
Steven Newmark
Let’s start with measles. As of July 23rd, the CDC has confirmed over 2300 measles cases in the United States this year. That already exceeds the total for all of 2025, and we still have several months left to go in the year. The CDC has identified 35 outbreaks this year, and 93% of confirmed cases have connections to an outbreak. In other words, we’re not simply seeing scattered infections throughout the country. We’re seeing measles find communities where enough people lack immunity for the virus to continue spreading.

00:02:10:16 – 00:02:48:16
Steven Newmark
Measles spreads with extraordinary efficiency. The virus can remain infectious after an infected person leaves a room. Early symptoms often resemble other respiratory illnesses: fever, cough, runny nose, red watery eyes. A rash generally follows a few days later. That creates a difficult problem. Someone can expose other people before anyone recognizes the illness as measles. And measles is not simply an uncomfortable childhood rash. It can cause pneumonia, inflammation of the brain, hearing loss, hospitalization, death. People who avoid these outcomes may still miss school or work, face medical expenses, or place medically vulnerable family members at risk.

00:02:48:17 – 00:03:31:13
Steven Newmark
The country eliminated continuous measles transmission in 2000, 26 years ago. We achieved that through widespread vaccination and strong public health response systems. But national vaccination numbers have moved in the wrong direction. The CDC reports that MMR vaccination coverage among kindergarten students fell from over 95% during the 2019-2020 school year to under 93% during the 24-25 school year. That may not sound like a big difference, but those small percentage points do matter. They can hide much larger gaps within individual schools, neighborhoods, certain communities, or certain geographic areas. Measles does not need an entire country to lose immunity. It needs one sufficiently large pocket of people whom the virus can infect.

00:03:31:14 – 00:04:11:00
Steven Newmark
Measles has also entered into our political arguments. Some people want to blame the current administration. Still others argue that the increase proves that vaccines do not work. None of those explanations capture what is actually happening. The people developing measles today often made their vaccination decisions many years ago. Declining confidence in vaccines did not begin with one president, one health secretary, or one election. At the same time, the decisions that government officials make today will influence what happens next year and several years from now. Public officials can strengthen vaccination programs, communicate honestly, support local health departments, and counter misinformation. Or they can undermine confidence and make the next outbreak more likely.

00:04:11:00 – 00:04:50:08
Steven Newmark
The same distinction matters when people blame immigration or folks coming in from overseas. International travel does bring measles into the United States because the virus continues to circulate in many parts of the world. Any traveler can carry it. The more important question is what happens after the virus arrives? Travelers may introduce the measles virus to the United States, but gaps in immunity allow it to spread. The CDC identifies both increasing global measles activity and declining vaccination coverage as major contributors to the current situation. Turning a public health problem into a political accusation may feel satisfying, but it does not vaccinate a child, protect an immunocompromised adult, or help a school respond to an exposure.

00:04:50:08 – 00:05:26:04
Steven Newmark
So what should parents and families do? First, check your vaccination records and your children’s records. Do not rely on a vague memory of when you may have received a vaccine. Confirm it, particularly before international travel or if you hear that measles is spreading in your community. Second, people who take immune-suppressing medications should speak to their healthcare professionals before receiving an MMR vaccine. MMR contains live, weakened viruses. Clinicians generally should not give it to people with severe immunosuppression. That answer can depend on the medication, dose, condition, and timing. So patients should not make that determination alone but rather in conjunction with their medical provider.

00:05:26:05 – 00:05:56:23
Steven Newmark
Third, act quickly after a possible exposure. People without evidence of immunity may qualify for an MMR vaccine within 72 hours of exposure or immune globulin within six days. A healthcare professional or health department should guide that decision. Finally, call before walking into your doctor’s office, urgent care center, or emergency department when you suspect measles. Calling ahead allows the facility to isolate you and avoid exposing infants, pregnant people, immunocompromised patients, and healthcare workers in a waiting room. That one phone call can prevent a much larger chain of infection.

00:05:57:00 – 00:06:30:02
Steven Newmark
Measles is not the only public health issue creating concern this summer. Federal officials have also investigated an unusually large number of illnesses called by cyclospora, a microscopic parasite that can contaminate food and water. One major outbreak has a connection recall to iceberg lettuce from Taylor Farms in Mexico. The FDA has identified illnesses in nine states and traced many cases to shredded lettuce served at certain restaurants. The company also recalled Marketside iceberg salad and shredded lettuce products sold at select Walmart locations around the country along with lettuce distributed to food service customers in numerous states.

00:06:30:03 – 00:07:01:10
Steven Newmark
Cyclospora commonly causes frequent diarrhea, abdominal cramps, bloating, nausea, loss of appetite, fatigue, and weight loss. The symptoms can continue for weeks. They may improve and then return. People with immune systems that are weaker may face greater risk of a severe or prolonged illness. Consumers don’t necessarily need to avoid every piece of lettuce in America, or raspberries another potential cause, or cilantro another potential cause. They should look to the FDA’s current recall information, identify the brand and the product, look at the date, discard any food that has been recalled.

00:07:01:10 – 00:07:26:09
Steven Newmark
It sounds simple until you consider what the average person has to do. First, you have to learn about the recall. You must remember where you bought the food. You must find the code printed, perhaps in a tiny package. And then you’re probably going to want to do an excessive amount of washing of the lettuce itself. The best you can do is to listen to your local, state, and national health departments in trying to figure out the best way to navigate and how to care for yourself and your family.

00:07:26:10 – 00:07:55:11
Steven Newmark
The FDA has also announced an investigation involving salmonella in recalled eggs. Midwest Poultry Services recalled certain white and brown cage-free eggs produced and distributed from farms in Texas. These are eggs that have sell by dates that run from July 20th through August 17th of 2026. We’ll include the FDA information in the episode notes because nobody should need to memorize such dates when listening to a podcast. But the key is certain eggs have been recalled in certain areas of Texas.

00:07:55:12 – 00:08:18:15
Steven Newmark
Check your refrigerator, do not eat a recalled product, return it or throw it away, and clean surfaces that may have come into contact. Food surveillance often works quietly behind the scenes. Laboratory staff identify clusters. Investigators interview patients. Officials trace products through complicated supply chains. That work prevents illness, but only when agencies communicate the results quickly and clearly enough for people to act.

00:08:18:19 – 00:08:35:04
Steven Newmark
You’re listening to The Health Advocates. Please subscribe wherever you listen to podcasts and share this episode with someone who may benefit from it. At the Global Healthy Living Foundation, we work to help people living with chronic illness understand the policies, scientific developments, and public health decisions that affect their lives. Now back to the show.

00:08:35:09 – 00:09:10:15
Steven Newmark
As of July 24th, the CDC has described national Covid 19 activity as low and relatively stable. Great news! However, the agency has identified early signs of increasing activity in the west and south of the United States. Separate CDC modeling has estimated that infections were growing or likely growing in 37 states as of July 22nd. The total level can remain low while the direction begins moving in an upward trend. Think of it like water at the bottom of the bathtub. The water may still be low at a low level, but once someone turns on the faucet, you start to pay attention to how fast it starts to rise.

00:09:10:16 – 00:09:47:16
Steven Newmark
We’re definitely not in a phase where we need to panic, but it’s probably time to prepare a little bit. People at greater risk for severe Covid 19, such as those who are immunocompromised, should consider whether they have usable home tests, know whom to call after a positive result, and understand whether they may qualify for antiviral treatment. Timing matters. Covid 19 treatments work best when patients start them early. Waiting several days to contact a healthcare professional can narrow the available options. Travel, summer gatherings, crowded indoor spaces increase exposure, as we all remember. So folks should make choices based on their own health risks and the risks of those around them.

00:09:47:17 – 00:10:12:10
Steven Newmark
For one person, that may mean doing very little differently. For someone receiving chemotherapy, taking immune suppressing medication, or caring for a medically fragile family member, it may mean using a high quality mask in crowded settings, improving ventilation, or testing before a visit. The goal is not to make everyone follow one universal rule, I think we learned that, but the goal is to give people accurate information so each person can make informed decisions that match their circumstances.

00:10:12:11 – 00:10:45:19
Steven Newmark
Speaking of Covid, an FDA advisory committee has recommended that the 26-27 Covid 19 vaccine target a newer JN.1-lineage variant known as XFG. Manufacturers and regulators still need to complete the steps that turn that recommendation into available vaccines and clinical guidance. Eligibility and timing may also depend on age, medical conditions, prior vaccinations, and evolving federal recommendations. Patients with chronic conditions should discuss timing with a knowledgeable healthcare professional, rather than assuming that everyone should follow the same schedule.

00:10:45:20 – 00:11:10:12
Steven Newmark
Another question receiving a lot of attention this summer concerns wildfire smoke in home gardens. Can you eat vegetables that have had exposure to smoke or ash? For smoke from burning vegetation, ash and smoke generally do not penetrate intact fruits and vegetables deeply. Thoroughly rinsing produce under cool running water can remove much of the material on the surface. You should also wash your hands after handling ash-covered produce. Do not use soap or household detergent on fruits and vegetables.

00:11:10:12 – 00:11:32:12
Steven Newmark
We’ve covered several concerning developments, but public health does not only consist of warnings. Researchers at Oxford have launched the world’s first phase one trial of a vaccine designed to protect against the Ebola virus. The trial will evaluate safety and immune responses in 50 healthy adult volunteers. Researchers and manufacturers have also prepared investigational doses that could support a faster response if the vaccine proved successful.

00:11:32:13 – 00:11:52:21
Steven Newmark
We’ve also received some encouraging news from El Salvador. The World Health Organization validated El Salvador as having eliminated trachoma as a public health problem. Trachoma can cause blindness and often affects communities with inadequate access to healthcare, clean water, and sanitation. El Salvador became the first country in Central America and the second in the Americas to reach this milestone. Excellent news!

00:11:52:22 – 00:12:13:23
Steven Newmark
The achievement did not come from one dramatic breakthrough, but rather from sustained surveillance, targeted assessments, and the willingness to keep looking for cases even as the numbers declined. That represents the part of public health that we often talk about that rarely receives enough attention. Success does not always look like a heroic rescue. Sometimes it’s just years of diligent work followed by the absence of a disease.

00:12:14:00 – 00:12:35:21
Steven Newmark
The stories we discussed today revealed many different public health futures. In one future, vaccination rates decline, preventable diseases return, food recalls leave consumers confused, and people with chronic illness struggle to obtain clear guidance. In the other, scientists are developing new vaccines, countries eliminate diseases that once caused blindness, and health systems give people the information they need before a crisis reaches them.

00:12:35:22 – 00:13:04:08
Steven Newmark
Neither future happens automatically. Public policy matters, scientific investment matters, trust matters, and individual choices matter. This week, consider taking three simple steps: check your family’s vaccination records, check your refrigerator for recalled foods, and update your personal plan for Covid 19 as we head into the fall season. Public health may feel invisible when it works. Those headlines show us both what happens when protection breaks down and what becomes possible when communities sustain it.

00:13:04:10 – 00:13:25:19
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please leave us a rating or review and share it with someone who cares about healthcare policy. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at ghlf.org/listen. I’m Steven Newmark, we’ll see you next time.

00:13:25:21 – 00:13:32:14
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

COVID-19 Isn’t Over for Everyone: Why FDA’s Next Decision Matters for Immunocompromised Patients

The COVID-19 public health emergency may be over, but for millions of Americans with weakened immune systems, the virus remains a serious concern.

In this episode of The Health Advocates, Steven Newmark breaks down a recent announcement from the U.S. Department of Health and Human Services to phase out COVID-19 Emergency Use Authorizations (EUAs) and explains why the decision matters for people who are immunocompromised. The transition will require the FDA to establish new regulatory pathways for certain COVID-19 drugs and biologics over the coming year, raising important questions about how patients will continue to access preventive therapies during that process.

Steven explains what an EUA is, why some immunocompromised patients need additional protection beyond vaccination, and why patient voices are essential as the FDA considers its next steps. Most importantly, he discusses how thoughtful patient advocacy can help ensure that regulatory decisions remain focused on science, continuity of care, and the needs of those who remain most vulnerable to COVID-19.

Whether you’re living with a chronic illness, caring for someone who is immunocompromised, or simply interested in how health policy affects patient care, this episode offers an accessible look at an important issue that could shape COVID-19 prevention for years to come.

COVID-19 Isn't Over for Everyone: Why FDA's Next Decision Matters for Immunocompromised Patients

00:00:00:10 – 00:00:09:08
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:10 – 00:00:27:22
Steven Newmark
Hello and welcome to The Health Advocates. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Each week, we break down the news and tell you what’s important in the world of health policy. Today, we’re talking about a federal announcement that hasn’t received much attention in the news, but could have important implications for millions of Americans who are immunocompromised.

00:00:27:23 – 00:00:59:22
Steven Newmark
Recently, the Department of Health and Human Services, HHS, announced its intention to phase out Covid 19 emergency use authorizations, known as EUAS. On its face, that may sound like a routine regulatory change. After all, we’re no longer living in the early days of the pandemic. But for many people living with chronic illnesses and weakened immune systems, the questions that follow are incredibly important. Will they continue to have access to the tools they rely on to protect themselves from Covid 19? Let’s talk about what this announcement means and why patient voices matter right now.

00:01:00:00 – 00:01:38:02
Steven Newmark
What is an emergency use authorization? An EUA is a mechanism that allows the Food and Drug Administration, the FDA, to make certain medical products available more quickly during a public health emergency. During the Covid 19 pandemic, EUAs helped bring vaccines, treatments, diagnostic tests and preventive therapies to patients much faster than traditional approval processes would have allowed. Now that the public health emergency has ended, HHS has announced that Covid-related EUAs will eventually come to an end as well. That doesn’t mean these products will disappear overnight. Instead, it means the FDA must determine the appropriate regulatory pathway moving forward.

00:01:38:03 – 00:02:02:01
Steven Newmark
Why does this matter? For many Americans, Covid 19 has become a manageable illness. But that isn’t true for everyone. Millions of us are immunocompromised because of an autoimmune disease, an organ transplant, cancer treatment, a primary immunodeficiency, or medications that we take that intentionally suppress our immune systems. These individuals often remain at much higher risk for severe illness as a result of Covid 19.

00:02:02:02 – 00:02:23:04
Steven Newmark
Vaccination continues to be one of the most important tools we have, and we strongly encourage everyone to discuss vaccination with your healthcare provider. But vaccines do not work equally well for every patient. Some people simply cannot mount a strong immune response even after receiving recommended vaccine doses. That’s why additional preventive options have been so important for many immunocompromised patients.

00:02:23:05 – 00:02:38:10
Steven Newmark
If any part of this is hitting close to home, raise your hand. Go to ghlf.org and sign up for our free newsletter. We break this down in plain language and tell you exactly what’s changing and what to watch for. You don’t need to follow a policy every day. That’s our job. But you should know when it affects you. Back to the show.

00:02:38:14 – 00:03:05:11
Steven Newmark
The issue today isn’t whether the EUAs should last forever. They should not. The real question is whether the FDA can establish a clear regulatory pathway before existing authorizations expire. If that pathway isn’t communicated in time, patients worry there could be an unnecessary gap in access to preventive therapies while manufacturers work through the traditional approval process. No patient wants to lose access because of regulatory timing rather than because of scientific evidence.

00:03:05:12 – 00:03:31:14
Steven Newmark
One thing we’ve learned over the years is that policymakers make better decisions when they hear directly from the people affected. Statistics are important, clinical trial data is important, but lived experience matters too. Patients understand what it’s like to carefully plan every trip outside of our homes, to wonder whether our medications make us more vulnerable, to worry whether the next Covid variant might affect us differently than it affects others. These perspectives deserve to be part of the conversation.

00:03:31:16 – 00:04:12:01
Steven Newmark
At GHLF our position is straightforward. We support science-based decision making. We support rigorous FDA review. We support moving from emergency authorities to traditional regulatory pathways when appropriate. At the same time, we believe immunocompromised patients should not experience unnecessary interruptions in access to evidence-based preventive options simply because regulatory processes are changing. Patients deserve clarity. Health care providers deserve clarity. And manufacturers deserve a predictable pathway that allows innovation while maintaining the FDA’s high standards for safety and effectiveness. Most importantly, patients deserve to know that their unique needs are being considered.

00:04:12:01 – 00:04:39:21
Steven Newmark
So, what can you do? If you or a loved one is immunocompromised, now is an appropriate time to make your voice heard. Follow developments from the FDA. Stay informed through trusted patient organizations like GHLF. Talk with your healthcare provider about your individual level of risk and the preventive options that may be appropriate for you. And if the FDA provides opportunities for public input, consider sharing your experience. Patient stories help policymakers understand the real-world impact of regulatory decisions.

00:04:39:22 – 00:04:59:09
Steven Newmark
Covid 19 may no longer dominate the headlines, but for many people living with chronic diseases, it remains a daily consideration. As the FDA develops the next chapter of Covid regulation, we hope patient voices remain at the center of that conversation. We’ll continue following this issue closely, and we’ll keep you informed as new developments emerge.

00:04:59:11 – 00:05:21:00
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please leave us a rating or review and share it with someone who cares about healthcare policy. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at ghlf.org/listen. I’m Stevan Newmark, we’ll see you next time.

00:05:21:01 – 00:05:27:19
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

How America Learned to Live Longer: 250 Years of U.S. Health Policy

Host Steven Newmark traces 250 years of U.S. health policy, beginning with George Washington’s bold decision to inoculate the Continental Army against smallpox and continuing through the development of life-saving vaccines, the creation of the National Institutes of Health, the Centers for Disease Control and Prevention, Medicare, Medicaid, and the Department of Health and Human Services.

The episode also explores America’s response to major public health emergencies, from the 1918 influenza pandemic and HIV/AIDS to COVID-19, including the remarkable development of mRNA vaccines and what they may mean for the future of medicine.

Whether you’re a history buff, a healthcare professional, or simply curious about how science, public policy, and innovation have transformed American life, this special Independence Day episode offers a fascinating look at the milestones that helped Americans live longer, healthier lives over the past two and a half centuries.

How America Learned to Live Longer: 250 Years of U.S. Health Policy

00:00:00:10 – 00:00:10:10
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:10:12 – 00:00:33:02
Steven Newmark
Welcome to The Health Advocates. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. We’re here to tell you what’s happening in the world of healthcare to make informed decisions to live your best life. This year, America is celebrating its 250th birthday. When we think about our nation’s history, we usually think about wars, presidents, constitutional debates, economic booms and busts, and technological breakthroughs.

00:00:33:02 – 00:01:06:07
Steven Newmark
But today, we’re going to tell a different story. The story of America through the lens of health. Because over the last 250 years, the United States has fought countless battles, not just on battlefields, but against epidemics, chronic diseases, infant mortality, unsafe food, contaminated water, smoking, HIV, cancer, Covid 19, and many other threats. Along the way, America built institutions, developed groundbreaking medical discoveries, expanded access to care, and dramatically increased both the length and the quality of our lives.

00:01:06:09 – 00:01:20:00
Steven Newmark
The story isn’t perfect. There have been mistakes along the way. There have been disagreements. There have been setbacks. But there has been extraordinary progress. Let’s begin before the United States was even born.

00:01:20:01 – 00:01:51:18
Steven Newmark
George Washington almost certainly saved the American Revolution with a public health decision. That’s right. As a teenager, Washington traveled to Barbados, where he contracted smallpox. He survived, but many others did not. Smallpox was among the deadliest diseases in human history, killing roughly one third of those infected and often leaving survivors permanently scarred or blind. Years later, during the Revolutionary War, Washington watched as smallpox swept through the Continental Army. Disease killed far more soldiers than British bullets. Washington faced a difficult choice.

00:01:51:19 – 00:02:25:04
Steven Newmark
At the time, there was no vaccine as we know it today. Instead, physicians practiced inoculation, intentionally exposing people to a milder form of smallpox to produce immunity. It carried real risks, but Washington realized that allowing smallpox to spread unchecked posed an even greater threat. In 1777, he ordered the mass inoculation of the Continental Army. Many historians believe that decision preserved the army that ultimately won American independence. One of America’s earliest victories depended not just on military strategy, but on public health strategy.

00:02:25:05 – 00:02:46:00
Steven Newmark
Few discoveries have saved more lives than vaccines. The first vaccine against smallpox appeared in the late 1700s. Over the next two centuries, vaccines protected generations of Americans against diseases like tetanus, pertussis, measles, mumps, rubella, hepatitis and many others. Then, of course, came one of the most feared diseases of the 20th century: polio.

00:02:46:01 – 00:03:06:10
Steven Newmark
Every summer, parents feared outbreaks. Swimming pools closed, movie theaters emptied. Children literally became paralyzed. Some spent months or years inside iron lungs because the disease prevented them from breathing. Then, in 1955, Doctor Jonas Salk introduced the first successful polio vaccine. The results transformed public health.

00:03:06:10 – 00:03:26:16
Steven Newmark
Within years, polio cases plummeted. When a reporter asked Doctor Salk who owned the patent, he famously replied, “Well, the people, I would say. There is no patent. Could you patent the sun?” His answer reflected the hope of an entire generation. Vaccines remain one of the medicine’s greatest achievements, preventing millions of deaths every year around the world.

00:03:26:17 – 00:03:57:05
Steven Newmark
Scientific discoveries alone are not enough. Countries also need institutions capable of protecting public health. That process begins gradually. A small federal laboratory established in the late 19th century eventually grew into the National Institutes of Health. Today, NIH supports research that has helped produce breakthroughs in cancer treatment, heart disease, and Alzheimer’s disease, autoimmune disorders, rare diseases, genetics, and precision medicine. Many medicines Americans rely on today can trace part of their development to NIH supported research.

00:03:57:06 – 00:04:25:09
Steven Newmark
Another milestone came after World War II. The Centers for Disease Control and Prevention, the CDC, evolved from a small agency focused on malaria control into America’s premier public health agency. For decades, the CDC has tracked disease outbreaks, investigated food borne illnesses, monitored vaccines, helped eliminate infectious diseases, reduced tobacco use, strengthened emergency preparedness, improved maternal and child health, and provided the surveillance systems that allow us to recognize new health threats quickly.

00:04:25:10 – 00:04:48:21
Steven Newmark
Health also gained a permanent seat in the president’s cabinet. The Department of Health, Education, and Welfare was established in 1953. In 1980, it became the Department of Health and Human Services that we know today. HHS currently oversees agencies that influence nearly every aspect of American healthcare, from biomedical research to Medicare/Medicaid, the Food and Drug Administration, and the nation’s general public health responses.

00:04:48:22 – 00:05:19:02
Steven Newmark
One of the most significant moments in American health policy arrived in 1965. President Lyndon Johnson signed Medicare and Medicaid into law. Before Medicare, many older Americans struggled to obtain health insurance after retirement. Medicare fundamentally changed that reality. Medicaid provided healthcare coverage for millions of low income children, adults, seniors, and people with disabilities. Together, these programs now provide health coverage to well over 100 million Americans and have become central pillars of the nation’s healthcare system.

00:05:19:03 – 00:05:54:12
Steven Newmark
America’s health system has also been tested by crisis. In 1918, the influenza pandemic killed hundreds of thousands of Americans and millions more worldwide. It revealed the devastating impact infectious diseases could have on entire societies. Beginning in the 1980s, HIV and AIDS challenged medicine, public health, and society itself. At first, doctors had few answers. Patients faced fear, stigma, and limited treatment options. Over time, remarkable scientific advances transformed HIV from what was often a fatal diagnosis into a chronic condition that many people can successfully manage for decades.

00:05:54:13 – 00:06:21:08
Steven Newmark
Public health also confronted threats ranging from Legionnaires disease and West Nile virus to H1n1 influenza, Ebola, Zika, and opioid overdoses. Each emergency has strengthened our surveillance systems, our preparedness, and our scientific collaboration. Then came Covid 19. The pandemic touched virtually every American family. It strained hospitals, it disrupted our school system, exposed weaknesses in our healthcare system, and it claimed more than 1 million lives here in the United States.

00:06:21:09 – 00:06:55:17
Steven Newmark
Healthcare workers performed extraordinary work under incredibly difficult circumstances. Scientists around the world collaborated at unprecedented speed. Perhaps the most remarkable scientific achievement was the rapid development of mRNA vaccines. Although they seemed to appear almost overnight, the technology rested on decades of research funded by governments, universities, and private industry. Messenger RNA, or mRNA, teaches our own cells to temporarily produce a harmless piece of a virus, allowing the immune system to recognize it and prepare defenses without exposing oneself to the virus itself.

00:06:55:18 – 00:07:18:23
Steven Newmark
The success of those vaccines demonstrated not only the power of modern science, but also the importance of sustained investment in biomedical research. Today, researchers are exploring mRNA technology for flu, RSV, and personalized cancer vaccines, among others. Covid also accelerated telehealth, strengthened laboratory networks, and highlighted both the strengths and challenges of America’s public health infrastructure.

00:07:19:00 – 00:07:47:09
Steven Newmark
The Affordable Care Act expanded health insurance coverage to millions of Americans. It prohibited insurers from denying coverage because of preexisting conditions. It also allowed young adults to remain on their parents healthcare plans until age 26. It expanded access to preventive services and strengthened patient protections. Like many landmark laws throughout history, it has generated rigorous political debate. But regardless of where one stands politically, the Affordable Care Act significantly reshaped the American healthcare system.

00:07:47:10 – 00:08:23:20
Steven Newmark
250 years after George Washington confronted smallpox, America’s health challenges continued to evolve. Today, we face chronic diseases that account for many deaths. We confront rising health care costs. Mental health needs continue to grow. Artificial intelligence promises to transform diagnosis and treatment. Gene therapies are curing diseases once thought incurable. Precision medicine allows treatments to be tailored to individual patients. Researchers continue working toward vaccines and therapies for Alzheimer’s disease, cancer, autoimmune conditions, and countless other rare diseases. The next breakthrough may already be taking shape in a laboratory today.

00:08:23:20 – 00:08:42:13
Steven Newmark
As we celebrate our 250th birthday, it’s worth remembering that the nation’s story is not only written in the Declaration of Independence or in the history books. It’s also written in the hospital wards, research laboratories, public health departments, in the lives of millions of patients whose futures changed because someone asked a simple question: how can we do better?

00:08:42:14 – 00:08:59:06
Steven Newmark
Over two and a half centuries, America has built one of the world’s most influential systems of biomedical research, public health, and medical innovation. It hasn’t always been easy. It’s not always perfect. But generation after generation has pushed medicine forward here in the United States. That is a legacy worth celebrating.

00:08:59:11 – 00:09:14:06
Steven Newmark
Thank you for joining me on this special 250th anniversary episode of The Health Advocates. If this episode helped you understand what’s happening in the healthcare world, if you found it interesting, please share it with someone who needs it. And if you have thoughts for us, please leave a comment down below. We’d love to hear from you.

00:09:14:07 – 00:09:30:23
Steven Newmark
You can find our podcasts on YouTube, Spotify, or Apple Podcasts, or wherever else you find your podcasts. Be sure to check out all of our podcasts at ghlf.org/podcasts. I’m Steven Newmark, we’ll see you next time.

00:09:31:00 – 00:09:37:18
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

What Patients Need to Know: Research, Innovation, and the Patient Voice At EULAR 2026

What happens at one of the world’s largest rheumatology conferences, and why should patients care?

In this special episode of The Health Advocates, Steven Newmark is joined by Dr. Shilpa Venkatachalam, Director of Patient-Centered Research at the Global Healthy Living Foundation (GHLF), to discuss the biggest takeaways from EULAR 2026, the annual congress of the European Alliance of Associations for Rheumatology.

The conversation explores why conferences like EULAR are so important for advancing patient care, how researchers, physicians, and patient advocates work together to shape the future of rheumatology, and why the patient voice has become an essential part of medical research.

Steven and Shilpa also highlight GHLF’s contributions to this year’s conference, including two original research posters examining barriers to the early recognition of hidradenitis suppurativa and the unmet informational and support needs of people living with Sjögren’s disease. Along the way, they discuss exciting emerging trends in rheumatology and clinical care, especially the increasing emphasis on patient-reported outcomes.

Whether you’re living with a rheumatic disease, caring for someone who is, or simply interested in the future of healthcare, this episode offers an inside look at how today’s research is helping shape tomorrow’s treatments—and why patient perspectives are more important than ever.

Access the GHLF HS Diagnosis Accelerator: https://ghlf.org/hscheck/

What Patients Need to Know: Research, Innovation, and the Patient Voice At EULAR 2026

00:00:00:10 – 00:00:09:14
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:16 – 00:00:43:16
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down issues, innovations, and policies shaping the future of healthcare. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Today we’re taking you inside EULAR 2026 once again, the annual congress of the European Alliance of Associations for Rheumatology. Each year, thousands of researchers, physicians, healthcare professionals, patient advocates, and industry leaders gather from around the world to share new research, discuss emerging treatments, and collaborate on improving care for people living with rheumatic and musculoskeletal diseases.

00:00:43:16 – 00:01:07:00
Steven Newmark
But EULAR is more than just a scientific conference. It is a place where research meets real world patient experience, and that’s one reason GHLF participates every year. Joining me today is my colleague Doctor Shilpa Venkatachalam. Shilpa serves as the Director of Patient Centered Research at GHLF, where she leads initiatives designed to ensure that patient experiences, priorities, and outcomes are incorporated into healthcare research.

00:01:07:00 – 00:01:09:06
Steven Newmark
Shilpa, welcome back to The Health Advocates.

00:01:09:07 – 00:01:11:11
Shilpa Venkatachalam
Thank you, Steven. Thanks for having me today.

00:01:11:12 – 00:01:19:06
Steven Newmark
Let’s start with the basics. For listeners who may not be familiar with EULAR, what is it and why is this such an important event in rheumatology?

00:01:19:07 – 00:01:54:09
Shilpa Venkatachalam
Yeah. So EULAR is the premier scientific and advocacy body for rheumatic and musculoskeletal diseases in Europe. So essentially it’s the annual state of the Union, think of it that way for the entire field. And the closest American equivalent is ACR, or the American College of Rheumatology. And together what they do is they set the global tone. So many of the most important guidelines for rheumatoid arthritis, lupus, and others are generally issued jointly by both organizations. So you can think of them as two pillars at the same house.

00:01:54:09 – 00:02:17:21
Shilpa Venkatachalam
Now, over about 12,000 health professionals attend annually alongside patient advocates. And what’s really important, at least for Global Healthy Living Foundation, as we’re a patient advocacy organization, is EULAR’s PARE program, which formally embeds patient voices into the scientific program, which is really a big part of why it matters beyond just the science.

00:02:17:22 – 00:02:25:17
Steven Newmark
You tend to think of conferences like EULAR as primarily being for physicians and researchers. Why is it important for groups like GHLF to be present?

00:02:25:18 – 00:02:53:11
Shilpa Venkatachalam
Yeah, so that’s a great question. So for patients, this is where future treatments are essentially born, right? So the drug your rheumatologist is going to prescribe, say, in five years, is being debated here today. And critically, the question of whether a clinical trial measures what you actually care about, and by you I mean the patient, your ability to work, sleep, hold your child, go to graduations and other social events gets decided in rooms like this one at EULAR.

00:02:53:12 – 00:03:22:10
Shilpa Venkatachalam
So when patients engage in spaces like EULAR, everything changes, right? The science changes. What we measure changes. How we measure changes. What’s important changes. And when they don’t participate, it quite simply doesn’t. And so because science is incomplete without the patient perspective, it is really important for advocates, patient advocacy organizations, and the patient voice to be one of the central voices in spaces like EULAR.

00:03:22:13 – 00:03:29:16
Steven Newmark
And you specifically presented a poster on hidradenitis suppurativa. Can you tell us about that research and what you found?

00:03:29:17 – 00:03:56:00
Shilpa Venkatachalam
Yes. So we’re very, very excited to present a poster on HS, or hidradenitis suppurativa, which is a chronic, painful inflammatory condition. It’s a skin condition. And the project actually came directly from the HS community that’s part of the Global Healthy Living Foundation’s ecosystem and what patients were telling us via that community. And so by the time patients got a diagnosis, how many years they’d lost, right?

00:03:56:01 – 00:04:20:00
Shilpa Venkatachalam
We used focus group discussions. We used rapid cycle community polls, to capture why this delay keeps happening in a disease like this one. And we tried to understand it from patient’s own experience and in their own voices. So again, you know, this is a very, very painful inflammatory skin condition causing recurring abscesses and lesions, most often in the underarms and in the groin.

00:04:20:00 – 00:04:47:07
Shilpa Venkatachalam
And so it also comes with a great deal of stigma. Our data, for example, showed more than a third of patients, so that’s a pretty big number, right, waited over six years for a correct diagnosis. Imagine living with a disease without a diagnosis. That means you can’t start treatment. So in our focus group, several people traced their first symptoms back, in fact, to ages 13 and 14. But weren’t diagnosed sometimes until their 30s or 40. So really heartbreaking.

00:04:47:07 – 00:05:10:03
Shilpa Venkatachalam
And we found that the most consistent barrier were symptoms being written off as a hygiene or infection issue. So, you know again, a lot of stigmatization, right? One participant in fact, told us that they saw four dermatologists before getting answers. The contrast case was striking. There was one patient diagnosed within a year and had a single provider who knew to refer them to the right specialist.

00:05:10:03 – 00:05:50:10
Shilpa Venkatachalam
So the takeaway for clinicians, when a patient keeps coming back with recurring painful symptoms in those characteristic locations is really to dig deeper. And that’s what we were trying to get across. It has recognizable patterns. And for patients who hear themselves in these stories, we built with the support of UCB, which is a pharmaceutical company, we built a HS diagnostic accelerator, which you can find at GHLF. And that diagnostic accelerator is meant to help patients identify their symptoms, talk to their clinicians better about this condition, so that clinicians can then help to get them to a diagnosis faster and get faster treatment.

00:05:50:10 – 00:05:55:21
Steven Newmark
And you also had a poster on, GHLF had a poster on Sjögren’s disease. What was that about?

00:05:55:22 – 00:06:17:11
Shilpa Venkatachalam
Yeah. So Sjögren’s is another chronically under-resourced condition relative to how much it disrupts people’s lives. Again, this is a systemic inflammatory condition. And patients told us that they felt pretty lost after diagnosis. You know, they were sort of handed a label but not a roadmap on how to navigate the many challenges that come with living with these conditions.

00:06:17:11 – 00:06:54:18
Shilpa Venkatachalam
So we conducted a structured international survey, again co-developed with patient partners. And a lot of people, I think more than 200 actually, responded. The top priority, reported by 83% of those people who took the survey, was requirement of better information and managing symptoms and flares. The other thing that we see repeatedly that keeps coming up across inflammatory and systemic autoimmune diseases is fatigue. And this came up again and again, even with the Sjögren’s community, which really matters because it’s one of the most disabling features of Sjögren’s, but one of the least understood in clinical care because it doesn’t show up in blood work and labs, et cetera.

00:06:54:19 – 00:07:21:20
Shilpa Venkatachalam
So by and large, I would say three gaps stood out: systemic symptoms, like musculoskeletal and neurological issues, weren’t being recognized is what we were told. There was almost no guidance around hormonal transitions like menopause. Again, a very under-resourced area. And even though many patients were reporting worsening symptoms during that time, they felt overwhelmed navigating a disease that touches nearly every organ system with very fragmented care.

00:07:21:20 – 00:07:46:14
Shilpa Venkatachalam
So, you know, these are the messages we wanted to get across the scientific community to help support better care, to help support better outcomes for patients. And so for the community, what we want is more evidence-based information, more support and understanding the priorities that patients put up there. What symptoms do patients need to be addressed in order to feel better alongside, of course, clinical control of the disease?

00:07:46:15 – 00:07:47:16
Steven Newmark
Absolutely, yeah.

00:07:47:17 – 00:08:02:06
Shilpa Venkatachalam
Just one thing to add, at GHLF we have a lot of support for the Sjögren’s community as well. So if you’re looking for additional information or you’re just diagnosed with Sjögren’s, then please know that GHLF.org has a ton of resources and support for you.

00:08:02:08 – 00:08:10:04
Steven Newmark
Did you see any evidence at EULAR that researchers are placing a greater emphasis on patient-reported outcomes and patient-centered research?

00:08:10:05 – 00:08:50:04
Shilpa Venkatachalam
So absolutely, Steven. It’s a really good question. It’s actually one of the most meaningful shifts that I’ve witnessed in the field. Let’s just go back even five years ago, right? Patient-reported outcomes were a secondary endpoint, almost like an afterthought. Now they’re increasingly the primary measure of whether or not a treatment actually works. And the old model was: design the study, run the trial or the study, then ask patients if they liked it. The new model now starts with patients asking, “What matters enough to even study this?” You know? Fatigue, cognitive function, brain fog, work participation: outcomes that never made traditional trials because they were considered too soft are now being integrated.

00:08:50:04 – 00:09:25:00
Shilpa Venkatachalam
And so EULAR has been a real driver of this, especially with their PARE track. And what we’ve noticed at this congress is that patient involvement is becoming an expectation. It’s not an exception anymore. So researchers are now increasingly being asked, and sometimes required actually, to demonstrate how patients shape their study. Is a patient centered? Is a patient designed? And that accountability is new and it really matters. So involvement still varies widely in quality. And, as we say at GHLF, ticking a box is not genuine partnership. Our job is really to keep raising that bar.

00:09:25:05 – 00:09:47:01
Steven Newmark
Well, this has been great. Thank you so much for all that you do, of course, on behalf of patients. I get to see it every day, day in and day out, all the great work. And thank you for sharing it with the audience, with our patients, our community. And in the theme of this episode, thank you specifically for going to places like EULAR, going to conferences, and making sure that the patient voice, patient centered outcomes are part of that equation.

00:09:47:01 – 00:09:57:16
Steven Newmark
And it’s fascinating to hear the difference in terms of how patient-centered outcomes are seen in the rheumatology community today versus a decade ago, as you described it earlier. So that’s fantastic. Thank you.

00:09:57:17 – 00:10:13:23
Shilpa Venkatachalam
Thank you, Steven. And a big shout out to our patient community who relentlessly and generously continues to participate in these efforts, and also to the clinicians we work with who are always committed to bringing the voice of the patient in everything that they do. So again, thank you for having me today.

00:10:14:00 – 00:10:25:14
Steven Newmark
Shilpa, thank you for joining us. One of the things I appreciate most about conferences like EULAR is that they remind us that healthcare innovation is not just about new medicines or new technologies, it’s about understanding patients better.

00:10:25:15 – 00:10:49:14
Steven Newmark
This year, GHLF contributed important research on both hidradenitis suppurativa and Sjögren’s disease, while also helping to ensure that patient experiences remain part of the broader scientific discussions. And that’s exactly where patient advocacy organizations can make a difference. By connecting science, medicine, and lived experience, we can help ensure that innovation ultimately leads to better outcomes for the people who matter most: patients.

00:10:49:16 – 00:11:01:22
Steven Newmark
Thank you to our listeners for tuning in to The Health Advocates. Find us wherever you listen to your podcasts, and be sure to leave us a rating or review as it will help others like you find us. I’m Steven Newmark, we’ll see you next time.

00:11:02:00 – 00:11:08:16
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

What’s Coming For Rheumatology: Why Conferences Like EULAR Matter for Patients

What actually happens at a major international medical conference — and why should patients care?

In this episode of The Health Advocates, Steven Newmark reports from EULAR 2026 in London, one of the world’s largest rheumatology conferences, to explain how meetings like this help shape the future of patient care. The episode explores why conferences matter not just for doctors and researchers, but for patients and advocacy organizations as well.

Steven discusses how practicing clinicians learn about the latest medical advances, how researchers connect directly with physicians treating patients every day, and why organizations like GHLF play an important role in bringing real-world patient experiences into scientific and medical conversations.

The episode also highlights several emerging themes already generating excitement at EULAR this year, including the growing role of artificial intelligence in rheumatology and the potential future of CAR-T and cell therapies for autoimmune diseases like lupus and rheumatoid arthritis.

Most importantly, the conversation explains how scientific innovation ultimately connects back to what matters most: improving the daily lives of patients.

What’s Coming For Rheumatology: Why Conferences Like EULAR Matter for Patients

00:00:00:10 – 00:00:09:06
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:08 – 00:00:29:10
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of what’s happening in the health care world. I’m Stephen Newmark, Chief Policy Officer of the Global Healthy Living Foundation, and this week I’m recording from London, where I’m attending one of the world’s largest rheumatology conferences: EULAR, the European Alliance of Associations for Rheumatology.

00:00:29:11 – 00:00:53:12
Steven Newmark
Now, if you’re not in medicine or research, you might hear the word “conference” and picture doctors sitting through endless PowerPoint presentations and drinking too much coffee. And yes, there is definitely some of that going on here. But conferences like EULAR are actually incredibly important for patients because this is where new science gets unveiled, researchers and clinicians exchange ideas, pharmaceutical companies present emerging therapies, and patient voices increasingly shape the future of care.

00:00:53:12 – 00:01:20:19
Steven Newmark
And for organizations like GHLF, these meetings are not just about networking. They are about making sure the patient perspective is present in rooms where important health care decisions and innovations are taking shape. So today, I want to pull back the curtain a little bit and explain what actually happens at conferences like EULAR, why they matter for patients, and some of the major themes already emerging this year, including artificial intelligence and the growing excitement around CAR T and cell therapies for autoimmune diseases.

00:01:20:20 – 00:01:40:16
Steven Newmark
Let’s start with the basics. One of the most important things that happens at EULAR is education. Thousands of rheumatologists from around the world gather to hear the latest research and clinical updates. And medicine changes very quickly as we all know. New drugs emerge. New safety information develops. Researchers discover new ways to diagnose and treat disease.

00:01:40:16 – 00:02:08:03
Steven Newmark
For practicing doctors, conferences are often one of the fastest ways to stay current, and this matters directly to patients because the doctors sitting in front of you next month may change how they approach treatment based on something they learned this week at EULAR. That can mean earlier diagnoses, better disease management, more individualized treatment approaches, or awareness of therapies that were not available even a few days ago. These conferences help bridge the gap between research and real world patient care.

00:02:08:04 – 00:02:46:23
Steven Newmark
Another critical part of conferences like EULAR is collaboration. Researchers do not work in isolation. At meetings like this, scientists present data directly to clinicians who treat patients every day, and those conversations matter enormously. Researchers may develop promising therapies in controlled clinical trials, but practicing doctors ask practical questions. How will this work in the real world? What about older adults? What about patients with multiple chronic conditions? What about quality of life and long term safety? That exchange improves the science itself, and importantly, it helps move innovation closer to the realities patients actually face every day.

00:02:47:00 – 00:03:10:18
Steven Newmark
Now let’s talk about where organizations like GHLF fit into all of this. Years ago, many medical conferences were almost entirely focused on researchers, physicians, and the industry. That has changed dramatically. Today, patient organizations are increasingly recognized as essential partners in health care discussions because patients bring something no lab test or academic paper can fully capture: lived experience.

00:03:10:21 – 00:03:40:09
Steven Newmark
At GHLF, part of our role is connecting scientific progress with real world patient outcomes. That means talking about access barriers, insurance challenges, medication affordability, fatigue, mental health, daily function, and quality of life. A treatment can look impressive on paper, but if patients cannot access it, tolerate it, afford it, or meaningfully benefit from it in their daily lives, then the story is not complete. Patient advocacy organizations help keep the healthcare system grounded in real life.

00:03:40:09 – 00:04:13:04
Steven Newmark
Now, let’s talk about one of the most exciting areas researchers are discussing at EULAR this year. Many listeners have heard of CAR T in the cancer world. These are advanced therapies where immune cells are engineered or modified to target disease in very precise ways: lupus, rheumatoid arthritis, Sjögren’s disease, and systemic sclerosis. This is one of the biggest conceptual shifts happening in rheumatology right now. For decades, treatment has largely focused on suppressing the immune system continuously over time. But researchers are increasingly asking, could we someday fundamentally reprogram the immune system itself?

00:04:13:04 – 00:04:40:06
Steven Newmark
Now, a very important caveat here. These therapies are still early on. They are complex, they are very expensive right now, and they are certainly not around the corner for most patients. But the excitement in the research community is real. I’m meeting with some of these doctors, some of these scientists, and I could feel the excitement. And one of the valuable things about conferences like EULAR is getting an early sense of where medicine may be heading over the next decade. So stay tuned to see what more is coming in the world of CAR T.

00:04:40:08 – 00:05:08:01
Steven Newmark
Another major theme at EULAR this year is artificial intelligence and digital health. AI is now showing up across almost every part of rheumatology research, including imaging analysis, predicting disease flares, identifying patterns in large data sets, remote monitoring of patients, and personalized treatment selection. Now, whenever people hear AI, there’s often a tendency to jump immediately to extremes: either AI will solve everything or AI is going to replace everything. Neither is realistic.

00:05:08:02 – 00:05:43:07
Steven Newmark
The more practical reality is that AI may increasingly become a tool that helps clinicians make better, faster, and more personalized decisions for patients. For example, AI may eventually help identify which patients are most likely to respond to certain therapies or which patients may be at higher risk for complications. That could improve care dramatically. But there are also important questions, such as data privacy, bias in algorithms, and access to technology. Technology is there to support, rather than replace, human relationships in the healthcare world. So this is an area with enormous promise, but also important caution.

00:05:43:08 – 00:06:01:09
Steven Newmark
If you want to help staying informed about the latest advances in rheumatology and chronic disease care, visit ghlf.org and sign up for our free newsletter. We translate complicated medical and policy developments into plain language, so patients and caregivers can stay informed without needing a medical degree. That’s what we’re here for. Back to the show.

00:06:01:10 – 00:06:29:12
Steven Newmark
One of the most encouraging trends in rheumatology is how much more attention researchers are paying to patient reported outcomes. Not just inflammation scores, imaging, lab results but also fatigue, pain, work limitations, emotional health, ability to function day to day. That shift did not happen by accident. It happened because patient organizations and advocates push the field to recognize that managing disease is not just about controlling lab values, it’s about helping people live fuller, healthier lives. And increasingly, researchers are listening.

00:06:29:12 – 00:06:52:23
Steven Newmark
So if you’re listening and wondering, “Why should I care about a healthcare conference happening in London?” here’s why: because these meetings help shape the future of care. They influence what our doctors learn, what treatments move forward, what researchers prioritize, and how patient experiences are incorporated into medicine. And while patients may not be physically in every room, organizations like GHLF work hard to make sure patient voices are represented.

00:06:53:00 – 00:07:26:00
Steven Newmark
At its best, medicine is collaborative. Researchers, clinicians, patient advocates and patients themselves all bring different perspectives and conferences like EULAR create a space where those perspectives can come together. That does not mean every exciting study becomes a breakthrough overnight, but it does mean progress happens faster when people share ideas, challenge assumptions, and keep patients at the center of the conversation. Over the next few days, I’ll continue listening, learning, and bringing back the most important themes and developments to our community, because scientific progress only matters if it ultimately improves people’s lives.

00:07:26:02 – 00:07:50:11
Steven Newmark
Thanks for listening to The Health Advocates. If this episode helped you understand why conferences like EULAR matter, share it with someone who may not realize how much happens behind the scenes in medicine and research. And don’t forget to visit ghlf.org to stay informed about the latest developments in healthcare, advocacy, and research. Be sure to hit that subscribe button on YouTube, Apple Podcasts, or wherever you’re listening right now, I’m Steven Newmark, we’ll see you next time.

00:07:50:13 – 00:07:57:06
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Inside the Growing Fight Over Vaccine Science

Something bigger than a single vaccine debate is unfolding inside America’s public health system.

In this episode of The Health Advocates, Steven Newmark explores the growing tension surrounding vaccine policy, scientific transparency, and public trust. From the FDA’s decision not to review a new mRNA flu vaccine application to reports of delayed vaccine safety studies and shifting federal recommendations, the episode connects a series of recent developments that together point to a broader transformation inside federal health agencies.

The conversation examines why some officials argue these changes are restoring scientific rigor, while many scientists and public health advocates worry they are creating confusion and weakening confidence in vaccines. Most importantly, the episode focuses on what this means for patients trying to navigate healthcare decisions in an increasingly uncertain environment.

Inside the Growing Fight Over Vaccine Science

00:00:00:10 – 00:00:08:13
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:08:15 – 00:00:28:23
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. For those who don’t know me, I lead advocacy and policy here at GHLF. I’m a lawyer by training a professor, and also someone navigating this health care system alongside you.

00:00:28:23 – 00:00:55:16
Steven Newmark
Today, we’re talking about something bigger than one vaccine, one agency or one headline. We’re talking about trust because right now, something important is happening inside America’s public health system. Federal health agencies are changing how they communicate about vaccines, how they review studies, and how they make recommendations. Scientists are raising concerns, public confidence is slipping, and patients are increasingly caught in the middle trying to figure out what and who to believe.

00:00:55:18 – 00:01:18:12
Steven Newmark
This month alone, the FDA declined to review a new Moderna flu vaccine application. Reports emerged about delayed or blocked vaccine safety studies. Legal fights over vaccine recommendations continued, and new polling showed declining confidence in several vaccines. At first glance, those might sound like separate stories, but together they point to a larger shift happening in public health right now.

00:01:18:12 – 00:01:32:07
Steven Newmark
So today we’re going to connect the dots. What’s changing inside federal health agencies, why scientists and advocates are concerned, why supporters say these changes are necessary, and what all this means for patients and families. Let’s start with the FDA.

00:01:32:09 – 00:01:53:10
Steven Newmark
Recently, the FDA declined to review a new flu vaccine from Moderna. The vaccine used mRNA technology, the same platform used in Covid vaccines. Now, this was not a rejection of the vaccine itself. The FDA said there were concerns related to how the study was designed and which comparison vaccine Moderna used in its trials. Scientific disagreements like this happen, but context matters.

00:01:53:10 – 00:02:23:19
Steven Newmark
This decision comes during a period where vaccine-related products appear to be receiving heightened scrutiny under new agency leadership. And for patients, the issue is not really about trial design. It’s about confidence in the process. When people hear a vaccine wasn’t reviewed, studies were delayed, recommendations are changing, they naturally start asking bigger questions. Is the science changing? Are standards changing? Is politics influencing public health decisions? And those questions matter because public health depends on trust.

00:02:23:20 – 00:02:45:05
Steven Newmark
The FDA recently also brought reports that federal officials delayed or blocked publication of several vaccine safety studies. According to these reports, the studies involved Covid vaccines and shingles vaccines and found that serious side effects were very rare. Administration officials reportedly argued the studies required additional review or had methodological concerns.

00:02:45:06 – 00:03:10:09
Steven Newmark
Critics argue that withholding or delaying findings, especially findings supporting vaccine safety, can undermine public confidence and fuel confusion. And here’s the difficult reality: even when scientific review is appropriate, a lack of transparency creates uncertainty. Patients do not see the internal methodological debates. They simply hear a study was blocked, and in today’s environment, that alone becomes part of the story.

00:03:10:10 – 00:03:33:17
Steven Newmark
At the same time, polling shows confidence in several vaccines is declining. Most Americans still believe vaccines are safe. That’s important. But trust in the flu vaccines, MMR vaccines, and Covid vaccines has declined over the last several years. And that decline is happening during massive outbreaks of measles, an ongoing Covid circulation, and a recently severe flu season. So what’s driving all of this?

00:03:33:18 – 00:04:01:02
Steven Newmark
It’s not just misinformation. It’s inconsistency. When messaging changes, when recommendations shift, when agencies appear divided, when politics and science become harder to separate, people lose confidence. And once trust erodes, rebuilding it becomes very difficult. One of the biggest changes happening right now is the move toward more individualized vaccine recommendations. Instead of broad universal recommendations, some vaccines are increasingly being placed under something called shared clinical decision making.

00:04:01:02 – 00:04:26:13
Steven Newmark
We’ve talked about this on the program before. That means that patients and doctors discuss risks and benefits together, and decide whether vaccination makes sense for that individual. Now, in some contexts, shared decision making is absolutely appropriate. It sounds like a great thing, right? But critics argue that when a vaccine moves from strongly recommended to an optional discussion, patients often interpret it that as the vaccine is less necessary or maybe less safe.

00:04:26:14 – 00:04:47:07
Steven Newmark
It also puts doctors in a disadvantage, as they don’t want to expend energy, time trying to convince a patient of something so critical as taking vaccines. That subtle shift can reduce vaccine uptake, even if the underlying science itself has not changed. That is one reason why public health organizations and medical societies are increasingly vocal right now.

00:04:47:08 – 00:05:06:22
Steven Newmark
If any part of this feels confusing, you’re not alone. Go to ghlf.org and sign up for our free newsletter. We break these issues down in plain language and explain what they actually mean for patients and families. You do not need to spend hours following FDA policy debates and scientific controversies. That’s our job. But you deserve clear information when these decisions affect your health. Back to the show.

00:05:06:23 – 00:05:34:03
Steven Newmark
Stepping back, this is about much more than one vaccine or one study. We are watching a broader transformation in how federal health agencies approach evidence, risk, communication, public trust. Supporters of these changes say agencies are restoring vigor, asking harder questions, and moving away from automatic deference to pharmaceutical companies. Critics worry the opposite is actually happening: that scientific norms are becoming politicized, communication is becoming inconsistent, and public confidence is weakening.

00:05:34:03 – 00:05:57:10
Steven Newmark
And for patients, this creates a difficult environment because most people are not reading clinical trial protocols or FDA briefing documents. They’re simply trying to answer, can I trust the system that is supposed to protect my health? So what should patients take away from all of this? First, do not confuse policy debate with sudden scientific collapse. Vaccines that have been studied for years did not suddenly become unsafe overnight.

00:05:57:11 – 00:06:20:04
Steven Newmark
Second, recognize that public health guidance is becoming more complicated and more individualized. That means conversations with trusted healthcare providers matters more than ever. And third, stay informed from credible, balanced sources. Because when trust becomes fragile, clear communication matters enormously. Public health depends on more than science alone. It depends on credibility, consistency, and trust.

00:06:20:05 – 00:06:38:12
Steven Newmark
Right now, all three are being tested. And whether these changes ultimately strengthen public confidence or weaken it may depend less on politics and more on whether patients feel they are getting honest, transparent, evidence-based information. That is the challenge facing public health right now, and it’s one we’ll continue following closely here at The Health Advocates.

00:06:38:13 – 00:06:54:07
Steven Newmark
If you want to take a step further, join us at the 50 State Network. You can sign up at 50StateNetwork.org. Because health policy does not just happen inside agencies and courtrooms. It affects real people making real decisions every day.

00:06:54:09 – 00:07:17:04
Steven Newmark
Thanks for listening to The Health Advocates. If this episode helped you understand what’s happening, share with someone who needs it. And if you have thoughts for us, leave a comment down below. We’d love to hear from you. To stay informed on all the policy information you need, click the button below that says subscribe. It’s totally free to you and lets you stay up to date when new episodes come out each week. I’m Steven Newmark, we’ll see you next time.

00:07:17:06 – 00:07:24:00
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

The Latest Updates on Vaccine Policy: What Patients Need to Know

Vaccine policy in the United States is going through a period of change — and for many patients, that change is creating confusion.

In this episode of The Health Advocates, Steven Newmark breaks down a series of recent developments that are reshaping how vaccines are reviewed, recommended, and discussed. From the FDA’s decision not to review a new mRNA flu vaccine, to shifting federal guidance around vaccine recommendations, to new data showing declining public confidence, the conversation connects the dots across what can otherwise feel like isolated headlines.

The episode also explores the growing legal challenge to recent changes in vaccine policy and what it signals about the broader direction of public health decision-making. Most importantly, it focuses on what all of this means for patients — including how to navigate mixed messages, where to turn for reliable information, and why the doctor-patient relationship is becoming more important than ever.

This is a moment of transition in public health. And for patients, understanding that shift is key to making informed decisions.

The Latest Updates on Vaccine Policy: What Patients Need to Know

00:00:00:10 – 00:00:09:02
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:04 – 00:00:24:01
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. For those who don’t know me, I lead advocacy and policy here at GHLF.

00:00:24:03 – 00:00:39:18
Steven Newmark
I’m a lawyer by training, a policy professional, and also someone living the system beside you. My job every day is to take what’s happening in Washington and translate it into what it actually means for patients. And sometimes what it means isn’t always obvious until it’s already affecting you.

00:00:39:18 – 00:01:06:15
Steven Newmark
Before we get into it, I want to ground this in something real. Recently, I heard from a parent in our community. She told me, “I don’t know what to believe anymore. One doctor says one thing, the news says another, and now I’m not even sure what the government recommends.” That’s what today is about. Because when it comes to vaccines right now, something is shifting. It’s not just policy, it’s not just messaging, but trust. And when trust starts to erode in public health, patients feel it immediately.

00:01:06:15 – 00:01:20:04
Steven Newmark
So today we’re going to start to connect the dots. What’s happening at the FDA, what’s happening with vaccine recommendations specifically, why confidence in vaccines is dropping, and what this all means for you when you sit down with your doctor.

00:01:20:04 – 00:01:52:20
Steven Newmark
Let’s start with the FDA. Last week, the FDA made a surprising move. It refused to review a new flu vaccine from Moderna. Now, this is important. The FDA did not just reject the vaccine outright. It declined to review the application as submitted. Here’s why this matters. The vaccine uses mRNA technology, the same platform used in Moderna’s Covid vaccines, and the disagreement centers on how Moderna designed its trials, specifically which existing flu vaccine used as a comparison.

00:01:52:20 – 00:02:17:08
Steven Newmark
That may sound technical, and it is, but zoom out for a moment. This is happening in a broader environment where vaccines are receiving more scrutiny than they have in the past. And for patients, the takeaway is not about trial design, it’s about uncertainty. When people hear that a vaccine isn’t even being reviewed, it raises questions. Is something wrong with the vaccine? Is the process changing? Are vaccines being treated differently?

00:02:17:08 – 00:02:40:03
Steven Newmark
Even if the answer is simply a scientific disagreement, the perception matters because perception shapes trust. Now let’s talk about the trust directly. New data shows that confidence in vaccines is slipping. We’re still talking about majorities, overwhelming majorities, in fact, of people who still believe that vaccines are safe. But the trend is moving in the wrong direction.

00:02:40:04 – 00:03:12:02
Steven Newmark
Confidence in flu vaccines is down. Confidence in the MMR vaccine is down. Confidence in Covid vaccines remains lower than all of the others. And this is happening during a measles outbreak, during a very recent difficult flu season and during other ongoing public health challenges. So what’s driving this? It’s not just misinformation, it’s mixed signals. When recommendations change, when agencies appear inconsistent, when scientific processes feel less clear, people don’t necessarily reject vaccines, they hesitate.

00:03:12:03 – 00:03:35:17
Steven Newmark
That brings us to one of the most important shifts happening right now the move towards something called shared clinical decision making. In simple terms, this means certain vaccines are no longer strongly recommended across the board. Instead, they are something you discuss with your doctor and decide together. On paper, that sounds quite reasonable. More choice, more conversation, more personalization.

00:03:35:17 – 00:04:04:03
Steven Newmark
But here’s the challenge: when a vaccine moves from strongly recommended to something optional, it changes how people interpret it. Doctors may feel less confident in recommending it, patients may interpret it as less important, and overall the signal becomes weaker. This is exactly what many public health experts are worried about because in population health, clarity matters. Strong recommendations lead to strong uptake. Uncertainty leads to hesitation.

00:04:04:03 – 00:04:25:16
Steven Newmark
And now this is moving into the courts. The American Academy of Pediatrics has challenged recent changes to vaccine policy. And they are not alone. More than 100 public health organizations and experts have stepped in to support that challenge. Their concern is straightforward. They believe changes to vaccine recommendations are weakening a system that is protected patients for decades.

00:04:25:17 – 00:04:48:17
Steven Newmark
The argument is not just about policy outcomes, it’s about process. For years, vaccine recommendations followed a structured, evidence based approach. When that process changes or appears to change, it raises concerns about consistency and credibility. And again, for patients, this shows up as confusion. Who should I trust? What is actually recommended? What is optional? Those are real questions people are asking right now.

00:04:48:20 – 00:05:05:23
Steven Newmark
If any part of this is staying close to home, raise your hand. Go to www.ghlf.org and sign up for our newsletter. We break this down in plain language and tell you exactly what’s changing and what to watch for. You don’t need to follow a policy every day. That’s our job. But you should know when it’s affecting you.

00:05:06:03 – 00:05:43:16
Steven Newmark
Okay, let’s take a step back, because all of these stories, FDA decisions, changing recommendations, legal challenges point to something bigger. We’re in a moment where the system that guides vaccine policy is shifting. Not collapsing, not disappearing, but changing. And when systems change, there is always a period of instability. For patients, that could mean more questions, that could mean less clarity, that could mean more reliance upon individual clinicians. That last point is very important because as federal guidance becomes less definitive, more responsibility shifts to the doctor patient relationship. And these doctors are often overburdened, as is.

00:05:43:17 – 00:06:10:08
Steven Newmark
So what should you take away from all of this? First, vaccines themselves have not suddenly changed. The science behind them, especially for long established vaccines, remains quite strong. Second, it’s the environment around the vaccines that is changing and that can make it harder to navigate decisions. Third, your relationship with your healthcare provider matters more than ever because in a world with less centralized clarity, that is where decisions are going to be made.

00:06:10:08 – 00:06:36:03
Steven Newmark
And finally, trust matters. Not blind trust, of course, but informed trust. Asking questions, seeking credible sources. Having real conversations. That’s how patients navigate moments like this. Public health works best when it is clear, consistent and trusted. Right now we are seeing cracks in that clarity, not because the science has disappeared, but because the system around it is evolving. And when that happens, patients feel it first.

00:06:36:04 – 00:06:51:00
Steven Newmark
So if you take one thing away from today’s episode, it’s this: if something feels confusing, you’re not alone. But don’t disengage, lean in, ask questions, stay informed. Because these decisions affect your health, your family, and your community.

00:06:51:01 – 00:07:12:00
Steven Newmark
If you want to go a step further, join us at the 50StateNetwork.org. That’s 50StateNetwork.org. Five zero state network dot org. It’s free , it’s patient driven, and it’s how thousands of people across the country are making sure their voices are heard. Because at the end of the day, health policy isn’t about headlines, it’s about people.

00:07:12:01 – 00:07:35:21
Steven Newmark
Thanks for listening to The Health Advocates. If this episode helped you understand what’s happening, share it with someone who needs it. And if you have thoughts for us, leave a comment down below. We’d love to hear your perspective. To stay informed on all the policy information you need, click the button below that says subscribe. It’s totally free to you and lets you stay up to date when new episodes come out each week. I’m Steven Newmark, we’ll see you next time.

00:07:35:23 – 00:07:42:16
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Proposed Cuts, Real Impact: Understanding the New Healthcare Budget

The federal budget may feel distant, but its impact on healthcare is anything but. In this episode of The Health Advocates, Steven Newmark breaks down the Trump administration’s newly proposed budget, which includes significant cuts to the Department of Health and Human Services, reductions in research funding, and a major restructuring of federal public health programs.

But this conversation goes beyond what’s proposed. We also examine what’s already happening on the ground following last year’s federal policy changes, including substantial reductions in Medicaid funding that are placing pressure on state budgets and leading to coverage losses for millions of Americans.

This episode connects the dots between federal decisions and real-world consequences — from access to care and public health preparedness to the future of medical research. For patients, caregivers, and advocates, it offers a clear look at where healthcare policy is heading and why these budget decisions matter now.

Proposed Cuts, Real Impact: Understanding the New Healthcare Budget

00:00:00:08 – 00:00:08:13
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:08:15 – 00:00:23:02
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer here at the Global Healthy Living Foundation. For those who don’t know me, I lead advocacy and policy here at GHLF.

00:00:23:04 – 00:00:43:04
Steven Newmark
I’m a lawyer by training, a professor, and also someone living the system alongside you. My job every day is to take what’s happening in Washington and around the country and translate it into what it actually means for patients. And sometimes what it means isn’t obvious until it’s already affecting you. Before we get into it, I want to ground this in something real.

00:00:43:06 – 00:01:05:01
Steven Newmark
Last week, I heard from a woman in our community, let’s call her Mary. She has a chronic condition, she relies on Medicaid, and she said to me, “I don’t follow policy, but I can feel something changing.” That’s what today is about because policy doesn’t stay in Washington. It shows up in your life. Today, we’re talking about the federal budget and why this moment is different.

00:01:05:03 – 00:01:20:09
Steven Newmark
Because this is no longer just about proposals. We’re already seeing real world impact. So today we’re going to connect the dots. What the new proposed budget includes, what has already changed on the ground, and what this means for patients right now.

00:01:20:11 – 00:01:30:21
Steven Newmark
Let’s start with the proposal. At a high level, the Trump administration is proposing a 12.5% reduction in discretionary spending for the Department of Health and Human Services.

00:01:30:23 – 00:01:57:11
Steven Newmark
That would bring HHS funding down to about $111 billion, compared to roughly 125 billion today. This is not as steep as what was proposed last year, but it is still significant. And like all budget proposals, it tells us something important: what is being prioritized and what is not. So what does that actually mean? It means fewer resources behind the scenes that help keep people stable before they ever show up in a doctor’s office.

00:01:57:12 – 00:02:17:00
Steven Newmark
One of the biggest structural changes is the creation of a new entity called the Administration for a Healthy America, or AHA. The goal is to consolidate programs across the CDC, HRSA, and SAMHSA. The administration says this will reduce duplication and save about $5 billion.

00:02:17:06 – 00:02:34:22
Steven Newmark
But consolidation also often means elimination. Programs tied to chronic disease, mental health, and community-based public health could be reduced or disappear entirely. So while the language focuses on efficiency, the impact is a redefinition of what public health priorities look like.

00:02:35:00 – 00:02:51:16
Steven Newmark
Additionally, there are pending cuts to research in this proposal. This proposal includes $5 billion in cuts to the National Institute of Health, NIH, which is about a 10% reduction. NIH funds the pipeline that leads to new treatments and long term medical progress.

00:02:51:18 – 00:03:09:06
Steven Newmark
Several institutes are also on the chopping block, including those focused on minority health and global research. Here’s the translation: fewer shots on goal for the treatments patients are waiting for. These cuts don’t show up tomorrow, but over time, they shape what medicine looks like in the next decade.

00:03:09:07 – 00:03:23:13
Steven Newmark
The budget also proposes reducing funding for public health infrastructure, including preparedness programs, emergency response systems, and hospital readiness programs. These are the systems you don’t think about until you need them, and by then it’s too late to rebuild them.

00:03:23:15 – 00:03:43:19
Steven Newmark
Several programs that directly impact access to care are also targeted, including family planning services, child health programs, community services, and energy assistance. These may not sound like healthcare programs per se, but they are deeply connected to health. When they go away, patients feel it through reduced access, increased financial stress, and worse outcomes over time.

00:03:43:21 – 00:04:01:15
Steven Newmark
So where is funding actually increasing in this budget? Well, there are increases in the health budget in areas such as food safety, environmental health, artificial intelligence, and some telehealth. These reflect a shift in priorities for the administration. But they exist, of course, alongside the broader reductions elsewhere.

00:04:01:17 – 00:04:25:01
Steven Newmark
Now here’s the critical point: what is already happening? This is not what’s proposed in a budget, but what is actually happening on the ground. We are not starting from zero here. Last year’s legislation already reduced Medicaid funding by about 665 billion over the next decade, and the effects are already showing up. States are tightening eligibility, adding work requirements, reducing enrollment.

00:04:25:03 – 00:04:46:15
Steven Newmark
The result is that an estimated 7.6 million fewer people are going to be enrolled on Medicaid over time. If you’re listening and you rely on Medicaid, or might one day rely on Medicaid, this is where it becomes personal. This is about whether you still qualify, whether your benefits change, whether your doctor still takes your plan. This is not theoretical, this is practical.

00:04:46:17 – 00:05:03:17
Steven Newmark
If any part of this is sitting close to home, raise your hand. Go to GHLF.org and sign up for our free newsletter. We break this down in plain language and tell you exactly what’s changing and what to watch for. You don’t need to follow a policy every day. That’s our job. But you should know when it affects you.

00:05:03:19 – 00:05:28:04
Steven Newmark
Okay, stepping back to the proposed budget, there is a broader shift that’s happening. The federal government is reducing its role and shifting more responsibility to the states. In theory, that creates flexibility for health plans. In practice, it creates variability across the healthcare ecosystem. Some states will be able to absorb these changes, others won’t. Which means where you live will increasingly determine the care that you get.

00:05:28:10 – 00:05:51:06
Steven Newmark
So what does this mean for patients? What should you take away? First, this is a moment of transition in our healthcare. Second, access is becoming more uneven across the country. Third, as always, advocacy matters. The reason deeper cuts didn’t happen last year is because people spoke up. And that will matter again. We need your voices to fight these pending cuts to our healthcare ecosystem.

00:05:51:08 – 00:06:06:11
Steven Newmark
Budgets are where priorities become real. And right now, we’re watching decisions that will shape who gets access to care and who doesn’t. So if you take one thing from today, it’s this: pay attention when things feel like they’re changing because they are. And you don’t have to navigate it alone.

00:06:06:12 – 00:06:23:01
Steven Newmark
If you want to go a step further, join us at the 50statenetwork.org. It’s free, it’s patient driven, and it’s how thousands of people across the country are making sure their voices are heard. Because at the end of the day, health policy isn’t about numbers. It’s about people.

00:06:23:03 – 00:06:36:06
Steven Newmark
Thanks for listening to The Health Advocates. If you found this episode helped you understand what’s happening, share it with someone who needs it. And don’t forget to sign up at GHLF.org to stay informed. I’m Steven Newmark. We’ll see you next time.

00:06:36:07 – 00:06:42:20
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Courts vs. Vaccine Policy: Who Decides?

A federal court has halted sweeping changes to U.S. vaccine policy, raising fundamental questions about who shapes public health decisions and how those decisions are made. In this episode, we break down the ruling, the role of the CDC’s vaccine advisory committee, and why the court found the administration’s actions unlawful. We also explore what this means for patients, providers, and the future of evidence-based policymaking.

Courts vs. Vaccine Policy: Who Decides?

00:00:00:08 – 00:00:08:22
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:09:00 – 00:00:26:06
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Health Policy Officer at the Global Healthy Living Foundation. Our goal is to help you understand what’s happening in the health care world, to help you make informed decisions to live your best life.

00:00:26:08 – 00:00:47:05
Steven Newmark
This week, we’re at a crossroads. Today, we’re diving into a major federal court ruling that just stopped, at least for now, a sweeping overhaul of U.S. vaccine policy. At the center of this case is who gets to decide vaccine recommendations in this country, and whether those decisions can ignore decades of scientific process. This is not just a legal story.

00:00:47:05 – 00:01:13:10
Steven Newmark
It’s a public health story. And it’s a patient story. So let’s start with the basics. A federal judge in Boston blocked efforts by the Trump administration to change the nation’s vaccine recommendations, including reducing the number of vaccines recommended for children. The court also put a hold on sanctions taken by the CDC’s key advisory body, known as ACIP, after all of its members were removed and replaced by the health secretary.

00:01:13:12 – 00:01:39:20
Steven Newmark
The judge’s reasoning was blunt. The administration acted in a way that was, quote, arbitrary and capricious, a legal term meaning it ignored scientific and procedural norms. As a result, the prior vaccine schedule is now back in place, at least temporarily. This case goes far beyond vaccines. It’s really about three things. First, the rule of law. Federal agencies can change policy, but they have to follow process.

00:01:40:00 – 00:02:09:19
Steven Newmark
You cannot just swap out experts and rewrite policy without justification. Second, the role of science in policymaking. For decades, vaccine recommendations have relied on a structured, evidence based process. The court is essentially saying you cannot bypass that process. Third, institutional integrity. When you remove an entire advisory committee and replace it with individuals who may not meet traditional qualifications, you risk undermining trust in the system itself.

00:02:09:21 – 00:02:35:17
Steven Newmark
Okay, so let’s get into what ACIP is and why you should care. We’ve spoken about ACIP many times on the podcast, but a little review is certainly in order here. ACIP is not a household name, but perhaps at this point it should be. This is the group that determines which vaccines are recommended, for whom and when. Those recommendations shape what doctors advise, what insurance companies cover, and what vaccines are required for school entry.

00:02:35:22 – 00:03:01:04
Steven Newmark
So when ACIP changes, the ripple effects hit every family in the country. And in this case, the court said those changes were not done properly. The administration didn’t just tweak the system here. It has attempted a major shift. It’s reduced the number of recommended childhood vaccinations. It’s currently reconsidering Covid vaccine guidance, and it’s moving essentially towards a very different model for how vaccine policy is set.

00:03:01:06 – 00:03:30:23
Steven Newmark
The judge in this case found that these decisions did not follow the longstanding scientific process, and instead appear to sidestep it entirely. That’s what triggered the initial legal challenge for major medical organizations, such as the American Academy of Pediatrics. So what happens next? This case is far from over. The administration has already said that it will appeal. This means that a federal appeals court will likely weigh in, and there’s a real chance that this eventually ends up at the United States Supreme Court.

00:03:31:04 – 00:03:56:13
Steven Newmark
So what we’re seeing now is a pause, not a final decision. So let’s bring this back to what matters most – patients. In the short term, The ruling creates stability. The existing vaccine schedule stays in place. But in the longer term, there are bigger questions. Will patients continue to trust vaccine recommendations? Will coverage decisions remain consistent? Will science continue to drive policy?

00:03:56:15 – 00:04:24:18
Steven Newmark
Or will politics play a larger role? These are not abstract questions. They affect whether people get vaccinated and whether they can access care. There is a broader tension here. On one side, a push to rethink vaccine policy and challenge longstanding assumptions. On the other, a system built on decades of scientific consensus and procedural safeguards. The court, at least for now, has come down on the side of the process and evidence at its core.

00:04:24:22 – 00:04:50:19
Steven Newmark
This case is about trust. Trust in science. Trust in institutions, and trust that decisions affecting millions of patients are carefully, transparently based on evidence. We’ll be watching this case closely, because the next chapter could reshape how public health policy gets made in this country. Thanks for listening to The Health Advocates, a podcast that breaks down major Health News of the week to help you make sense of it all.

00:04:50:21 – 00:05:12:07
Steven Newmark
If you found this episode helpful, please leave us a rating or review and share it with someone who cares about health care policy. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcast at GHLF.org/listen. I’m Steven Newmark. We’ll see you next time.

00:05:12:09 – 00:05:18:22
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

What an NDA Means for Patients with Osteoarthritis

For people living with osteoarthritis, news about potential new treatments often comes with more questions than answers. In this episode of The Health Advocates, we slow things down to explain what it really means when a company submits a New Drug Application, or NDA, to the U.S. Food and Drug Administration.

Steven Newmark is joined by Erich Horsley and Dr. Yusuf Yazici from Biosplice Therapeutics to walk through this important regulatory milestone and why it matters for patients. Together, they break down what an NDA is, what happens during FDA review, and what patients should and should not expect while a therapy is under evaluation. The conversation also explores the current osteoarthritis treatment landscape, why progress in this disease has been so challenging, and what researchers mean when they talk about disease-modifying approaches.

What an NDA Means for Patients with Osteoarthritis

00:00:00:08 – 00:00:06:20
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:06:22 – 00:00:08:16
Narrator

00:00:08:18 – 00:00:25:18
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Our goal is to help you understand what’s happening in the health care world, to help you make informed decisions to live your best life.

00:00:25:19 – 00:01:01:01
Steven Newmark
Today’s conversation is educational. We’re discussing a recent regulatory milestone involving an investigational therapy that has been submitted to the FDA for review. We’ll explain the process and help make patients make sense of what these headlines actually mean. Our guests today are Erich Horsley, CEO of Biosplice Therapeutics, and Dr. Yusuf Yazici, Chief Medical Officer of Biosplice. Mr. Horsley, as I mentioned, is the CEO of Biosplice, a biotechnology company focused on developing novel therapies for musculoskeletal and other serious conditions and diseases, including osteoarthritis.

00:01:01:04 – 00:01:32:16
Steven Newmark
He brings more than a decade of leadership experience across biotech, pharmaceuticals and health care innovation. With a background spanning decades in private equity, corporate strategy, commercialization and late stage drug development. At Biosplice, he oversees the company’s strategic direction, operations and regulatory strategy as Biosplice works to address conditions with significant unmet patient needs. Dr. Yusuf Yazici is the chief medical officer of Biosplice Therapeutics and a practicing rheumatologist with extensive experience in clinical research and patient care.

00:01:32:16 – 00:02:08:14
Steven Newmark
He is internationally recognized for his work in inflammatory and degenerative joint diseases, including osteoarthritis, and has led or participated in numerous clinical review trials evaluating new therapies for chronic musculoskeletal conditions. Dr. Yazici has led the development of Biosplice’s innovative osteoarthritis drug for the past decade through 11 clinical trials and now the regulatory approval stages. In addition to his role at Biosplice, he brings a patient centered perspective grounded in decades of treating people living with chronic pain and mobility limitations.

00:02:08:16 – 00:02:11:14
Steven Newmark
Well, welcome. Thank you for being here, both of you, today.

00:02:11:16 – 00:02:13:12
Erich Horsley
Thank you very much. It’s a pleasure to be here.

00:02:13:18 – 00:02:14:13
Dr. Yusuf Yazici
Thank you very much.

00:02:14:13 – 00:02:33:14
Steven Newmark
We hear a lot of scientific headlines, especially when it comes to new drugs, but very few of them explain what’s actually happening behind the scenes. So we’re going to slow this down. Recently, a new drug application, often called an NDA was submitted for an investigational osteoarthritis therapy called Lorecivivint.

00:02:33:15 – 00:02:36:20
Steven Newmark
I hope I pronounce that correctly, but if not, one of you will correct me, right?

00:02:36:23 – 00:02:38:00
Dr. Yusuf Yazici
Lorecivivint.

00:02:38:01 – 00:02:51:10
Steven Newmark
We’ll call it LOR for today. To make my life a little bit easier. Now for patients, this NDA process raises questions. What does that mean? Is this a decision? Is this access or are we still years away or is something sooner coming on the horizon?

00:02:51:11 – 00:03:08:08
Steven Newmark
So to help unpack all of this, we’ll get into it. To start off, could you briefly introduce yourself? I gave little bios before we started, but if you have anything to add, you know, at least if you might mention how long you’ve been working in this space, what do patients with osteoarthritis most often tell you about their experience and so forth.

00:03:08:09 – 00:03:10:04
Steven Newmark
We’ll start with Mr. Horsley, the CEO.

00:03:10:05 – 00:03:28:01
Erich Horsley
Sure. So I’ve been here about a decade. My background, as you mentioned, has been in private equity, where I’ve kind of grown and developed companies for many years. But Biosplice is quite unique. You know, biotechs, they don’t typically have any revenue. What they do is they they raise money and they invest in the development of drugs.

00:03:28:04 – 00:03:49:20
Erich Horsley
And very often biotechs develop a drug in the early stages and flip it to a pharma company. We’re one of the very few biotechs to design, in this case Lorecivivint, our asset for OA, really from scratch. So we designed the molecule, we discovered the science. We took it through phase one, phase two, phase three. And now it’s on the doorstep of approval with the FDA in the form of an NDA application.

00:03:49:20 – 00:04:17:09
Erich Horsley
And so that is what makes us a bit unique as we’ll get into arthritis is an extremely difficult disease to develop in. We’ve run 11 clinical trials over the years, all very well controlled, U.S.-run, placebo-controlled trials. And we’ll get into the data and what that means for patients. But it’s been a long journey and we’re just thrilled to have this asset potentially available for patients after approval, because there is simply nothing out there for patients that is both safe and effective, in my opinion.

00:04:17:11 – 00:04:22:17
Erich Horsley
And we’ll talk a little bit about that more. But we’re just we’re really thrilled to be able to potentially put forth this asset.

00:04:22:17 – 00:04:29:18
Steven Newmark
And Dr. Yazici, can you tell us a little bit more about your background, particularly as a rheumatologist, in working with OA patients?

00:04:29:21 – 00:04:38:09
Dr. Yusuf Yazici
I’m a rheumatologist by training. I’ve been with Biosplice for close to about 12 years now, but I’ve been a practicing rheumatologist for over 25 years.

00:04:38:09 – 00:04:57:05
Dr. Yusuf Yazici
And osteoarthritis is a very common condition. It is the most common joint disease that rheumatologists see. It can be in the hip or the knee. Knee osteoarthritis is more common than the hip. And that’s what we’re working in right now. And what happens basically is these patients really do not have any good options to stop the progression of the condition.

00:04:57:07 – 00:05:20:18
Dr. Yusuf Yazici
Now, you may be familiar with rheumatoid arthritis, which is another inflammatory condition which affects about 3 million or so patients in the US. Whereas knee osteoarthritis is about 25 to 30 million, but we have, over the last 20 to 25 years, developed many disease modifying drugs and familiar names are Enbrel, Humira, Remicade and such, which have changed the course of rheumatoid arthritis.

00:05:20:21 – 00:05:40:13
Dr. Yusuf Yazici
No such drugs have been available for osteoarthritis, even though there are more than ten times the number of patients. So that’s a huge unmet need. And the current therapies, as we can talk about, are not very effective and have potentially a lot of adverse events. So that has limited their use and the benefit they provide to osteoarthritis patients.

00:05:40:14 – 00:05:59:18
Steven Newmark
You know, it’s always fantastic when we hear about new therapies coming out in this space or any space really involving diseases. I just want to dig in a little bit more about what is a new drug application. When you hear that a company has submitted a new drug application, what does that actually mean? What is an NDA in plain language?

00:05:59:18 – 00:06:28:12
Dr. Yusuf Yazici
So you can think of it as the final document. That’s the culmination of years of both starting with animal studies, then going over to human studies and multiple phases of human studies. And we have been doing it for close to ten years. That’s if you look at the literature, that’s the average time it takes to take a drug from the very beginning, when it’s just a molecule, through all the stages that you’re required to go through to get it to the drug stage, where it can be used in humans.

00:06:28:16 – 00:06:55:21
Dr. Yusuf Yazici
So you start first with animal studies that where you show the safety of the drug, you find the dose that’s appropriate for human use. And then you submit those to the FDA and they review it And if they agree that this is safe enough and there is potential for efficacy, then they allow you to start testing it in humans. So the next stage is first you do the human trials where you look at the safety and then you establish the safety in humans. Then you go to larger numbers of patients where you look at the efficacy.

00:06:55:21 – 00:07:16:16
Dr. Yusuf Yazici
And for osteoarthritis, the major efficacy that any drug in osteoarthritis has to show is in improving pain. However, that’s not usually the only thing that’s wrong in the disease. There’s functional impairment. There is structural damage that happens to the joint. So we have been able to show benefits in all those areas. But those are this what’s called the phase two and phase three trials.

00:07:16:16 – 00:07:38:16
Dr. Yusuf Yazici
And you usually do a multiple of those. And you need to get at least the minimum number of patients exposed to the drug. So you can establish a reliable safety data set. And then you meet with the FDA when all of this is done, and you go over your data, you tell them that you’re going to prepare the package for submission, they give you pointers, they ask you to do certain things, which we’ve gone through all those stages.

00:07:38:16 – 00:07:56:00
Dr. Yusuf Yazici
Then you basically work on it. So we last met with the FDA the summer of 24. It took us about a year, year and a half to put the NDA package, the new drug application. You also, in addition to all your clinical data, you have to manufacture the drug to certain specification and quality.

00:07:56:02 – 00:08:20:08
Dr. Yusuf Yazici
So when, if it’s approved, then it’s available and those quality measures are in place. So we have been doing that in parallel also. So you put that data, the manufacturing data, the animal data, the human data all into this large document, which in our case is about close to about 100,000 pages. Then you submit it to the FDA, which we have done December 31st, 2025. So about a month ago.

00:08:20:12 – 00:08:41:06
Dr. Yusuf Yazici
And then the process is in the FDA’s hands. And what they do is they take the first 60 days to do kind of a technical review of the package that you sent to decide if it’s reviewable, because it has many parts. There are certain programs they want specified and how the package is submitted so they can review it appropriately so they go over that.

00:08:41:06 – 00:09:11:00
Dr. Yusuf Yazici
So after 60 days, what’s called they accept it which means they file it. So we submit 60 days. They file. And that filing is what starts the official FDA review clock, which usually is about ten months. And that’s what we expect is going to be happening. So in March we’re hoping to be filed then ten months to March, which takes you to the end of this year as the first time we will be hearing if it’s approved or not. And after that, of course, then it becomes available for patients to use.

00:09:11:00 – 00:09:21:10
Steven Newmark
So just for clarification, we are looking at if all is successful, all goes well, we are looking at approximately a 2027 date of launch for the therapeutic itself?

00:09:21:15 – 00:09:23:05
Dr. Yusuf Yazici
Yeah, early 2027.

00:09:23:07 – 00:09:24:10
Steven Newmark
Early 2027.

00:09:24:10 – 00:09:27:15
Erich Horsley
If we’re lucky, it could be late 26. But that’s roughly the timeline.

00:09:27:20 – 00:09:38:21
Steven Newmark
Okay. Well that’s helpful. You know, it’s also as a side note, it’s a reminder of how extensive the FDA process actually is in terms of reviewing for safety and efficacy. So that’s always great.

00:09:39:02 – 00:09:49:14
Steven Newmark
Let’s talk about osteoarthritis itself because there are millions of people of course, living with this condition. I once had a doctor tell me you may not have osteoarthritis today, but if you live long enough, you will.

00:09:49:17 – 00:10:02:11
Steven Newmark
It’s as hard to avoid as getting gray hairs is what the doctor actually said to me. You mentioned the current treatment landscape and where it’s lacking. Why is OA historically been such a difficult disease to make progress in compared to other chronic conditions?

00:10:02:11 – 00:10:18:18
Dr. Yusuf Yazici
That’s a very good question. So up until recently, osteoarthritis was felt to be well, it’s just part of aging. There isn’t much you can do, everybody ages, just like you can’t do much for the white hairs. Joint gets worn out, it gets painful. And people felt that was part of just the aging process.

00:10:18:18 – 00:10:50:05
Dr. Yusuf Yazici
But now we know that osteoarthritis isn’t just a simple wear and tear disease. Wear and tear of course, does play a role. Obesity is a risk factor. Trauma in the past is a risk factor. There are some genetic risk factors, but it’s a complicated disease in that there are inflammatory events that are happening that contribute to the pain and the cartilage degeneration, there are changes not in the cartilage in the joint, but also the bone and other tissues around it. So it’s been realized over the last 10 to 15 years that it’s not a simple wear and tear, age related condition only.

00:10:50:05 – 00:11:12:05
Dr. Yusuf Yazici
That has led to identification of a lot of targets of things that are going wrong in the knee that could be targeted with medications. So the last 10 to 15 years has seen a lot of new drugs coming into clinical trial space. When we first started, there were about 8 to 10 other companies with other drugs that were starting out that clinical trials, too.

00:11:12:06 – 00:11:41:21
Dr. Yusuf Yazici
Right now, as far as we know, from publicly available information, we’re the only ones that have finished phase three and submitted an NDA. There are some earlier phase ongoing work with some other molecules. So there is a lot of interest for sure, especially with the realization that this is a more complicated disease than people have assumed. Not only that, about half the patients with osteoarthritis of the knee are younger than 65, which is they’re in their productive years, they’re working. They really functional limitations doesn’t do them any justice.

00:11:42:00 – 00:12:07:02
Dr. Yusuf Yazici
So it’s a serious unmet need. That’s one of the reasons FDA recognizes osteoarthritis as a serious condition, because it’s also been shown to increase not just morbidity, but mortality. Osteoarthritis, in addition to because it affects the function, patients don’t move around as much, it just makes things worse overall and contributes to coronary artery disease, diabetes and is a separate risk factor.

00:12:07:02 – 00:12:30:01
Dr. Yusuf Yazici
So this has also led to more interest in osteoarthritis. So we’re hoping we’re leading kind of the wave of potentially new drugs that will come into the osteoarthritis field. The other issue has been all the currently available drugs for osteoarthritis only try to treat pain. The most common ones are not anti-inflammatories. However, they provide short term pain relief and they have potentially also side effects.

00:12:30:01 – 00:12:55:08
Dr. Yusuf Yazici
They can impact gastrointestinal stomach bleeding. They can impact the heart. They can impact the kidneys, blood counts. They interact with other medications. So most rheumatologists and orthopedists use these at the lowest dose for the shortest duration of time. Then we have opioids for pain. But as you know, because of the opioid crisis, it is very hard to use opioids or anything really, other than oncology related pain. And they do have a lot of side effects, of course.

00:12:55:10 – 00:13:13:20
Dr. Yusuf Yazici
Then there are a couple injection options. Steroid, corticosteroid injections, into the joint, into the knee, are very commonly used. But even though they do provide about 6 to 8 weeks, let’s say, pain relief, maybe sometimes up to three months, repeated uses of corticosteroid injections have been shown to actually damage the cartilage.

00:13:13:20 – 00:13:32:06
Dr. Yusuf Yazici
So it’s a balance that we have to hit by, we have to and want to help the patients, but we might be damaging the joint even further. And then the last one is the hyaluronic acid derivative injections, which are approved as devices because they kind of are supposed to improve the lubrication in the joint. We use them too. There are several of them approved for use.

00:13:32:06 – 00:13:49:08
Dr. Yusuf Yazici
However, they’re not really supported by the American College of Rheumatology or American Association of Orthopedic Surgeons because even though they’re safe, the efficacy data has always been questionable in some people’s mind. So, but we still use them. I use them because patients really do not have any options and they might help.

00:13:49:10 – 00:14:19:20
Dr. Yusuf Yazici
Now, all of these are to help the pain. There is nothing available, very unlike rheumatoid arthritis where the drug actually stops and even reverses the damage to the joint’s structure itself. So if you have a drug that helps with the symptoms of pain and improves function and improves the structure, that’s what we call a disease modifying drug. So that’s what we feel Lorecivivint is the first one because in our clinical trials, we have been able to show improvement in pain, improvement in function and improvement in structure.

00:14:19:23 – 00:14:35:04
Dr. Yusuf Yazici
And that’s kind of the holy grail because we want to improve the symptoms of course. But if we could slow down, stop or reverse the damage, that would of course mean a lot more to the patients down the road, because it would also avoid the ultimate treatment option that they have when everything fails is the knee replacement surgery.

00:14:35:04 – 00:14:51:02
Erich Horsley
And just to be clear, this notion of improvement in structure may not mean much to the layman, but what we’ve studied, and really the endorsed way by all agencies to study structural improvement in a way, is to mimic what the orthopedist will do when you go in to see him with OA in the knee, they take a frontal x-ray.

00:14:51:02 – 00:15:14:22
Erich Horsley
In the case of our clinical trials, we use a fixed positioner to take a frontal x-ray, and we look at, in our case and on a blinded basis, the joint space, the space between the femur and the tibia. Because in between those two bones, which show up on the x-ray very well, is cartilage. And so what you do in clinical trials is you evaluate whether that joint space is narrowing, in which case it would be disease progression or leveling off or potentially improving.

00:15:14:22 – 00:15:21:23
Erich Horsley
And we see in our case the leveling off and improvement of joint space with in a very robust long term two year phase three trial.

00:15:21:23 – 00:15:34:03
Steven Newmark
Wow. I mean that’s really exciting. It’s like hard to even contain myself. You know, to have an opportunity like this for OA patients and future OA patients to come. So thank you for what you’re doing.

00:15:34:04 – 00:15:46:04
Steven Newmark
Erich, I want to ask you a very specific question from an organizational standpoint. What does it take to responsibly move a therapy from research into regulatory review and potentially to approval without over promising to patients?

00:15:46:04 – 00:16:00:02
Erich Horsley
Sure. I think it takes very careful attention to clinical trials, running them well, running them responsibly, usually in the U.S. or Europe, using robust number of patients, not counting on a small number of patients to have this kind of outlier result.

00:16:00:02 – 00:16:19:18
Erich Horsley
Ideally doing that over years, which we’ve done. And we really are led by the science in our data. And it happens to be that both the totality of the data and individual studies happen to really point in the right direction that this is a safe drug that can and should be approved for patients. But you have to lead with the clinical data first, and not just hopes and dreams and pseudoscience.

00:16:19:18 – 00:16:45:16
Erich Horsley
So it really, as I mentioned in our case, we started from identifying a number of really attractive mechanisms that cause OA, addressing those with a small molecule inhibitor we have in Lorecivivint, formulating the drug properly to make sure that in our case, the drug stays in the joint is not available systemically, leading to a very attractive safety profile monitoring both the pain effects, the functional effects, the structural benefit over time, and letting that data lead the way.

00:16:45:19 – 00:16:57:10
Erich Horsley
And then at the right time, which for us is now communicating that the availability of that data, the fact that hope exists for patients and that it’s in the hands of the FDA. We’re not approved yet. We’re hoping to be approved.

00:16:57:10 – 00:17:14:02
Erich Horsley
So we always kind of mention to patients where we are in the process, we get thousands of emails from patients asking, “When can this be approved? I really need this.” And we usually respond with the same sort of response, which is we’re working on it, we’re trying, it’s in the hands of the FDA. Patients have a voice and they should articulate that voice.

00:17:14:04 – 00:17:24:00
Steven Newmark
Okay. Yeah, I wanted to ask about that. Yeah. I mean, very important question for our audience. What can patients do, if anything, to help accelerate just generally drug innovations in this space?

00:17:24:03 – 00:17:43:06
Erich Horsley
Absolutely. So patients vote and patients can call their congressmen and senators. And patients have an influence over the attention that the FDA may pay to certain disease areas. And let me just back up a minute. So we are at a state of innovation in OA that is gone nowhere, essentially, for 30 years. The last approved novel drug in OA was in 1998.

00:17:43:12 – 00:18:02:08
Erich Horsley
We’re still using that today. What other area have we been satisfied with 30 year old technology? I mean, think about 30 years ago we were using rotary phones. Cars had, you know, eight miles per gallon gas mileage, right? There was no internet. There were no flatscreen television. Would we be happy just pausing development for 30 years in any other walk of life?

00:18:02:08 – 00:18:18:15
Erich Horsley
No. Even rare diseases have made a ton of progress. You look at rare oncology diseases, you look at a number of difficult disease areas. And here we have this disease, OA, that’s gone nowhere in this amount of time. And it’s because it’s a very difficult disease to develop in. And I also feel it hasn’t gotten the necessary attention.

00:18:18:15 – 00:18:30:02
Erich Horsley
Not from pharma companies, not enough, not from biotechs. It’s very expensive to develop in this field and potentially not for regulators. I hope this is a new day, but patients have a voice and they should exercise that voice and demand better.

00:18:30:02 – 00:18:42:14
Steven Newmark
Yeah, no. Absolutely. That’s very helpful for our audience. What are we likely to hear from the FDA between now and the approval, if anything? Or is it just we wait and hear and potentially raise our voices?

00:18:42:14 – 00:18:57:12
Erich Horsley
No, no. So once the review process starts, so the FDA is in touch with us basically asking questions about the data. They look at our analysis, they have access to all of the data, they run their own analysis, they bring up questions, they might ask for additional analysis.

00:18:57:12 – 00:19:16:19
Dr. Yusuf Yazici
But not only that, in that ten month period, they also audit both us, the clinical trial sites, the manufacturing side. So there are FDA visits that we meet them there, we prepare, we answer their questions. They come out, review everything. And towards the end, maybe 2 or 3 months before that, there is also the opportunity to have what’s called an advisory committee meeting.

00:19:16:23 – 00:19:40:03
Dr. Yusuf Yazici
Now, we have proactively asked for one. Advisory committee meeting is a public forum where patient advocates, physicians, a group of experts that makes up the committee basically hears how the FDA’s interpreting the data and how we’re interpreting the data. And the FDA asks them various questions to answer. So they use ad comms usually to help them when needed to make their final decisions.

00:19:40:08 – 00:20:05:21
Dr. Yusuf Yazici
So that’s a public meeting. So that would be heard. And people can log in and watch, and we’ve watched many of them for other drugs in the past. And patients can sign up to make statements, which is very common too. And those are all, we feel, are important because it’s important to discuss the benefits, the vague safety data, the benefits ratio where there’s efficacy and very minimal to no potential side effects should be heard publicly.

00:20:05:21 – 00:20:28:18
Dr. Yusuf Yazici
Patients should opine on the unmet need that they feel. And so that’s another milestone during the review period. And then all of that’s taken into consideration. Then you discuss the label with the FDA, what the actual package insert that pharmacists give to doctors and patients is going to say on it. And then the ten months is done, hopefully when it’s done and then we get a final decision.

00:20:28:19 – 00:20:43:08
Steven Newmark
This is great. Again, I hope I’m not repeating myself when I keep saying this is very exciting to say the least. Before we wrap up, I want to bring this discussion back to patients. If there’s one thing you would want people living with osteoarthritis to take away from this moment, what would that be?

00:20:43:12 – 00:21:08:11
Erich Horsley
Let me opine on that in a very personal way. And that is OA is not something you just need to accept. It’s not simply a fact of aging. It’s something that you can fight and you can actively seek better treatments for. And the personal aspect here is that I’m an OA patient myself. So I have, I’m 53, I’ve had two knee replacements already. The likes of what Lindsey Vonn got. In my phenotype was really just wear and tear, maybe bad knee genetics.

00:21:08:11 – 00:21:24:07
Erich Horsley
But about 15 years ago I started having some pain. I ignored it for a while, kept running on it, kept skiing on it, etc. And by the time I got to an orthopedist, I was, you know, pretty close to bone on bone and it was a dismal experience. And I think this will resonate with a number of your listeners.

00:21:24:07 – 00:21:42:05
Erich Horsley
What I experience is what many patients do, which is this long litany of drugs that don’t really work, are bad for you, may be bad for your organs, bad for your liver, bad for your gastrointestinal system. In my case, I got several corticosteroid shots, felt great temporarily, and then it got worse. And it just went down this road.

00:21:42:05 – 00:21:57:16
Erich Horsley
And the doctors, of course, want to push off knee replacements as long as possible. I’m pretty young to get one, to say nothing of two. And it’s a really, really tough experience. And I went through, you know, all the HAs, all the knee braces and whatever you can. It’s really, really, really disheartening.

00:21:57:16 – 00:22:17:10
Erich Horsley
But there is hope now, so don’t lose hope. Don’t simply accept it as a fact of growing old because it isn’t. There are many factors that can lead to it. Of course you need to exercise as much as possible, lose weight if you’re overweight, etc. But there is hope for patients and hopefully we are on the cusp of bringing that hope to reality. And so I just want to deliver that positive message for folks.

00:22:17:12 – 00:22:32:03
Steven Newmark
Wow, that’s very powerful to say the least and thank you for that. And with that, I’ll just say thank you both so much for joining us and for all that you’re doing for osteoarthritis patients and for helping bring clarity to a process that can feel overwhelming for patients.

00:22:32:06 – 00:22:32:20
Dr. Yusuf Yazici
Thank you.

00:22:32:22 – 00:22:44:13
Steven Newmark
To our listeners, milestones like an NDA submission matter, but they are part of a longer, careful process. Staying informed, asking questions, and partnering with your health care provider remain the most important steps you can take.

00:22:44:18 – 00:22:52:10
Steven Newmark
As always, we’ll continue breaking down the health issues that matter to patients without hype, without shortcuts, and with transparency.

00:22:52:12 – 00:22:58:03
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all.

00:22:58:04 – 00:23:15:20
Steven Newmark
If you found this episode helpful, please leave us a rating or review and share it with someone who cares about health care policy. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at GHLF.org/listen. I’m Steven Newmark. We’ll see you next time.

00:23:15:22 – 00:23:22:11
Narrator
Be inspired, supported, and empowered. This is the Global Healthy Living Foundation podcast network.

Vaccine Crossroads: FDA Scrutiny, TrumpRx, and the Fight Over Public Trust

This week on The Health Advocates, we unpack a series of developments that signal a pivotal moment in U.S. health policy. The FDA has refused to review Moderna’s new mRNA-based flu vaccine, raising questions about regulatory standards and the future of vaccine innovation. At the same time, the Trump administration has launched TrumpRx, a new prescription drug discount platform that promises savings but faces scrutiny over its scope and real-world impact.

We also examine new polling showing declining confidence in flu, COVID-19, and MMR vaccines, and the growing legal battle over changes to the federal childhood vaccine schedule. With public trust, regulatory rigor, and patient access all in play, this episode breaks down what these headlines mean for patients — and why clarity and credible science matter more than ever.

Vaccine Crossroads: FDA Scrutiny, TrumpRx, and the Fight Over Public Trust

00:00:00:08 – 00:00:08:17
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:08:19 – 00:00:25:23
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Our goal is to help you understand what’s happening in the healthcare world, to help you make informed decisions to live your best life.

00:00:26:00 – 00:00:45:21
Steven Newmark
This week, we’re at a crossroads. The FDA has refused to review a new flu vaccine for Moderna. The Trump administration has launched a new prescription drug website called TrumpRx. Confidence in vaccines is slipping, not surprising. And more than 100 public health organizations have joined a lawsuit challenging changes to the nation’s childhood vaccine schedule.

00:00:46:03 – 00:01:00:01
Steven Newmark
At first glance, these may seem like separate headlines, but they’re connected to a larger theme – trust in public health institutions, how vaccines are evaluated and what patients can rely on when science and politics collide. Let’s unpack it.

00:01:00:03 – 00:01:13:15
Steven Newmark
We begin with a somewhat surprising development. The FDA has refused to review Moderna’s application for a new influenza vaccine. This vaccine uses mRNA technology, the same platform used in Moderna’s Covid 19 vaccine.

00:01:13:21 – 00:01:40:09
Steven Newmark
Now, this is not the FDA rejecting the vaccine outright. It is refusing to even review the application in its current form. That is an important distinction. At the heart of the dispute is a technical but significant issue: which existing flu vaccine Moderna should have used as a control in its clinical trials to compare effectiveness. The FDA’s biologics division, now led by Vinay Prasad, determined that the chosen comparator was not appropriate.

00:01:40:14 – 00:02:01:11
Steven Newmark
On one level, this is scientific disagreement about trial design. That happens, but the context, of course, matters. This decision comes at a time when vaccine policies already under intense scrutiny. HHS Secretary RFK Jr has a long history as a vaccine critic, and observers note that vaccines appear to be receiving stricter scrutiny than in previous administrations.

00:02:01:13 – 00:02:36:06
Steven Newmark
For patients, here is what matters. This flu vaccine is not approved. The FDA review process is independent and designed to be rigorous. Regulatory disputes are normal, but the timing and tone can influence public confidence. The flu remains a major public health issue every year. MRNA technology offers potential advantages in speed and adaptability for these vaccines. Whether this particular vaccine ultimately advances will depend on further data and regulatory negotiations. But the broader question lingers. Are vaccines being evaluated differently now? And if so, what does that mean for innovation?

00:02:36:07 – 00:02:54:21
Steven Newmark
Second big news of the week: TrumpRx launches. Now, we’re going to talk about prescription drug prices. The Trump administration has launched TrumpRx, a new government-backed website that promises dramatic savings on prescription drugs. At a press conference, the president called it “the largest prescription drug price reduction in history.”

00:02:54:23 – 00:03:17:00
Steven Newmark
Here’s what we know. The website lists 43 medications. Of those, more than half are already available in generic form at significantly lower prices. There are many, in fact, that we were able to find that were available cheaper elsewhere. That being said, the website itself can be used and can be a good tool for helping patients, quote unquote, shop around when looking for the best deal.

00:03:17:04 – 00:03:39:12
Steven Newmark
The site is powered by GoodRx, which already provides coupon based discounts. Some medications can be purchased directly from manufacturers or specialty pharmacies, though these purchases often do not count towards insurance deductibles or out-of-pocket maximums. Some of the best deals, that I at least was able to find while I was playing around on the website, are with GLP-1 medications, such as Wegovy and Ozempic.

00:03:39:14 – 00:04:04:18
Steven Newmark
They are listed and they are listed at prices that seem to be a lot lower than folks who aren’t able to obtain those medications through their insurance. Another avenue that I was able to find discounts, at least in my own research on TrumpRx, was for medications having to do with in vitro fertilization. What links GLP-1s and in vitro fertilization medications are that they are often not covered by insurance.

00:04:04:20 – 00:04:33:07
Steven Newmark
So this could be an area where folks do find significant savings. Now, this is not a systemic reform of drug pricing by any means. It’s essentially a place to go and find discounts or coupons on existing products. It’s nothing more than that, despite the name and despite promises. One funny comment I can’t help but ignore. President Trump said you’re going to see savings like you’ve never seen 500%, 600%, 700% cost savings in certain drugs.

00:04:33:08 – 00:04:52:18
Steven Newmark
My basic math skills lead me to understand that if you’re saving more than 100% on any product, it means that you are essentially being paid to take the product. So if a product costs $100 and the savings is 500%. That essentially means that you’re being paid $500 to take that product. Obviously, that is not happening. That would be ridiculous.

00:04:52:21 – 00:04:59:16
Steven Newmark
But take it for what it’s worth. Check it out. You may be able to find cheaper drugs, you may not be able to. But it’s another tool in the arsenal.

00:04:59:18 – 00:05:17:07
Steven Newmark
Now let’s get back to the vaccine confidence dropping. There’s new polling from the University of Pennsylvania’s Annenberg Public Policy Center showing declining confidence in several vaccines. One recent study shows that 83% of the adults say the MMR vaccine is still safe – 83%

00:05:17:07 – 00:05:47:00
Steven Newmark
80% say the flu vaccine is safe and 65% say the Covid vaccine is safe. That represents a three percentage point drop from 2024 for MMR and flu. And compared to 2022, it’s an even sharper drop of five percentage points for MMR and flu and eight percentage points for the Covid vaccines. Now, these numbers still represent a vast majority of the United States feels safe with vaccines, but the trends are troubling, to say the least.

00:05:47:06 – 00:06:12:18
Steven Newmark
The decline comes during measles outbreaks and a difficult flu season. At the same time, federal officials have shifted to a shared clinical decision making model for certain vaccines. As we’ve spoken about, shared clinical decision making means patients and clinicians discuss whether a vaccination is appropriate. And while it sounds patient centered, labeling a vaccine as a “shared decision making item” rather than routinely recommended can signal ambivalence.

00:06:12:20 – 00:06:31:15
Steven Newmark
Doctors often rely on CDC recommendations to guide conversations, and when that language softens, confusion can increase. Public health relies on clarity. Vaccines protect individuals, but they also protect entire communities. When confidence declines, we’re going to see real world consequences with preventable disease outbreaks.

00:06:31:20 – 00:06:40:19
Steven Newmark
That brings us finally to the courts. The American Academy of Pediatrics has filed a lawsuit challenging recent changes to the federal childhood vaccine schedule.

00:06:41:00 – 00:07:07:04
Steven Newmark
More than 100 public health organizations and academics have filed an amicus brief in support. Their argument is straightforward. Recent federal actions weaken routine vaccine recommendations and may undermine protections that have dramatically reduced disease and death. The concern is not simply about policy, it’s about process. For decades, vaccine recommendations followed a structured, evidence based process to the Advisory Committee on Immunization Practices, ACIP.

00:07:07:04 – 00:07:07:23
Steven Newmark

00:07:07:23 – 00:07:29:19
Steven Newmark
When changes occur outside that framework or without clear scientific input, trust can erode further. The courts will now play a role in determining how far these changes can go. So where does this leave us? Well, these headlines tell a larger story. A vaccine under regulatory dispute, a new drug discount website, declining confidence in vaccine safety, and a lawsuit over pediatric vaccine policy.

00:07:30:00 – 00:07:48:16
Steven Newmark
They reflect the broader tension in American health policy right now. When regulatory agencies appear to shift standards, when vaccine recommendations change, when public messaging becomes inconsistent, patients can feel it. As always, we’ll keep watching what happens next, not from a political lens, but from the perspective that matters most – patients.

00:07:48:18 – 00:08:13:04
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please leave us a rating or review and share it with someone who cares about healthcare policy. And be sure to follow us wherever you get your podcasts. You can find all GHLF’s podcasts at GHLF.org/listen. I’m Steven Newmark. We’ll see you next time.

00:08:13:06 – 00:08:19:19
Steven Newmark
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

Congress Funds Health Care: What This Means for Patients

Congress has passed, and President Trump has signed, a major government funding bill that includes a wide range of health care policies, from telehealth extensions and hospital-at-home programs to long-sought reforms targeting pharmacy benefit managers. But alongside those wins, the legislation also raises serious questions about the future direction of federal health policy.

In this episode of The Health Advocates, Steven Newmark breaks down what the new spending package actually does for patients, what it leaves unresolved, and why some lawmakers and advocates are uneasy about increasing funding for federal health agencies under current leadership. The conversation explores how these decisions affect access to care, drug costs, public health programs, and trust in health institutions.

Whether you’re a patient, caregiver, clinician, or advocate, this episode offers a clear, practical look at how congressional budget decisions shape health care on the ground, and why continued engagement and oversight matter more than ever.

Congress Funds Health Care: What This Means for Patients

00:00:00:08 – 00:00:08:16
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

00:00:08:18 – 00:00:25:23
Steven Newmark
Welcome to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. I’m Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation. Our goal is to help you understand what’s happening in the healthcare world, to help you make informed decisions to live your best life.

00:00:26:01 – 00:00:43:12
Steven Newmark
This week, Congress did something that has become increasingly rare in Washington. It passed a major government funding bill, bipartisan too. And buried inside that bill are a number of health policy decisions that will directly affect patients from telehealth and hospital-at-home programs to drug pricing middlemen and public health funding.

00:00:43:14 – 00:01:11:16
Steven Newmark
But the bill also raises some questions. What does it mean to give more money to federal health agencies in a moment when many patients, clinicians and advocates are deeply concerned about the direction of health policy coming out of the Department of Health and Human Services under secretary Robert F Kennedy Jr? Today, we’re going to walk through what Congress actually passed, what’s in it for patients and providers, what didn’t make the cut and why some lawmakers and advocates are worried that more funding without guardrails could do real harm.

00:01:11:18 – 00:01:36:03
Steven Newmark
Let’s start with the basics. Congress passed a large spending package that funds much of the federal government, including the Department of Health and Human Services, through the end of the fiscal year. This bill helped avert a prolonged government shutdown and sets the operating budget for many health agencies Americans rely on every day. For healthcare, this bill is notable because it does several things patients and providers have been pushing for, often unsuccessfully, for years.

00:01:36:05 – 00:02:01:23
Steven Newmark
First, it extends Medicare telehealth flexibilities. These were originally created during the Covid 19 pandemic and allow Medicare beneficiaries to see their doctors virtually from home. Without congressional action, many of these flexibilities would have expired. This bill extends them again, giving older adults and people with disabilities and rural patients continued access to care without unnecessary travel or disruption.

00:02:02:01 – 00:02:25:21
Steven Newmark
It also extends the hospital-at-home program. This allows eligible patients to receive hospital-level care in the comfort of their homes instead of inpatient facilities. For many patients, particularly those with chronic illnesses, this model has improved outcomes, reduced infections, and increased comfort. The bill extends this program for several more years, providing stability for health systems that have invested in it.

00:02:25:23 – 00:02:46:01
Steven Newmark
Additionally, this bill continues funding for community health centers. These centers serve millions of patients, particularly those who are uninsured, underinsured, or living in medically underserved areas. While advocates continue to push for longer term funding certainty, even a short term extension helps prevent sudden clinic closures or service reductions.

00:02:46:03 – 00:03:03:06
Steven Newmark
Fourth, the bill includes funding to continue implementation of the No Surprises Act. You’ll recall that this law is designed to protect patients from unexpected medical bills, like out-of-network charges, after emergency care. Without continued funding, enforcement of these protections could have stalled.

00:03:03:08 – 00:03:35:16
Steven Newmark
All of this is very meaningful. For many patients, especially those already navigating fragile access to care, these provisions matter a great deal. One of the most significant patient wins in this bill involves pharmacy benefit managers or PBMs. We’ve spoken at length about PBMs here on the health advocates. They act as a middleman between drug manufacturers, insurers, employers and pharmacies. For years, patients and independent pharmacists have raised concerns about opaque pricing practices, spread pricing in Medicaid and incentives that favor higher priced drugs.

00:03:35:21 – 00:04:02:20
Steven Newmark
This bill takes several important steps to rein in these middlemen. It prohibits PBMs from charging Medicaid more than they pay pharmacies for drugs, effectively banning what we call spread pricing in Medicaid. It requires greater transparency around PBM contracts and business practices, and it begins to separate PBM revenue from the list price of drugs in Medicare Part D, instead allowing PBMs to collect clearer service-based fees.

00:04:02:22 – 00:04:26:08
Steven Newmark
So what does this matter to patients? Because PBM practices can directly affect out-of-pocket costs, pharmacy closures, and whether patients can access the medications their doctors prescribe. These reforms are not perfect, but they represent years of advocacy finally showing results. For patients who have watched drug costs rise while access shrinks, this part of the bill is a real step forward.

00:04:26:10 – 00:04:54:06
Steven Newmark
So now let’s talk about what didn’t make it into this legislation. Most notably, Congress did not extend enhanced Affordable Care Act premium subsidies. These subsidies would have helped millions of people afford health insurance through the ACA marketplaces. Without extension, many families could face significant premium increases or are simply priced out of coverage altogether. Lawmakers largely avoided this issue because it requires tough negotiations and long term funding commitments.

00:04:54:07 – 00:05:22:22
Steven Newmark
But for patients, this omission is not abstract. It means higher costs and more uncertainty in the short term. The bill also avoids codifying several controversial health policy proposals coming from the Trump administration and HHS, including proposals around international drug pricing and broader structural changes to the federal health programs. We’ll discuss more about these proposals in future episodes, but for now, Congress focused on what it could pass and punted on what it couldn’t agree to.

00:05:23:00 – 00:05:45:00
Steven Newmark
Here’s where the story gets a little bit complicated. While Congress rejected many proposed cuts to health agencies, it also gave HHS significantly more funding than the Trump administration itself had requested. On paper, that is a win. More money for public health, research and federal programs is a good thing. But under current leadership, many clinicians and advocates are uneasy.

00:05:45:03 – 00:06:15:18
Steven Newmark
Why? Because Senator Kennedy has already moved aggressively to reshape vaccine policy, public health messaging and scientific advisory processes. Critics worry that additional funding, without clear constraints, could be used to advance agendas that undermine evidence-based medicine and public trust, ultimately harming patients. Some lawmakers have privately acknowledged the tension. They wanted to protect agencies like the CDC and NIH from deep cuts, but they are also concerned about how expanded resources might be used under the current leadership.

00:06:15:20 – 00:06:45:19
Steven Newmark
It’s a paradox, for sure. Defunding public health agencies would harm patients, but funding them without guardrails, transparency and oversight could also harm patients if resources are redirected towards policies that contradict established science. The concern is not theoretical. We have already seen major disruptions to vaccine advisory committees, public health communications and long standing norms. We’ll obviously keep this in mind as we see what HHS does throughout the year and continue staying vigilantly on top of all of these developments.

00:06:45:21 – 00:07:01:15
Steven Newmark
So what should patients take away from all of this? Well, as always, advocacy works. Telehealth extensions, PBM reforms, hospital-at-home programs, these did not happen by accident. They happened because patients, clinicians, advocates and organizations like GHLF stayed engaged.

00:07:01:17 – 00:07:11:06
Steven Newmark
Second, funding alone is not enough. How money is used matters just as much as how much money is allocated. Patients should care not only about budgets but also about governance.

00:07:11:08 – 00:07:26:06
Steven Newmark
Third, vigilance is essential. The bill buys time and preserves access in key areas, but does not resolve deeper debates about health policy direction, scientific integrity or coverage affordability. Those fights are still to come and we’ll be here fighting them at GHLF.

00:07:26:08 – 00:07:50:06
Steven Newmark
At The Health Advocates, we believe patients deserve clarity. This funding bill contains real wins, real gaps and real risks. It shows that Congress can still act when pressure is applied, but also that health policy decisions are increasingly shaped by power struggles far removed from exam rooms and pharmacy counters. As always, we’ll keep watching what happens next, not from a political lens, but from the perspective that matters most – patients.

00:07:50:08 – 00:08:14:10
Steven Newmark
Before we wrap up, a quick reminder, even in February, it’s still not too late to get your flu and Covid 19 vaccines. Staying up to date on these vaccines will help protect you, your loved ones, and your community as we continue to deal with influenza and Covid 19 viruses circulating. To learn more about vaccine recommendations and find reliable resources for patients, visit GHLF.org/vaccines.

00:08:14:12 – 00:08:39:20
Steven Newmark
Thanks for listening to The Health Advocates, a podcast that breaks down major health news of the week to help you make sense of it all. If you found this episode helpful, please leave us a rating or review and share it with someone who cares about health care policy. And be sure to follow us wherever you get your podcasts. You can find all of GHLF’s podcasts at GHLF.org/listen. I’m Steven Newmark. We’ll see you next time.

00:08:39:22 – 00:08:46:12
Narrator
Be inspired, supported and empowered. This is the Global Healthy Living Foundation podcast network.

Redefining Care Through Lived Experience: Cynthia Overton on Person‑Centered Care

In this episode of The Health Advocates, Steven Newmark sits down with Dr. Cynthia Overton to explore what person‑centered care truly looks like, through the eyes of someone who has lived it.

At age 26, Cynthia experienced a sudden spinal cord injury that left her temporarily paralyzed—an event that fundamentally reshaped her understanding of health care. Today, she draws on both lived experience and evidence‑based frameworks to help organizations and individuals rethink how care is delivered, with an emphasis on dignity, communication, and whole‑person support.

Together, Steven and Cynthia discuss disability inclusion, health equity, and why every patient interaction has the power to transform not only individual outcomes, but the system as a whole.

Congress Reaches Rare Bipartisan Health Deal: What’s In It for Patients

In this episode of The Health Advocates, Steven Newmark breaks down a surprising moment of bipartisan agreement in Congress: a new Health and Human Services funding bill that includes meaningful wins for patients and public health.

From protecting CDC and NIH funding to extending telehealth flexibilities and hospital-at-home programs, the bill also takes historic steps to reform Pharmacy Benefit Managers (PBMs), aiming to make drug pricing more transparent and patient-centered. Steven walks through what’s in the legislation, what was left out, and why PBM reform could have a direct impact on out-of-pocket costs and medication access.

Plus, what this deal signals about the power of patient advocacy in shaping policy—even in a divided political climate.

Championing Public Health in Politics: A Conversation with State Rep. Michele Grim

In this episode of The Health Advocates, Steven Newmark speaks with Ohio State Representative Michele Grim, the only public health professional currently serving in the Ohio legislature. Rep. Grim shares how her background in public health advocacy led her to politics, where she now champions legislation to expand access to care, fight misinformation, and protect vulnerable populations.

Together, they dive into the challenges of health policy in today’s polarized environment, and the importance of having voices at the table who understand the system from the inside out.

The Pediatric Vaccine Rollback: What ACIP Changed and Why It Matters

In this episode of The Health Advocates, we break down one of the most pivotal and controversial ACIP meetings in recent history. The CDC’s vaccine advisory committee voted to roll back the universal hepatitis B birth dose, a policy that has protected newborns from chronic liver disease for more than three decades. We explain what ACIP decided, why the changes were not based on new scientific evidence, and how misinformation and ideological viewpoints shaped the discussion.

We also explore the real-world consequences for families, clinicians, and health systems. From confusing new recommendations to unnecessary blood tests to disruptions in the overall childhood immunization schedule, these changes will make it harder for parents to access safe, routine preventive care. But the meeting also revealed something hopeful: strong advocacy — from medical societies, public health experts, grassroots organizers, and patient groups — helped prevent even more extreme proposals from becoming policy.

Finally, we discuss what comes next as ACIP reviews additional childhood vaccines and how advocates, clinicians, and community members can stay engaged to protect science-based immunization policy.

2025 Year-End Public Health Recap

In this special year-end episode of The Health Advocates, host Steven Newmark takes a step back to review several of the most significant public health developments of 2025.

The episode covers major leadership changes at the U.S. Department of Health and Human Services, key meetings and votes of the Advisory Committee on Immunization Practices (ACIP), ongoing challenges related to vaccine access and uptake, and continued debates over prescription drug pricing, including “Trump Rx.” Steven also examines the rapid expansion of GLP-1 medications, the implementation of Inflation Reduction Act health provisions, public health workforce pressures, infectious disease monitoring beyond COVID-19, maternal health initiatives, and the evolving role of data and communication in public health.

Rather than an opinion piece, this episode offers a straightforward recap of how policy decisions, advisory processes, and healthcare system dynamics shaped public health in 2025 and set the stage for the year ahead.

ACIP Meeting Recap: What Happened and What It Means for Patients

In this episode of The Health Advocates, we break down one of the most pivotal and controversial ACIP meetings in recent history. The CDC’s vaccine advisory committee voted to roll back the universal hepatitis B birth dose — a policy that has protected newborns from chronic liver disease for more than three decades. We explain what ACIP decided, why the changes were not based on new scientific evidence, and how misinformation and ideological viewpoints shaped the discussion.

We also explore the real-world consequences for families, clinicians, and health systems. From confusing new recommendations to unnecessary blood tests to disruptions in the overall childhood immunization schedule, these changes will make it harder for parents to access safe, routine preventive care. But the meeting also revealed something hopeful: strong advocacy — from medical societies, public health experts, grassroots organizers, and patient groups — helped prevent even more extreme proposals from becoming policy.

Finally, we discuss what comes next as ACIP reviews additional childhood vaccines and how advocates, clinicians, and community members can stay engaged to protect science-based immunization policy.

Building Trust in Health: A Texas Lawmaker’s View on Prevention, Access, and Equity

How can lawmakers rebuild public trust in health, and make prevention a shared priority?

In this episode of The Health Advocates, Steven Newmark speaks with Texas State Representative Nicole Collier, a leading voice on health equity, women’s health, and preventive care. From her work on the Select Committee on Preventable Diseases and Women’s Health to her advocacy for fair access to vaccines, Rep. Collier brings a clear message: prevention isn’t political, it’s essential.

Together, Steven and Rep. Collier explore:
– How preventive care, including vaccines, strengthens community trust
– Why health equity starts with access to reliable information and local leadership
– How Texas can serve as a model for bipartisan public-health collaboration

To learn more about vaccine recommendations and find reliable resources for patients, visit: ghlf.org/vaccines

Turkey Day Conversations: How to Talk About Vaccines With Your Family

In this special Thanksgiving episode, Steven helps our community prepare for the conversations that matter most. Every year, GHLF shares its “Turkey Day Talking Points” to support people living with chronic illness or who are immunocompromised as they navigate discussions about vaccines with family and friends.

This episode breaks down simple, compassionate ways to explain why vaccines are so important, and why protection for immunocompromised people relies not only on their own shots, but also on the vaccination decisions of those around them. Steven emphasizes that for many patients, vaccines aren’t political; they’re personal. They’re about staying healthy enough to participate in holidays, gatherings and everyday life.

Whether you’re looking for language to make yourself heard without sparking conflict, or you want to help loved ones understand what vaccine protection really means for you, this episode offers guidance rooted in empathy, clarity and lived experience.

To learn more about vaccine recommendations and find reliable resources for patients, visit: ghlf.org/vaccines

Government Shutdowns & IgG4-RD: What Patients Need to Know

In this episode of The Health Advocates, host Steven Newmark breaks down what the recent federal government shutdown means for health care access and vulnerable patients. Then, he’s joined by Mahsa Pazokifard, a passionate patient advocate living with IgG4-related disease (IgG4-RD), a rare and often misunderstood autoimmune condition. Mahsa opens up about the challenges of getting diagnosed, how the disease has impacted her life and career, and why raising awareness is essential.

Whether you’ve never heard of IgG4-RD or are living with a chronic illness yourself, this episode offers powerful insights into patient advocacy, rare disease awareness, and the human side of health care policy.

To learn more about IgG4-Related Disease, visit: creakyjoints.org/igg4-rd-guide

To learn more about vaccine recommendations and find reliable resources for patients, visit: ghlf.org/vaccines

What Pandemics Reveal: Dr. Tyler Evans on Poverty, Politics, and Public Health

Pandemics aren’t only about pathogens, they’re about people, politics, and the deep inequities in our health systems. In this episode of The Health Advocates, Steven Newmark speaks with Dr. Tyler Evans, an infectious disease and public health leader whose career has spanned the front lines of global outbreaks from Ebola to COVID-19. As the former Chief Medical Officer for New York City and co-founder of the Wellness and Equity Alliance, Dr. Evans brings firsthand insight into how societal structures can shape, and sometimes worsen, the course of a public health crisis.

The conversation dives into key themes from Dr. Evans’ new book, Pandemics, Poverty, and Politics (Johns Hopkins Press, August 2025), which examines how inequality, poverty, and fractured health systems accelerate the spread of disease. Dr. Evans explains why scientific breakthroughs alone aren’t enough, we must also tackle the injustices that leave vulnerable communities at greatest risk.

From vaccine mandates to climate change’s role in infectious disease, from disinformation to the erosion of public trust, this episode offers both a sobering reality check and a call to action. Whether you’re a healthcare professional, policymaker, or concerned citizen, you’ll come away with a deeper understanding of why true pandemic preparedness starts with equity.

To learn more about Dr. Tyler Evans’ book, Pandemics, Poverty, and Politics, click here.

Open Enrollment 2026: What Patients Need to Know

Open enrollment for 2026 is underway — and for millions of Americans managing chronic or rare diseases, understanding your health insurance options is essential. In this episode, The Health Advocates host Steven Newmark breaks down what open enrollment is, what’s new this year, and how to navigate changes in your plan.

Drawing from Aimed Alliance’s 2026 Open Enrollment guide, Steven explains key terms like deductibles and out-of-pocket limits, explores what to watch for in your plan’s formulary, and outlines the impact of potential changes to ACA subsidies. Whether you’re reviewing employer coverage or shopping through HealthCare.gov, this episode will help you make informed, patient-centered choices for the year ahead.

Raising Awareness on GCA Awareness Day: Kathi Lopez’s Story

In this special episode of The Health Advocates, Steven Newmark speaks with Kathi Lopez, who shares her journey of being diagnosed with Giant Cell Arteritis (GCA). Kathi talks about the challenges of getting a proper diagnosis, navigating treatment, and managing life with a rare autoimmune condition. She shares how staying informed, connected, and engaged in advocacy has helped her take control of her care, and how she now helps others do the same. Her story sheds light on the realities of living with GCA and the importance of raising awareness for rare conditions.

Tune in to hear Kathi’s inspiring story and help us raise awareness for GCA.

To learn more about Giant Cell Arteritis, visit https://ghlf.org/gca

How Nobel-Winning Science is Bringing Hope to People With Autoimmune Diseases

The 2025 Nobel Prize in Physiology or Medicine recognized groundbreaking advances in understanding immune regulation — but what do they mean for people living with autoimmune disease? In this episode, Dr. Shilpa Venkatachalam, Chief Patient-Centered Research and Ethical Oversight Officer at GHLF, joins Steven to explore how our immune system knows when to act — and when to stop. Shilpa explains the importance of these discoveries, why immune “brakes” matter in autoimmune conditions like lupus or rheumatoid arthritis, and how research breakthroughs can lead to better treatments. She also shares why patients are key partners in turning lab science into real-world therapies.

Tune in to learn how Nobel-winning science could help unlock better care for autoimmune disease.

To read the full article — “How a Nobel Prize Discovery Gives New Hope for Calming the Immune System in Autoimmune Diseases” — visit: https://creakyjoints.org/research/research-immune-nobel-prize-autoimmune/

When the Lights Go Off — Public Health in a Shutdown

What happens to America’s health when Washington grinds to a halt? In this episode of The Health Advocates, we break down the latest federal government shutdown and what it means for public health agencies across the country. We explain what a shutdown actually is, drawing from past shutdowns over the last 30 years, and then dive into the immediate and long-term impacts on the CDC, FDA, NIH, and other agencies that millions of people depend on for research, vaccines, food safety, and emergency response.

We also look at the political stalemate behind the shutdown, focusing on Democrats’ push to restore pending cuts to Affordable Care Act subsidies and what those cuts could mean for healthcare costs. Finally, we explore whether there’s a realistic path to resolution soon—and what’s at stake for patients and the healthcare system if Congress fails to act.

Turning Data Into Impact: RJ Kedziora’s Approach to Improving Health Outcomes

In this episode of The Health Advocates, Steven Newmark sits down with Richard (RJ) Kedziora, co-founder of Estenda Solutions, to explore the intersection of technology, data, and patient advocacy. With decades of experience in healthcare technology, RJ shares how he and his team design digital tools that help patients take control of their health while supporting providers and payers alike. They also discuss patient engagement, accessibility, and the future of artificial intelligence in healthcare.

Whether you’re a tech enthusiast, a healthcare professional, or a patient advocate, this conversation offers insights on building smarter, more empathetic digital health solutions.

ACIP’s COVID-19 Vote and Trump’s Tylenol Claim: Another Wild Week!

In this episode of The Health Advocates, we unpack a turbulent week in public health. The CDC’s vaccine advisory committee (ACIP), now reshaped under Health Secretary Robert F. Kennedy Jr., met to debate changes to the COVID-19, MMRV, and Hepatitis B vaccine recommendations. Despite heated rhetoric and process irregularities, the committee ultimately kept broad access to COVID-19 vaccines — a short-term win for patients and a reminder that advocacy pressure works.

We also break down President Trump’s recent claims linking Tylenol use during pregnancy to autism, and his renewed suggestion of a connection between vaccines and autism. We review what the science actually shows, what public health experts are warning about, and what patients and families should know moving forward.

Tune in for clarity on a confusing week — and why these debates matter for access, trust, and the future of public health.

Fall Vaccines 2025: What You Need to Know

This fall’s Covid-19 vaccine rollout is more confusing than ever. The FDA has narrowed eligibility to older adults and people with high-risk conditions, while major medical societies are urging broader access — and insurance companies are waiting for new guidance from ACIP, the advisory committee that’s been reshaped by RFK Jr.

In this episode of The Health Advocates, host Steven Newmark explains who qualifies as high-risk, what “off-label” vaccination means, how coverage is likely to work, and what parents, pregnant people, and adults should know heading into the fall season.

Unpacking Polymyalgia Rheumatica: Expert and Patient Insights

In this special episode of The Health Advocates, we take a closer look at Polymyalgia Rheumatica (PMR), a condition that affects tens of thousands of older adults each year in the U.S. but is often misunderstood. Host Steven Newmark is joined by GHLF’s Angela Degrassi, patient advocate Eileen Salsman, and two leading experts — Dr. Leonard Calabrese and Dr. Jeffrey Curtis — to unpack what PMR is, how it impacts daily life, and why a patient-centered approach to research and care is so important. Together, they explore symptoms, diagnosis, steroid treatment challenges, and emerging insights from new research and lived experience.

Special note: We invite you to a live webinar on Polymyalgia Rheumatica (PMR) that will explore critical gaps in diagnosis and disease monitoring.

Date and time: Thursday, September 18th at 6:30 PM Eastern
Register here.

Turmoil at the CDC

CDC Director Susan Monarez has been fired after less than one month on the job, sparking a wave of resignations by senior leaders and raising alarms about the politicization of public health. In this episode of The Health Advocates, host Steven Newmark unpacks what happened, why it matters, and what the loss of experienced leadership means for patients and communities. From vaccines to emergency preparedness, the future of the CDC — and public trust in science — is on the line.

Leaked MAHA Proposal Aims to Protect Kids’ Health – What’s in the Plan?

A leaked draft of the Trump administration’s Make Our Children Healthy Again plan reveals a strategy to improve kids’ health that’s far less sweeping than many expected. Instead of bold action on processed foods and pesticides, the draft emphasizes “awareness” campaigns and industry-friendly guidelines, while reopening old battles over vaccines, fluoride, and even WiFi.
In this episode of The Health Advocates, Steven unpacks what’s actually in the leaked report, what’s missing, and why these proposals could reshape public health for children across the country. From school nutrition to pesticide regulation to vaccine safety, we break down what the draft means for families, industry, and the future of U.S. health policy.

Reimagining Pain Management: A Conversation with Dr. Zameer Pirani

In this episode, Steven is joined by Dr. Zameer Pirani, an interventional pain specialist and co-founder of the Afiya Spine and Pain Institute in Canada. Dr. Pirani shares his path to pain medicine, from early training in Ireland to his experiences with anesthesia and chronic pain fellowships. He discusses how the opioid crisis, gaps in the health care system, and the stigma surrounding pain patients shaped his career and passion for multidisciplinary, patient-centered care. Dr. Pirani also shares his insights on the challenges of treating invisible illnesses, building trust with patients, and why true healing requires listening, empathy, and a team-based approach.

Preventive Care Under Fire, a NYC disease Outbreak, and the Value of Screening

In this episode, host Steven Newmark breaks down four critical public health stories making headlines:

  • Senators Angus King and Elizabeth Warren introduce a resolution to defend the U.S. Preventive Services Task Force amid reports that RFK Jr. may fire its members.
  • What’s really at stake if the Task Force is dismantled—and how evidence-based guidelines are already saving lives, from colon cancer screenings to heart health.
  • A deadly outbreak of Legionnaires’ disease in Harlem has claimed two lives and sickened dozens. What you need to know if you live in the area.
  • The alarming defunding of mRNA vaccine research.

Science, policy, and prevention—all in one sharp, timely episode.

How the 340B Program Can Transform Communities — If Used Right

In this episode, Steven Newmark, Chief of Policy at GHLF, is joined by Clayton Ruley, Director of Strategic Initiatives, Mission Advancement & Impact at the Community Liver Alliance. Clayton shares his decades-long journey from frontline harm reduction work to shaping national health policy. Together, they discuss the need for compassion in healthcare, the importance of patient-centered policymaking, and the urgent challenges facing programs like 340B and Medicaid. Clayton also highlights how community-level work and federal health policies intersect — and why transparency and access matter now more than ever.

Budget Tools or Policy Weapons? How Congress Shapes Health Care

What exactly are reconciliation and rescission—and why do they matter for your health? In this episode, Steven Newmark, Chief Policy Officer at GHLF, demystifies two powerful — and often misunderstood — budget tools: reconciliation and rescission. What do they mean? How do they bypass the normal budget process? And why do they matter for healthcare, public programs, and patients?
Steven breaks down the differences between these mechanisms, explains where they fit into the broader federal budget process, and examines Congress’s recent $9.4 billion rescission vote. If you care about how Congress funds — or defunds — healthcare, this episode will give you the clarity you need.

Tune in to learn:

  • What reconciliation really is, and how it’s used to pass major healthcare policy
  • Why rescission gives presidents the power to cancel already-approved spending
  • How these tools operate outside the regular appropriations process
  • What the latest moves in Congress mean for public health funding in 2025

RFK Jr. Sued Over Vaccine Policy: A Legal and Public Health Crisis

In this episode of The Health Advocates, Steven Newmark takes a deep dive into the high-stakes lawsuit against Health Secretary Robert F. Kennedy Jr. Six major medical organizations, and a pregnant physician are challenging Kennedy’s directive to remove COVID-19 vaccine recommendations for children and pregnant people — and they’re asking the courts to intervene. Steven unpacks the legal arguments, explains key concepts like standing and injunctions, and explores what’s at risk for public health, the rule of law, and the integrity of vaccine policy in the U.S.

What’s Going On at HHS? Vaccines, Measles, and a Cancelled Meeting

In this week’s episode of The Health Advocates, host Steven Newmark unpacks a whirlwind of health news that could reshape the foundation of U.S. public health. From a major lawsuit against HHS Secretary Robert F. Kennedy Jr. to record-high measles cases and the quiet cancelation of a critical preventive care meeting, Steven explains what’s at stake. Plus, he shares a hopeful update on bird flu and the importance of defending science-based health policy amid political disruption.

Slashing Medicaid and Facing the Heat: Urgent Health Threats

In this episode of The Health Advocates, Steven Newmark breaks down two urgent public health threats: a Senate proposal that would deeply cut Medicaid funding and an extreme heat wave affecting more than 265 million Americans. Steven explains how the Senate bill could gut essential health services for millions, all to fund tax cuts—and how this could impact everyone, not just Medicaid enrollees. He then turns to the record-breaking heat, sharing crucial safety tips and resources. Finally, Steven discusses a new COVID-19 variant known for its painful “razor blade throat” symptom.

Tune in to stay informed and take action.

Behind the Headlines: Jon Erlichman Opens Up About Living with Crohn’s

In this episode of The Health Advocates, Steven Newmark sits down with Jon Erlichman — founder of Ticker Take and a well-known financial journalist whose videos have reached nearly a billion views across platforms including YouTube, TikTok, Instagram and X. Jon shares his personal journey of living with Crohn’s disease and what inspired him to open up about it publicly. He also talks about the importance of family support, how he manages daily life in the spotlight, and why he’s optimistic about the future of IBD research and care.

Tune in for an inspiring conversation about resilience, advocacy, and the power of sharing your story.

Vaccine Policy Under Fire: What the ACIP Purge Means for You

In this week’s special episode of The Health Advocates, Steven Newmark breaks down a major and alarming development in U.S. public health policy: the removal of all 17 members of the Advisory Committee on Immunization Practices (ACIP) by HHS Secretary Robert F. Kennedy Jr. Steven explains what ACIP does, why its role is crucial to vaccine access and confidence, and how this sudden and sweeping dismissal could erode trust, limit insurance coverage, and leave vulnerable populations at risk.

Tune in to learn what’s at stake, why it matters for people living with chronic illness, and how patients can raise their voices in support of science-based policy.

Health Agencies Face Major Cuts: What’s at Stake in the 2026 Budget

This week on The Health Advocates, Steven Newmark, Chief of Policy at GHLF, breaks down two major stories: sweeping proposed cuts to key federal health agencies in the 2026 U.S. budget, and a new national partnership between GHLF and Walgreens aimed at improving care for chronic skin conditions. Steven explains what’s at stake, how advocacy can influence policy decisions, and why pharmacists are essential allies in supporting skin health.

Who’s Left Out? What New Vaccine and Medicaid Policies Could Mean for You

The FDA just made a surprising move that could reshape COVID-19 vaccination in the U.S. going forward, and the House passed a major budget bill with proposed cuts to Medicaid. In this episode of The Health Advocates, Steven Newmark breaks down the changes, debates, and potential impacts on people living with chronic conditions.

Tune in to understand what these updates mean and what steps advocates can take to make their voices heard.

Brain Cancer Changed Rob Long’s Life — Now He’s Changing the Game for Rare Disease Patients

In this episode of The Health Advocates, Steven Newmark is joined by Rob Long, Executive Director of Uplifting Athletes. Rob shares his journey from All-American punter at Syracuse University to rare brain cancer survivor and patient advocate. Diagnosed during his senior season, Rob’s football career was cut short, but his passion for teamwork and purpose found new life in advocacy. Through his leadership at Uplifting Athletes, Rob helps amplify rare disease awareness, fund groundbreaking research, and connect patients to uplifting experiences across the country.

Join us for a conversation about resilience, purpose, and how sports can unite and empower the rare disease community.

Medicaid on the Chopping Block: What $880 Billion in Cuts Could Mean

In this episode of The Health Advocates, Steven Newmark breaks down the potential $880 billion in cuts to Medicaid currently under debate in Congress. Steven walks through what’s at stake, who could be affected, and why this moment matters. He explains the proposed changes to work requirements, federal matching cuts, and Medicaid expansion support — and outlines what patients, caregivers, and advocates can do to stay protected and make their voices heard.

Tune in to better understand the real-life impact of these proposed cuts and how you can take action.

Measles Outbreaks, Vaccine Delays, and Food Dye Concerns: This Week in Health Policy

In this episode of The Health Advocates, Steven Newmark breaks down the latest public health developments you need to know. From a surge in measles and dengue cases to proposed changes in food dye regulations, Steven explains what’s happening, why it matters, and how it could impact people living with chronic illness. He also unpacks the delay in FDA approval for the Novavax COVID-19 vaccine and introduces the Vaccine Integrity Project — a new initiative working to preserve trust in vaccine guidance.

Tune in for the insights you need to stay informed and protect your health.

What Sjögren’s Really Looks Like: Cristina Montoya on Living, Advocating, and Educating

In this episode of The Health Advocates, we’re joined by Cristina Montoya, a registered dietitian, advocate, and patient living with both rheumatoid arthritis and Sjögren’s disease. Cristina shares her diagnosis journey, the challenges of managing symptoms from childhood to adulthood, and how she uses her lived experience to guide others through nutrition and advocacy. We also hear from Erik Stone, Director of Data, Learning, and Evaluation at GHLF, who breaks down insights from a recent GHLF survey of people living with Sjögren’s. Together, they highlight the need for better education, tailored treatments, and more support for the Sjögren’s community.

Living with Lupus, Leading with Love: How Gaile Valcho Turned Advocacy Into Action

In this episode of The Health Advocates, we’re joined by Gaile Valcho, founder and president of the Brady Valcho Autism Foundation. Gaile shares her powerful story as the mother of a child with autism and her journey to address a gap in community resources in Holly Springs, North Carolina. She opens up about the challenges and triumphs of caregiving while living with lupus, the importance of community support, and her foundation’s work to build inclusive, joyful spaces for neurodiverse families.

Tune in for a conversation about resilience, empathy, and the everyday ways we can show up for one another.

The Price of Politics: Healthcare Impacts of Tariffs, Budget Cuts, and Misinformation

In this episode, Steven breaks down a tumultuous week in public health and healthcare policy — from a growing trade war with China and its potential impact on medical imports, to the elimination of a vital pain research office at the National Institutes of Health (NIH). He also unpacks the mixed messaging from HHS Secretary RFK Jr. on vaccines, including unchecked claims about measles treatments.

Tune in for a timely and important public health update.

Layoffs, Resignations, and Measles … Oh My: A Troubling Week in Public Health

It’s been a whirlwind week in public health. In this episode, host Steven Newmark breaks down a string of major developments coming out of the U.S. Department of Health and Human Services (HHS). From mass layoffs across HHS, including at the FDA, to the resignation of the country’s top vaccine regulator, these changes raise serious concerns—especially amid a rising measles outbreak.

Tune in to hear what this means for patients, public health efforts, and the fight against vaccine hesitancy.

Measles Outbreaks, Medicaid Cuts, and More: A Health Policy Update

In this episode, our hosts break down the latest health care news, from the cancellation of a long-running diabetes study to the rising number of measles cases across the U.S. They also discuss the nomination of Dr. Oz to lead the Centers for Medicare and Medicaid Services (CMS), potential Medicaid cuts tied to tax policy changes, and major layoffs at a key health research agency.

Tune in to hear what these developments mean for patients and how they could impact access to care.

Legislating for Patients: Sen. Shane Reeves, A Pharmacist in Public Office

In this episode our hosts sit down with Tennessee State Senator Shane Reeves, a pharmacist-turned-legislator, to discuss his journey from pharmacy to public office. Senator Reeves shares his firsthand insights into the obstacles pharmacists face in patient care and policy, the role of pharmacy benefit managers (PBMs), and why transparency in health care pricing is crucial for patients. He also breaks down his legislative efforts to support independent pharmacies, improve medication adherence, and advocate for patient-first policies.

Tune in for an engaging conversation on the intersection of health care and policy, and why patients should build strong relationships with their pharmacists.

Finding Strength and Support: Brindley Brooks on Living with Hidradenitis Suppurativa (HS)

In this episode of The Health Advocates, our hosts welcome Brindley Brooks, founder and executive director of HS Connect. Brindley shares her powerful journey living with Hidradenitis Suppurativa (HS) since age 10, including her misdiagnosis, the stigma surrounding HS, and how her life-changing decision to undergo surgery led her to become a passionate patient advocate. The conversation highlights the critical role of advocacy in supporting the HS community, including initiatives like GHLF’s HS Patient Guide and the impactful work of HS Connect in raising awareness, providing education, and fostering a supportive community for those living with HS.

It Takes a Team: Dr. Georges Benjamin on Public Health, Equity & Community Impact

In honor of Black History Month, The Health Advocates welcome Dr. Georges Benjamin, Executive Director of the American Public Health Association (APHA). Dr. Benjamin shares his journey from emergency medicine to public health leadership, offering insights on health equity, community-based advocacy, and the ongoing challenges in public health. He discusses critical topics such as health care access and the importance of listening to communities to drive meaningful change.

Tune in for an insightful conversation about advancing public health for all.

Special Episode: A Heated Debate on Science and Policy with HHS Nominee Robert Kennedy Jr.

In this timely episode, The Health Advocates break down the recent Senate hearings for HHS nominee Robert Kennedy Jr. They discuss the critical role of the HHS Secretary in shaping public health policy and managing key agencies like the FDA and CDC. The hearings exposed Kennedy’s controversial views on vaccines, concerns over scientific integrity, and notable missteps in understanding health policies.

Tune in to hear what this means for patients and what happens next in the confirmation process.

Health Policy Shakeup: Executive Orders and What They Mean for Patients

In this episode, our hosts break down the executive actions taken during the early days of President Trump’s second administration. They discuss the wave of executive orders impacting health care, including changes to the Affordable Care Act (ACA), prescription drug pricing, and federal health agency communications. Our hosts also explore what these changes mean for patients and what to expect in the coming months.

Veterans & Health Care: Navigating the System for Chronic Illness Care with Joel Aguilar

After years of searching for answers and enduring pain, veteran Joel Aguilar was finally diagnosed with psoriatic arthritis. In this episode, he shares his long road to diagnosis, the challenges of navigating the health care system, and how he found life-changing treatment. Joel also discusses how fitness has become a crucial part of managing his condition and offers valuable advice for veterans seeking care through the VA system.

Tune in for an inspiring conversation about perseverance, self-advocacy, and taking control of your health.

From COVID to Drug Pricing: How Biden’s Presidency Shaped Health Care

As we transition into a new administration, our hosts reflect on President Biden’s legacy in health care policy, focusing on three major areas that impacted patients: the COVID-19 response, the opioid crisis, and the Inflation Reduction Act. They discuss key achievements such as vaccine rollouts, reduced overdose deaths, and efforts to lower prescription drug costs, while also examining ongoing challenges and concerns. With the health policy landscape set to shift in 2025, this episode breaks down what patients need to know and how to stay engaged in advocacy for better care.

Building Community Through Chronic Illness: Nitika Chopra’s Journey with Chronicon

In this season premiere of The Health Advocates, our hosts welcome Nitika Chopra, the Founder and CEO of Chronicon. Nitika shares her personal journey of living with psoriasis and psoriatic arthritis and how her experiences inspired her to create Chronicon, a platform and community aimed at empowering people living with chronic illnesses. Together, they discuss the importance of amplifying marginalized voices, making accessibility a priority, and building a supportive network for those with chronic conditions.

Tune in to hear Nitika’s inspiring story and her vision for fostering change and connection in 2025.

Health Policy and Advocacy: 2024 Reflections and What’s Ahead in 2025

In this special season finale of The Health Advocates, our hosts look back on a year of legislative wins, advocacy milestones, and patient-driven successes in 2024. From step therapy reforms to copay accumulator bans, they highlight progress at both state and federal levels. Steven and Zoe also share priorities for 2025, including the Safe Step Act, Help Copays Act, and continued vaccine advocacy. Join us as we celebrate the power of patient stories, look ahead to a critical year in health policy, and thank the advocates who made this progress possible.

Crohn’s and Colitis Awareness Week with Keyla Caba

This Crohn’s and Colitis Awareness Week we’re joined by Keyla Caba, who lives with Crohn’s disease and ulcerative colitis, and is the founder of the nonprofit Connecting Pieces. Keyla shares her patient journey, talks about the common misconceptions people have about inflammatory bowel disease (IBD), and why awareness and community is important.

Turkey Day Conversations: Advocating Against Weight Stigma

In this year’s Thanksgiving special of The Health Advocates, Steven and Zoe delve into an important topic — weight bias — and how it impacts the chronic illness community. They explore the misconceptions surrounding weight and health, share strategies for fostering compassionate care, and encourage listeners to use the holiday as an opportunity to educate and advocate with loved ones. Join them for an inspiring conversation filled with practical advice, personal reflections, and gratitude for the patient advocacy community.

Live from ACR Convergence: Key Takeaways from Rheumatologists, Researchers, and Patients

We’re reporting live from the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C., a yearly gathering for rheumatology experts worldwide. Join us as we talk to rheumatologists, researchers, and patients to discover how these advancements in research are shaping the future of health and advocacy.

Advocating for Fair Health Care: Health Insurance Battles and Burnout with Ron Howrigon

In this episode, we’re joined by Ron Howrigon, President of Fulcrum Strategies, who specializes in guiding doctors through the complexities of insurance policies. Ron shares his unique journey from working on the insurance side to advocating for physicians and patients against unfair industry practices. We dive into the challenges of prior authorization, insurance denials, and their impact on physician burnout. Ron sheds light on the incentives driving insurance companies and the reasons behind coverage battles, while offering thoughtful solutions to improve the system for patients and health care providers alike.

Post-Election Recap: What Trump’s Return Means for Health Care

In this special post-election episode of The Health Advocates, Steven Newmark, Chief Policy Officer at the Global Healthy Living Foundation, provides an update on the potential impacts of Donald Trump’s second non-consecutive presidential term on health care. With changes expected in the Senate and possible shifts in the House, Steven breaks down how Trump’s administration, along with controversial figures like Robert F. Kennedy Jr., may influence public health agencies, Medicaid, Medicare, and the Affordable Care Act. Tune in for a quick, informative recap of the election’s health care implications.

Spooky Tales from the Health Care System: Lessons in Advocacy

In this special Halloween episode of The Health Advocates, we’re diving into some spine-chilling experiences in the health care system. Our guests open up about their scariest moments — from misdiagnoses and panic attacks in MRI machines to doctors dismissing their pain. But it’s not all fright! They share how these tough experiences helped them become stronger self-advocates, turning fear into resilience.

Get Vaccinated, Stay Protected: 2024-2025 COVID and Flu Shots

In this episode, we discuss the 2024-2025 fall vaccine lineup, covering everything you need to know to stay protected this season. We start with updates on the latest COVID and flu vaccines, and Zoe shares her personal experience getting these shots. We then dive into the recent approval of self-administered FluMist, exploring how it compares to the traditional injectable flu vaccine in terms of effectiveness and convenience. Plus, we provide a brief update on RSV.

See the Future: Eye Health, World Sight Day, and Thyroid Eye Disease

In this special World Sight Day episode, Steven and Zoe are joined by Caroline Casey, President of the International Agency for the Prevention of Blindness (IAPB), and Seth Ginsberg, President of the Global Healthy Living Foundation (GHLF). Together, they explore the critical importance of eye health, especially for those living with chronic diseases like thyroid eye disease and diabetes. Caroline and Seth discuss global initiatives, innovative campaigns like “Love Your Eyes,” and how advocating for better eye health can transform lives.

Tune in as we raise awareness for blindness prevention, highlight the need for regular eye checkups, and share valuable insights on how chronic conditions can impact vision.

Celebrating Hispanic Heritage Month: Advocacy and Awareness in the Lupus Community

In this episode, we are joined by Estela Mata, President and CEO of Looms for Lupus, a non-profit dedicated to raising awareness and providing support for those living with lupus, and other chronic conditions. Estela shares her personal and family journey with lupus and the profound impact of advocacy. She highlights the importance of community, the need for increased awareness, and the power of sharing personal stories, especially within the Hispanic community. Estela’s message of hope and resilience is a reminder of the strength found in community and the critical role of advocacy in chronic illness management.

Spreading Awareness This Asthma Peak Week

In this episode, we’re joined by Jessica Buckley, President and CEO of the Lung Health Foundation (LHF), and Dr. Dawn Bowdish, scientist and the Executive Director of the Firestone Institute for Respiratory Health and member of the Board of Directors of the LHF. We talk about how asthma, despite being common, can be complicated to diagnose and that many are living with uncontrolled asthma. Jessica and Dawn also share recent survey results of asthma patients’ experience, and how patients can set health goals with an asthma action plan and advocate for better air quality.

“A Politician’s Job is to Listen” with Yvan Baker, MP

Yvan Baker, member of the House of Commons of Canada, joins us to talk about Canadians’ health care issues and needs. Mr. Baker discusses the benefits of Canada’s universal health care system for essential services and needs, but highlights gaps in the system like doctor shortages, delays in services, and how until recently dental care was not part of the system. He shares how he’s helped advocate for the expansion of dental care, for the government to consider patient outcomes, and his work with the older adult community.

Voices from Capitol Hill: Advocating Together for Autoimmune Patients

We’re joined by Amanda Krzepicki, Policy Director at the Autoimmune Association. We talk about the long process of getting legislation passed, top issues the Autoimmune Association is advocating for, and how patient groups can come together to make a difference. Amanda also offers advice for if you’re feeling nervous on connecting with stakeholders.

Special Episode: The Power of Patient Stories

Welcome to our special episode of The Health Advocates hosted by our 50-State Network and the Obesity Action Coalition (OAC). This episode features advocates Jody Quinn, Judy Nagy, Yolanda Clay, and Alecia Smith, who share their personal journeys — how they began sharing their stories, the invaluable support of community, the challenges they faced, and their successes along the way. You’ll also hear their advice for others looking to make a difference.

Addressing Obesity: Kevin’s Story of Change and Advocacy

We’re joined by Kevin Stephens, a weight loss surgery patient, and an active advocate with the Obesity Action Coalition (OAC). In this episode, we learn about Kevin’s struggle with his weight since childhood and the many health issues that come along with obesity. We talk a lot about the importance of health insurance coverage and reducing barriers to accessing treatment.

Immunocompromised and Informed: Navigating Current Viral Risks and Heat

In this episode, we’re breaking down the current viral landscape, focusing on COVID-19, mpox, norovirus, bird flu, and pertussis. We will discuss the unique challenges these viruses pose to immunocompromised individuals and offer practical advice on how to stay protected from viruses during this hot summer. We also recap the recommendations from the recent ACIP meeting, the advisory committee to the CDC on vaccines.

Dr. Omole: Combating Racial Disparities in Health Care

In this episode, breast surgical oncologist and president of the Black Physicians’ Association of Ontario, Dr. Mojola Omole, joins us to talk about her advocacy work. She shares how she aims to increase the percentage of Black physicians in Ontario, reduce systemic barriers and racism in medicine, and support Black mental health. We also discuss the need for more robust data that accounts for racial differences to inform screening recommendations.

Inclusive Care: Addressing LGBTQ+ Needs in IBD

In this episode, The Health Advocates are joined by their colleagues Kelly Gavigan, Chief Data and Analytics Officer, and Adam Kegley, Associate Director of Global Partnerships at GHLF. Together they delve into the unique challenges faced by the LGBTQ+ community in managing Inflammatory Bowel Disease (IBD). Based on the analysis of the results from a survey GHLF recently conducted, they explore how identity impacts health care experiences and treatment outcomes. This episode shines a light on the critical need for inclusive health care practices and offers valuable insights on improving patient-provider relationships. Join us as we uncover the lessons learned and steps forward for LGBTQ+ individuals living with IBD.

Public Health in Action: Tackling Bird Flu and New COVID Strains

In this episode, join The Health Advocates as they dive into the latest health news with a focus on the emerging H5N1 bird flu and its implications. They discuss the virus’s potential to affect humans, current states with detected cases, and public health strategies to mitigate its spread. The hosts also touch on recent COVID-19 variants and the development of combined COVID and flu vaccines, reflecting on public health lessons learned from past pandemics and how these insights are shaping responses to new threats.

Tune in as our hosts discuss ongoing infectious disease challenges and the proactive measures in place to protect public health.

Four Transplants, One Powerful Voice: Liz Schumacher’s Advocacy Journey

After being diagnosed with a type of kidney disease called acute glomerulonephritis at the age of 10, Liz Schumacher learned how to find her voice and become her own best advocate for her treatment. Now through her work in health advocacy and health sustainability, Liz uses the lessons of resilience she learned through her diagnosis journey to inspire other patients to be their own advocates too.
Join Liz as she describes her health care journey, gives tips on strength and resilience, and shares how she advocates for other persevering patients like her.

Fighting for Improved Access to Care for IBD Patients with Dr. Brad Pasternak

In this episode, we’re joined by gastroenterologist Dr. Brad Pasternak who talks about how his personal experience with ulcerative colitis inspired him to become a pediatric gastroenterologist. Dr. Pasternak realized he needed to advocate for policies that increase access to care after seeing his patients face denied treatments by insurance. He shares the tremendous effect that harmful policies have on the medical community, in delaying treatment for patients and getting in the way of shared decision-making. Finally, he leaves us with hope, discussing the advancements in treatment for inflammatory bowel disease.

Celebrating Lupus Awareness Month with New York City Council Member Shahana Hanif

In honor of Lupus Awareness Month and Lupus Day of Action in New York City, we’re joined by New York City Council Member Shahana Hanif. Council Member Hanif shares about her life as a lupus patient and how her condition informs her work as a member of the city council. She underscores the importance of accessibility within New York City and the idea of creating infrastructure to help patients with chronic conditions live and age in peace.

The Balancing Act of Chronic Illness with Shonta Chambers

We’re joined by Shonta Chambers, who serves as the Executive Vice President-Health Equity Initiatives and Community Engagement for the Patient Advocate Foundation (PAF). Shonta explains how social drivers impact one’s health, including things such as housing and economic status. We dive into the case work she does with PAF to combat these challenges and connect patients to resources. She also shares about her personal journey of being a caregiver.

For more information about the Patient Advocate Foundation visit: www.patientadvocate.org

“Advocate for Yourself and Don’t Give Up” with Cyndi Lauper and Michelle Bernstein

The Health Advocates are joined by singer, songwriter, actress, and activist Cyndi Lauper and chef and restauranteur Michelle Bernstein to talk about their journey with psoriasis and psoriatic arthritis. Recently, the two of them have joined forces to bridge the worlds of music and cuisine to deliver a powerful message of hope and empowerment for patients living with psoriatic disease. Here, they share about their personal journeys with diagnosis, the importance of connecting with other patients, and why they are spreading awareness.

For more information on the resources mentioned by Cyndi Lauper and Michelle Bernstein, you can visit: ThePSConnection.com

Beyond the Gut: Creating Change for LGBTQ+ IBD Patients with Dr. Carlton

Zoe and special co-host Adam Kegley, Associate Director of Global Partnerships at GHLF, are joined by San Diego-based gastroenterologist Carlton Thomas, MD, to learn all about LGBTQ+ health and inflammatory bowel disease (IBD). Dr. Carlton shares how not enough people are talking about sexual health and IBD, how people can have more open and honest conversations with their doctors, and the challenges faced in the LGBTQ+ community when it comes to accessing health care.

If you are an LGBTQ+ person living with IBD, make your voice heard and take the survey at https://bit.ly/lgbtq-ibd

“Obesity is a Disease” with Kristal Hartman from Obesity Action Coalition

We’re joined by Kristal Hartman who is a proud member of the Obesity Action Coalition (OAC) and is honored to serve as the Chair of the OAC National Board of Directors. In this episode, we learn about her patient journey, including her bariatric surgery in August 2014, which she describes as the hardest and best decision she ever made for herself. She shares how she now fights for access to quality, compassionate, and affordable access to care for all people living with the chronic disease of obesity.

Chronic Resilience: Jae Walker’s Journey

In this episode we are joined by Jae Walker, who lives with multiple autoimmune diseases including rheumatoid arthritis, fibromyalgia, and a rare neurological disease. Jae shares their emotional journey to diagnosis, offering advice for other people living with chronic illness on advocating for yourself and not giving up.

Measles Outbreak: A Look at Florida’s Response

Measles has been reported in about a dozen states across the U.S. this year. In this episode, we’re discussing Florida’s response to this recent outbreak, and why it’s not in the best interest of protecting public health. In the news recap, we give an update on our advocacy related to Prescription Drug Affordability Boards (PDABs), discuss how nonprofits profited from COVID misinformation, explore lessons from a new report on vaccines, and talk about the rise in norovirus cases.

New COVID Isolation Guidance? What Immunocompromised Need to Know

The Washington Post released a story that the CDC is considering replacing the COVID five-day isolation period guidance with staying home until 24 hours fever free and improving symptoms. In this episode, we’re breaking down all we do and don’t know so far about COVID, its impact, and this potential change in recommendation from the CDC.

In the news highlights, we discuss how unfortunately two million Texans have lost Medicaid coverage, and we also share the latest results on our quick poll on the patient experience with clinical trials.

Health Equity and Black History Month: Breaking Down Barriers

Black History Month is a time to celebrate the great achievements and commemorate important Black heroes and events throughout our history. It’s also a time to reflect and raise awareness of racial and ethnic disparities across health care sectors.

The Health Advocates are joined by Sarah Shaw, Senior Manager of BIPOC Community Outreach at GHLF for a discussion on the disproportionate burden of chronic disease in the Black community, barriers to health care, addressing racism in health care, and ultimately how we can come together as a community and advocate for our health year-round. In this conversation, we delve into actionable steps for fostering inclusivity and driving future advancements in health care access and equity.

Prescription Drug Affordability Boards: What Patients Need to Know

About half of U.S. adults say it is difficult to afford health care costs, and about one in five adults say they have not filled a prescription because of the cost. So, what can we do about lowering costs to ensure timely access to affordable care and treatment? In this episode, the hosts give us the 411 on Prescription Drug Affordability Boards (PDABs), how they aim to reduce drug prices, and why patients must be part of this process.

Advocacy in Action: Shaping 2024’s Health Care Policies with Corey Greenblatt

Corey Greenblatt, Associate Director of Policy and Advocacy at GHLF, joins Zoe Rothblatt, Associate Director of Community Outreach at GHLF, as co-host of this episode to share advocacy and policy priorities for the patient community in 2024. Corey breaks down which states are active in passing legislation that protects patients from step therapy and copay accumulators, and how patients can share their story to help pass these laws. Corey also highlights the need for patients to share their story to prescription drug affordability boards (PDABs). Finally, Corey shares federal policy updates, including exciting momentum for The Safe Step Act.

Measles Outbreak: Where’s the Public in Public Health?

With measles outbreaks making headlines in the U.S., The Health Advocates are diving into the history of measles in this country, how we got to these outbreaks after eliminating measles, the role of public health trust, and where we go from here to rebuild public health authority.

“I think there tends to be this idea that the measles is just a rash or some spots on your skin. But no, and when you contract it, it’s pretty bad,” says Steven Newmark, Director of Policy at GHLF.

The Latest News: Drug Imports, Biosimilars, and COVID/Flu/RSV Season

The Health Advocates are back and breaking down all the latest news so far in 2024. Steven gives us a debrief on what to look for this election year. We then dive into Florida’s plan to import drugs, why you may be switched from Humira to a biosimilar, and finally the latest hospitalizations and case rates this respiratory illness season.

About Our Hosts

StevenNewmark_3669

Steven Newmark

Steven Newmark, JD, MPA, is Director of Policy and General Counsel. Steven leads global advocacy and policy initiatives. He was most recently Special Counsel to the President of NYC Health + Hospitals in New York City. Before that he served as the Senior Health Policy Adviser to New York City Mayor Bill de Blasio. He also served as General Counsel in Mayor de Blasio’s Public Advocate office, and as a Health Sciences Litigation Associate at Orrick, Herrington & Sutcliffe, LLP in New York City where he was part of the team that successfully defended the Vaccine Act before the Supreme Court in Bruesewitz v. Wyeth.
Additionally, he has taught Public Policy at Columbia University and is an Adjunct Professor in U.S. Health Policy at the City University of New York, Baruch College. He received his Juris Doctor from Fordham University School of Law and his Master of Public Policy and Administration, Advanced Policy and Management from Columbia University School of International and Public Affairs. He received his Bachelor of Arts, Philosophy, Politics and Law from the State University of New York at Binghamton.

Zoe-Photo

Zoe Rothblatt

Zoe Rothblatt, MPH, is a Patient Advocate, Community Outreach Manager and engages in direct patient communications, supporting GHLF’s patient councils and board of governors. Zoe is responsible for understanding patient needs and creating patient-centered resources as well as researching policy initiatives. She earned a Master of Public Health at Columbia University’s Mailman School of Public Health, with a focus on Health Policy and Management. She received a Bachelor of Arts in Health: Science, Society and Policy from Brandeis University. Prior to joining GHLF, Zoe worked at the Community Service Society of New York as a community health advocate providing direct service, advocacy, advice and referrals for patients needing assistance.

Subscribe for weekly patient advocacy news right to your inbox

By subscribing, you agree to receive emails from GHLF. We will never sell your data. See our Privacy Policy.

Do you have questions about health care news? Submit your question below and it may be answered live on our podcast.

Submit to us at [email protected]

Back To Top